![]() | Stephen V Faraone∗Department of Psychiatry and Behavioral Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210 | Departments of Psychiatry and Neuroscience and ... |
kolの履歴書 Stephen V Faraone∗
Year | |
---|---|
2022 | Department of Psychiatry and Behavioral Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210 |
2021 | Department of Neuroscience and Physiology, State University of New York Upstate Medical University, Syracuse, New York Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, Massachusetts, USA |
2020 | K.G. Jebsen Centre for Psychiatric Disorders, Department of Biomedicine, University of Bergen, Bergen, Norway Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical Center, Syracuse, NY, USA Department of Psychiatry and of Neuroscience and Physiology, State University of New York (SUNY) Upstate Medical University, Syracuse, NY, United States The full list of authors in the ENIGMA working groups, author affiliations, author disclosures, and acknowledgments are provided in online supplements. |
2019 | Departments of Psychiatry and Neuroscience and Physiology, SUNY Upstate Medical University, New York, USA The Department of Human Genetics, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands (Klein, Bralten, Roth Mota, Arias-Vasquez, Franke); University Medical Center Utrecht, UMC Utrecht Brain Center, Department of Psychiatry, Utrecht, the Netherlands (Klein); the Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Walters, Neale); Program in Medical and Population Genetics (Walters) and Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, Mass (Walters, Neale); the Department of Biomedicine and the Center for Integrative Sequencing, Aarhus University, Aarhus, Denmark (Demontis, Mattheisen, Børglum); the Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Denmark (Demontis, Børglum); the Department of Genetics and the Neuroscience Center, University of North Carolina, Chapel Hill (Stein); the Imaging Genetics Center, USC Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles (Hibar, Thompson); the Department of Epidemiology and the Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, the Netherlands (Adams); the Department of Psychiatry and the Research Institute, Hospital for Sick Children, University of Toronto, Toronto (Schachar); the Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (Sonuga-Barke); the Department of Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany (Mattheisen); the Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institute, Stockholm (Mattheisen); Stockholm Health Care Services, Stockholm County Council, Stockholm (Mattheisen); the Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles (Thompson); the Quantitative Genetics Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Medland); the Department of Psychiatry and the Department of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, N.Y. (Faraone); the K.G. Jebsen Center for Neuropsychiatric Disorders, University of Bergen, Bergen, Norway (Faraone); and the Department of Psychiatry, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands (Roth Mota, Arias-Vasquez, Franke). Department of Psychiatry, Upstate Medical University, Syracuse, New York; Department of Neuroscience and Physiology, Upstate Medical University, Syracuse, New York. SUNY Upstate Medical University, Syracuse, NY |
Stephen V Faraone∗:統計に影響を与えます
Concept | World rank |
---|---|
dust addictive drug | #1 |
relatives control probands | #1 |
hyperactivity comorbidity humans | #1 |
rs2498799 | #1 |
adhd sex | #1 |
genetic sexual dimorphism | #1 |
subthreshold pediatric | #1 |
slc9a9 disease associations | #1 |
increased expression methylation | #1 |
fm pain tolerance | #1 |
depression adhd child | #1 |
deficit hyperactivity | #1 |
rs550818 | #1 |
paternal over‐transmission | #1 |
fam mothers | #1 |
children teaes | #1 |
adhd sample | #1 |
abstinence pharmacological treatment | #1 |
euphoria cardinal symptom | #1 |
desr adhd | #1 |
ldx masir | #1 |
arch ger psychiatry | #1 |
hamshere | #1 |
offspring sud parents | #1 |
methylphenidate efficacy | #1 |
diagnosis adhd | #1 |
overlapping symptoms | #1 |
cdh13 memory performance | #1 |
comorbid odd adhd | #1 |
stimulant treatment differences | #1 |
serotonin genetic | #1 |
motor preference | #1 |
parental adhd sud | #1 |
genetic risk severity | #1 |
patients adhdpi | #1 |
mania pdd | #1 |
efficacy adderall | #1 |
schizophrenia fhrs | #1 |
vcfsadhd adhd | #1 |
genes sexdifferentiated effects | #1 |
boys social disability | #1 |
mania manic features | #1 |
comorbid oppositional | #1 |
asd youth adhd | #1 |
osa genetic heterogeneity | #1 |
girls disorder | #1 |
gene interaction comt | #1 |
adhd brain alterations | #1 |
treatment mts | #1 |
onset distribution | #1 |
inattention items | #1 |
association attention | #1 |
distal genomic region | #1 |
behaviors substances | #1 |
intellectual delays | #1 |
adhd income loss | #1 |
bpd parents | #1 |
ld addh children | #1 |
molecular genetic studies | #1 |
affective symptoms dbds | #1 |
familial subtype | #1 |
relatives multiplex | #1 |
rels persons | #1 |
adherence stimulant treatment | #1 |
treatment moderated | #1 |
iiv hyperactivity behavior | #1 |
adhd higher | #1 |
daonrg1 | #1 |
cases adhd | #1 |
common genetic risk | #1 |
df39 | #1 |
stimulants comorbidity | #1 |
comorbid problems adhd | #1 |
risk disorder | #1 |
timely renewal | #1 |
suds adhd | #1 |
stimulant misuse | #1 |
hyperactivity cross | #1 |
anterior insular lobule | #1 |
risk aggressive symptoms | #1 |
adults neurodevelopmental disorder | #1 |
relatives adhd probands | #1 |
adhd probands adhd | #1 |
drd4 association | #1 |
adhd sexes | #1 |
nfspds | #1 |
odd affective symptoms | #1 |
increasing resource demand | #1 |
smoking schizophrenia families | #1 |
adhd module mwq | #1 |
135–526 | #1 |
adhd disorder | #1 |
longacting medications | #1 |
bpi disorder relatives | #1 |
latrophilin 3 gene | #1 |
adhd asm snps | #1 |
adhd children mania | #1 |
genes adhd | #1 |
prevalence attention | #1 |
children motor domain | #1 |
familial association adhd | #1 |
genetic heterogeneity adhd | #1 |
depressed children depression | #1 |
motorendophenotypes | #1 |
confusability analyses | #1 |
p81e06 | #1 |
aud adhd | #1 |
palauans maps loci | #1 |
innovative sms intervention | #1 |
productivity adhd | #1 |
chi28783 | #1 |
clinically diagnosed obesity | #1 |
pdag mdd mdd | #1 |
treatment stimulant | #1 |
slc9a9 adhd | #1 |
preschool comorbidity | #1 |
fsiq comt | #1 |
subthreshold adhd | #1 |
adhd adhd probands | #1 |
genetic association rorb | #1 |
qms adult adhd | #1 |
adhd subjects controls | #1 |
adhd volumetric reductions | #1 |
vall66 | #1 |
psychopathology reward dysfunction | #1 |
childhoodonset mania | #1 |
ldx bmi | #1 |
adhd depressed children | #1 |
illness child comorbidity | #1 |
nonaffected siblings children | #1 |
schizophrenia nonpsychotic relatives | #1 |
np functioning chr | #1 |
adhd medications placebo | #1 |
rf025 | #1 |
adhd dsm | #1 |
emotional problems pmee | #1 |
anachronisms | #1 |
nfspd | #1 |
desr adults | #1 |
firstdegree relatives children | #1 |
children adolescents cohorts | #1 |
risk female relatives | #1 |
adherence stimulant medication | #1 |
criteria age | #1 |
bpi relatives | #1 |
druggable genome adhd | #1 |
criteria pdd | #1 |
paternal smoking conception | #1 |
adolescent follow youth | #1 |
items 99item cbs | #1 |
concurrent adhd | #1 |
stimulant treatment risk | #1 |
adhd long term | #1 |
nasal nmu nmu | #1 |
apol1 schizophrenia | #1 |
oral nmu nmu | #1 |
sob sob association | #1 |
criteria mania | #1 |
dsmiv subtypes adhd | #1 |
pippi longstocking | #1 |
nonreferred sample | #1 |
mania criteria | #1 |
adhd serotonin | #1 |
bpd girls | #1 |
psychopathology implications | #1 |
cgsq ermph | #1 |
adhd prs gwas | #1 |
htf9c | #1 |
bmi mts | #1 |
aadhd cadhd | #1 |
subthreshold diagnoses valid | #1 |
adhd children exposure | #1 |
siblings adolescent | #1 |
ermph placebo groups | #1 |
trait impulsivity adhdct | #1 |
adhd chinese population | #1 |
ldx expected height | #1 |
adhd hyperactivity automobile | #1 |
adhd psychoactive substance | #1 |
behavioral inhibition parents | #1 |
oih pain tolerance | #1 |
biased maternal reporting | #1 |
prss psychiatric disorders | #1 |
vulnerability indicators schizophrenia | #1 |
deficit | #1 |
adults adhd subjects | #1 |
p97e−03 | #1 |
23 candidate genes | #1 |
adhd comorbid disorders | #1 |
pepple | #1 |
adhd drug dependence | #1 |
adults cadhd | #1 |
rs3027400 | #1 |
adhd efds | #1 |
git1 association adhd | #1 |
1236a | #1 |
hypothesis disorders | #1 |
structured interview mania | #1 |
adhdmethodcurves | #1 |
adhd maternal | #1 |
adhd obesity overweight | #1 |
adhd adolescent patients | #1 |
personality traits adults | #1 |
exposure maternal smoking | #1 |
teachers cbt intervention | #1 |
adhd comorbid | #1 |
desipraminestimulants | #1 |
growth outcomes adhd | #1 |
pilot study adhd | #1 |
individuals attention | #1 |
bpi probands | #1 |
fiveminutespeechsample | #1 |
adhd responders | #1 |
relatives greater activation | #1 |
unfamiliar challenges | #1 |
schizophrenia bipolar psychoses | #1 |
age onset criterion | #1 |
adhd control probands | #1 |
adhd antisocial comorbidity | #1 |
impairments adults | #1 |
adhd pdics | #1 |
greater risk add | #1 |
normal sexual dimorphisms | #1 |
efds youth | #1 |
adhd methods | #1 |
prss adhd | #1 |
adolescent response inhibition | #1 |
adhd genetic studies | #1 |
dyscalculia adhd | #1 |
cbclbp profile | #1 |
adhd antisocial disorders | #1 |
versus disability | #1 |
aud alcohol disorders | #1 |
oral methylphenidate treatment | #1 |
marijuana cocaine crack | #1 |
mph adult adhd | #1 |
opd add opd | #1 |
motor problems adhd | #1 |
risk adhd | #1 |
inattention shr | #1 |
asrs‐v11 | #1 |
ldx growth delays | #1 |
association maoa | #1 |
impactnl | #1 |
meaningful anxiety phenotype | #1 |
adhd 5 | #1 |
schizophrenia european samples | #1 |
aadhd hyperactivity biomarkers | #1 |
drd5 vntr | #1 |
schizotaxia negative schizotypy | #1 |
oih fm | #1 |
adhd comorbid odd | #1 |
adhd mdd prss | #1 |
mwq adhd module | #1 |
larger samples | #1 |
pain tolerance fm | #1 |
tass adhdrs | #1 |
ptsd bpi disorder | #1 |
anxious depressed subscales | #1 |
followup assessment | #1 |
self‐reported adhd | #1 |
time qualitative review | #1 |
postmortem brain identifies | #1 |
p758e08 | #1 |
hyperactivity female | #1 |
model ermph | #1 |
desr siblings | #1 |
parental sud adhd | #1 |
highiq youths adhd | #1 |
prescription stimulant adults | #1 |
autistic traits youth | #1 |
siblings control probands | #1 |
adoption studies | #1 |
diagnostic efficiency analysis | #1 |
based association study | #1 |
discipline problem | #1 |
sud adolescence | #1 |
adults life | #1 |
treatment masxr | #1 |
psychiatric disorders adhd | #1 |
2327t | #1 |
pdd criteria | #1 |
onset attention | #1 |
nhe inhibitors adhd | #1 |
oral nmu | #1 |
schizophrenia hrscz | #1 |
proband child | #1 |
187 children | #1 |
controls adhd probands | #1 |
adhd community | #1 |
disorders parents | #1 |
network‐level assessment | #1 |
chronic emotional dysregulation | #1 |
youth informant source | #1 |
ptsd adhd probands | #1 |
locus adhd | #1 |
youth adhd prss | #1 |
adhd cognition | #1 |
nonreferred siblings | #1 |
diagnoses adhd | #1 |
children growth delays | #1 |
siblings adhd children | #1 |
gene comt | #1 |
impact tic disorders | #1 |
paediatric adhd | #1 |
disorder adhd | #1 |
pathways adhd | #1 |
mania conduct disorder | #1 |
cardinal symptom mania | #1 |
bpi disorder | #1 |
lifetime impairment survey | #1 |
adhd children depression | #1 |
relatives drug dependence | #1 |
adhd risk alleles | #1 |
bpd firstdegree relatives | #1 |
adolescent sud | #1 |
adhd aud | #1 |
rs41084 | #1 |
adolescent outcome adhd | #1 |
symptoms aggregation | #1 |
relatives control | #1 |
life adult adhd | #1 |
hartsough | #1 |
gene attention | #1 |
medications adult adhd | #1 |
multi‐stage study | #1 |
family‐based association test | #1 |
tass internal consistency | #1 |
offspring behavioral disinhibition | #1 |
prsanalyses | #1 |
persistence adhd | #1 |
context adhd | #1 |
substantial genetic component | #1 |
“forgetfulness | #1 |
neuropsychological performance adhd | #1 |
predictors adhd | #1 |
severe dysregulation | #1 |
expected growth children | #1 |
adhd followup | #1 |
rs2469758–rs2461489 | #1 |
adhd oppositional | #1 |
boys female gender | #1 |
juvenile antisocial traits | #1 |
late‐onset adhd | #1 |
parental bpd | #1 |
adhd neuropsychological impairments | #1 |
pair health | #1 |
tomoxetine adult adhd | #1 |
adolescents sud treatment | #1 |
4‐year follow‐up study | #1 |
adhd females | #1 |
2276tc | #1 |
ptsd siblings | #1 |
relatives default network | #1 |
caregiver strain cgsq | #1 |
htf9c gene | #1 |
genetic variation nr3c1 | #1 |
smd higher rates | #1 |
subcortical structure volume | #1 |
cbclbp profile children | #1 |
galantamine hydrogen bromide | #1 |
unipolar relatives bipolars | #1 |
offspring parental adhd | #1 |
schizotaxia negative symptoms | #1 |
bmi ldx | #1 |
druggable genome disorder | #1 |
age stimulant treatment | #1 |
diagnoses relatives | #1 |
oros methylphenidate orosmph | #1 |
genetic studies sud | #1 |
ats siblings | #1 |
treating adhd | #1 |
adhd familial | #1 |
bipolar disorder switches | #1 |
bpi disorder adhd | #1 |
disorder boys | #1 |
impulsive behavioral aggression | #1 |
aisrs asrs | #1 |
onset chronological age | #1 |
pdics | #1 |
loci adhd | #1 |
lobe mri measures | #1 |
adhd mini | #1 |
adhd psychiatric | #1 |
educational failure | #1 |
sbrv adhd | #1 |
adhd france | #1 |
adhd child comorbidity | #1 |
cortical thickness adhd | #1 |
adhd cbcl | #1 |
new phenotype definition | #1 |
manic symptoms disorder | #1 |
dysfunctional gene | #1 |
rates relatives | #1 |
rationaleadhd | #1 |
mspi allele | #1 |
relatives wm performance | #1 |
depressed children adhd | #1 |
clinical response orosmph | #1 |
autism‐associated brain regions | #1 |
treatment effects values | #1 |
actual motor performance | #1 |
anxiety disorders families | #1 |
experts abstinence | #1 |
desr adult probands | #1 |
daodisc1 | #1 |
adhd alcohol dependence | #1 |
cigarette smoking siblings | #1 |
disorder familial | #1 |
adhd rat | #1 |
disorder report | #1 |
familially | #1 |
norepinephrine transporter gene | #1 |
maoa neuropsychological functioning | #1 |
adhd neuropsychological functioning | #1 |
rs1076560t | #1 |
p44e05 | #1 |
familial risk gender | #1 |
–rs2272080 | #1 |
gene studies | #1 |
ermph cgsq | #1 |
child psychiatry referrals | #1 |
adhd attention | #1 |
amses amrs | #1 |
stimulant nonmedical | #1 |
children motor competence | #1 |
symptom burden adults | #1 |
predicted clinical response | #1 |
adhd outcome | #1 |
pdi hyperactivity | #1 |
20183 cases | #1 |
genetic frontal schizophrenia | #1 |
bpi disorder aspd | #1 |
pharmacological treatment adolescents | #1 |
tdt analysis | #1 |
adhd valid | #1 |
adhd predictors | #1 |
ldx sizes adults | #1 |
adhd population | #1 |
findings adhd | #1 |
rs2469770 | #1 |
comt fsiq | #1 |
relatives multiplex families | #1 |
overweight obesity males | #1 |
pediatric bipolar spectrum | #1 |
gsprss | #1 |
drd2 disrupts | #1 |
variance oppositional symptoms | #1 |
99item cbs | #1 |
families adhd | #1 |
d10s2327 | #1 |
structured interview pdd | #1 |
interviews disease humans | #1 |
new psychometric definition | #1 |
pdd pdd subjects | #1 |
suds crosssectional studies | #1 |
bipolars unipolar relatives | #1 |
stimulant treatment adhd | #1 |
17year | #1 |
variants aggressive behavior | #1 |
2064 trios | #1 |
mdd pdag mdd | #1 |
pain tolerance oih | #1 |
risk subsequent substance | #1 |
major depression youth | #1 |
candidate genes adhd | #1 |
rs7118422 | #1 |
non‐adhd children | #1 |
controls rels | #1 |
parental md | #1 |
genes association studies | #1 |
studies depressed children | #1 |
parents md | #1 |
treatment stimulants | #1 |
adolescent patients adhd | #1 |
medications adhd | #1 |
alcohol disorders offspring | #1 |
proband youth bpdsud | #1 |
aspd youth | #1 |
disorder molecular | #1 |
orosmph adult adhd | #1 |
bpd anx relatives | #1 |
adhd stimulant treatment | #1 |
association tph2 | #1 |
adhddbds adhd | #1 |
remission definition | #1 |
substance disorders relatives | #1 |
fbxo33 | #1 |
psychiatric comorbidity md | #1 |
age groups cohorts | #1 |
african children adhd | #1 |
adolescent attention | #1 |
disorders comorbid mania | #1 |
male individuals adhd | #1 |
risk anxiety disorders | #1 |
adolescence longitudinal analysis | #1 |
conduct bipolar disorders | #1 |
probands clinical status | #1 |
siblings adhd | #1 |
gender adhd | #1 |
tourettes syndrome adhd | #1 |
kiaa1292 | #1 |
adhd siblings | #1 |
downward extension adolescents | #1 |
disability asthma | #1 |
adult persistence | #1 |
pooleddata | #1 |
anx relatives | #1 |
4q3121 | #1 |
validity adhd | #1 |
risk factors opd | #1 |
patients attentional disorders | #1 |
features adhd | #1 |
palau scz | #1 |
adhd children | #1 |
nonreferred adult | #1 |
48basepairrepeat | #1 |
adhd reliability | #1 |
adhdtd siblings | #1 |
cadhd aadhd | #1 |
higher pdi | #1 |
adhd teenage parents | #1 |
analysis adhd | #1 |
adhd smoking risk | #1 |
adhd conclusions | #1 |
adhd candidate | #1 |
adhd conduct disorder | #1 |
risk suds | #1 |
ainslbl | #1 |
familial risk analyses | #1 |
adult adhd | #1 |
patterns psychiatric comorbidity | #1 |
or133 | #1 |
desr probands siblings | #1 |
onset distributions | #1 |
adhd probands | #1 |
rs3776512 | #1 |
neuropsychological functioning boys | #1 |
adhd ads | #1 |
adhd adoption studies | #1 |
sbrv | #1 |
brain activity flow | #1 |
children idiopathic adhd | #1 |
rate symptoms | #1 |
relatives 1 probands | #1 |
relatives adhd girls | #1 |
major depression share | #1 |
probands adhd | #1 |
112 80 | #1 |
genes disorder | #1 |
earlyandmoderate | #1 |
controls adhd children | #1 |
bpd bpd anx | #1 |
smoking wm microstructure | #1 |
intelligence additive effects | #1 |
compared adhd | #1 |
hyperactivity child child | #1 |
comorbid adult adhd | #1 |
parental sud sud | #1 |
familial moderators | #1 |
nplz | #1 |
desr subjects | #1 |
disorganized symptom dimensions | #1 |
impulsive subtype | #1 |
comorbid psychopathology childhood | #1 |
stimulant nmu | #1 |
week treatment response | #1 |
cbcl clinical scales | #1 |
asds clinical scales | #1 |
nonreferred subjects | #1 |
relatives 3 probands | #1 |
impulsive drive | #1 |
140 adhd | #1 |
sample adhd | #1 |
drug frequency variables | #1 |
increased adhd symptoms | #1 |
predictors persistence | #1 |
model adult samples | #1 |
aklt01 adhd | #1 |
adhd linkage | #1 |
adhd adult adhd | #1 |
probands add | #1 |
aklt01 tova api | #1 |
psychiatric comorbidities adhd | #1 |
notch4 polymorphisms schizophrenia | #1 |
opd add | #1 |
adhd dbds | #1 |
adhd findings | #1 |
repeat allele | #1 |
faraone | #1 |
adhd genetic | #1 |
adhd youth ld | #1 |
efs girls | #1 |
inattentive subtype adhd | #1 |
nonreferred adults | #1 |
schizotaxia subjects | #1 |
relatives children | #1 |
dopamine d4 gene | #1 |
insular lobule | #1 |
bpi disorder efds | #1 |
adhdfamilies | #1 |
familial transmission adhd | #1 |
adhd adhdtd | #1 |
adhdassociated alleles | #1 |
biological schizophrenia stress | #1 |
dat1 adhd | #1 |
5‐generation | #1 |
visual memory deficit | #1 |
adhd drd4 | #1 |
anxiety disorders siblings | #1 |
hyperactivity case | #1 |
bipolar disorder parents | #1 |
unexplored void | #1 |
asrs | #1 |
drugplacebo response curve | #1 |
13052159 | #1 |
intron8 | #1 |
adult adhd diagnosis | #1 |
snp quantitative phenotype | #1 |
maternal inattention anxiety | #1 |
idir aversion | #1 |
tass adhd | #1 |
pharmacogenetics predictors | #1 |
antisocial disorders risk | #1 |
p902e−07 | #1 |
psychiatric comorbidity girls | #1 |
adhd alleles | #1 |
sud adolescent | #1 |
patients adhdct | #1 |
scz palau | #1 |
4q28 | #1 |
hyperactivity pdi | #1 |
rs1040399 | #1 |
pediatric bipolari disorder | #1 |
elaborative verbal encoding | #1 |
stable behavioral inhibition | #1 |
subtype adhd | #1 |
assess adult adhd | #1 |
studies adhd | #1 |
risk tourette spectrum | #1 |
asrs aisrs | #1 |
referred juveniles | #1 |
european treatment guidelines | #1 |
odd control | #1 |
add opd | #1 |
callingalgorithms | #1 |
genetic correlation adhd | #1 |
rs2279805 | #1 |
add 73 probands | #1 |
comt maoa | #1 |
molecular psychiatric genetics | #1 |
deficits expected growth | #1 |
unique impairments | #1 |
schizophrenia rs1076560t | #1 |
volume alterations | #1 |
adhd disorders comorbidity | #1 |
affs add | #1 |
adhd neuropsychological | #1 |
parental polygenic risk | #1 |
adhd phenotypes | #1 |
rs3792452 | #1 |
addh dmi | #1 |
antisocial disorder relatives | #1 |
adhd personality traits | #1 |
expression adhd | #1 |
persistence pediatric disorder | #1 |
odd familial disorders | #1 |
greater risk adhd | #1 |
adhdrsivinv | #1 |
specific psychopathology children | #1 |
adhd 11 years | #1 |
switches bipolar disorder | #1 |
mwq inattention items | #1 |
nimh genetics initiative | #1 |
2327ct | #1 |
anxiety disorders relatives | #1 |
longitudinal analysis childhood | #1 |
competitivep | #1 |
benefit‐risk ratio | #1 |
consensus combination | #1 |
anxiety disorders twins | #1 |
alphaglx | #1 |
infas | #1 |
nonmental diseases adhd | #1 |
ctcata | #1 |
growth deficits deficits | #1 |
p179e06 | #1 |
adhd cigarette smoking | #1 |
girls learning disabilities | #1 |
metabias | #1 |
ldx growth | #1 |
etiology adhd | #1 |
peer environmental factors | #1 |
neuropsychological impairments relatives | #1 |
bpd probands | #1 |
pediatric panic disorder | #1 |
anxiety disorders baseline | #1 |
tidqam | #1 |
illness adolescent | #1 |
adhd dat1 gene | #1 |
noninhibited children | #1 |
sp067 | #1 |
adhd switches | #1 |
height ldx | #1 |
childhood predictors adhd | #1 |
hyperactivity child genome | #1 |
groups girls | #1 |
neuropsychological probes | #1 |
tic persistence | #1 |
ldx sizes | #1 |
smoking adhd | #1 |
effects lisdexamfetamine dimesylate | #1 |
motor skills attention | #1 |
adhd african | #1 |
authors adhd | #1 |
pdd mania mania | #1 |
increased methylation genes | #1 |
trait educational attainment | #1 |
highiq youths | #1 |
relatives girls | #1 |
bpd bpdsud | #1 |
oih cpt | #1 |
21 circadian genes | #1 |
adolescents genetic risk | #1 |
volumes participants | #1 |
genotype calling procedures | #1 |
adhd risk factors | #1 |
dat1 vntr | #1 |
siblings antisocial families | #1 |
drd4 7repeat allele | #1 |
229 families | #1 |
psychiatric conditions adults | #1 |
motor preference adhd | #1 |
stimulant treatment youth | #1 |
morbidity bipolar disorder | #1 |
relatives conduct disorder | #1 |
relation stress exposure | #1 |
racial heterogeneity | #1 |
genetic studies adhd | #1 |
comt odd | #1 |
dsm bipolar disorder | #1 |
potential endophenotypes adhd | #1 |
disorders aa | #1 |
comorbidity major depression | #1 |
schizophrenia notch4 | #1 |
adhd genetic exome | #1 |
deletioncarrier | #1 |
familial vulnerability schizophrenia | #1 |
multiplex sample | #1 |
cacng2 genes schizophrenia | #1 |
severe emotional dysregulation | #1 |
aggregate cutoff score | #1 |
rtv adhd prs | #1 |
structural differences children | #1 |
adhd susceptibility genes | #1 |
diagnostic criteria adhd | #1 |
interaction adhd | #1 |
allele adhd | #1 |
children disorder | #1 |
chronological age age | #1 |
risk childhood onset | #1 |
anx bpd | #1 |
onset criterion adhd | #1 |
p647e07 | #1 |
cortical networks attention | #1 |
comorbidity conduct | #1 |
relatives pediatric probands | #1 |
efds bpi disorder | #1 |
schizophrenia families smoking | #1 |
hyperactivity disorder scores | #1 |
rs6077690 | #1 |
starsadhd | #1 |
sob association adhd | #1 |
comt intelligence | #1 |
adhd studies | #1 |
parental suds | #1 |
notch4 polymorphisms | #1 |
“3 | #1 |
association evidence | #1 |
rs1051312 | #1 |
adhd aes | #1 |
neuropsychological testing individuals | #1 |
teacher combined | #1 |
schizophrenic probands1portions | #1 |
adult probands siblings | #1 |
adhd neuroimage study | #1 |
dsm5 adult adhd | #1 |
adhd context | #1 |
standardized manner | #1 |
disorder versus disability | #1 |
validity diagnosis | #1 |
motorendophenotype | #1 |
adhd pattern | #1 |
adhdoddcd | #1 |
palau early | #1 |
regulation desr | #1 |
bipolar disorder bpprss | #1 |
hypothesized precursors | #1 |
smd greater severity | #1 |
studies method | #1 |
140 adhd probands | #1 |
comparison subjects participants | #1 |
mtbi adhd | #1 |
elevated rates adhd | #1 |
quantitative phenotype snp | #1 |
parents sud | #1 |
adhd somatosensory functioning | #1 |
adhd slc6a3 genotype | #1 |
5q23q31 | #1 |
subjects lateonset adhd | #1 |
stress adhd severity | #1 |
daorasd2 | #1 |
adult adhd treatment | #1 |
teacher report | #1 |
higher adhd | #1 |
control probands | #1 |
subjects ldx | #1 |
comorbid problems | #1 |
subsets linkage | #1 |
adhd follow | #1 |
transient financial stress | #1 |
valid disorder | #1 |
consensus statement combination | #1 |
familial evidence | #1 |
inattentive symptoms adults | #1 |
foursnp | #1 |
17yearold boys | #1 |
add aff | #1 |
autism symptoms adhd | #1 |
criteria☆ | #1 |
genes hallucinations states | #1 |
chinese outpatient sample | #1 |
adhd haplotype block | #1 |
offspring parental md | #1 |
hyperactivity biomarkers | #1 |
p446e08 | #1 |
add relatives | #1 |
suggestive linkage | #1 |
adhd proband | #1 |
low attention | #1 |
bpd anx bpd | #1 |
addictive drugs dust | #1 |
mania clinical interview | #1 |
fidgety philipp | #1 |
adhd community sample | #1 |
24 gm day | #1 |
children mania diagnosis | #1 |
prs58502974 | #1 |
vivo neuroreceptor imaging | #1 |
sex bpi disorder | #1 |
31item | #1 |
memory adults | #1 |
high‐risk adolescent offspring | #1 |
persistence childhood adhd | #1 |
familiar disease | #1 |
autistic traits presence | #1 |
motor preference disability | #1 |
adhd functional | #1 |
children bpi disorder | #1 |
rs1482337–rs2252471 | #1 |
linkage wave | #1 |
parental panic disorder | #1 |
parental children | #1 |
manic children pdd | #1 |
late onset adhd | #1 |
administration marijuana | #1 |
clock genes rorb | #1 |
diagnostic continuity adhd | #1 |
risk psud | #1 |
treatment bsd | #1 |
selfreport adhd symptoms | #1 |
95 hrr | #1 |
nonverbal social–emotional cues | #1 |
schizophrenia code | #1 |
n6979 | #1 |
children behavioral | #1 |
asrs scores | #1 |
higher prevalence girls | #1 |
d10s195 | #1 |
method authors | #1 |
drug dependence relatives | #1 |
persistent adhd adults | #1 |
sud risk offspring | #1 |
pediatric bpi disorder | #1 |
taf9bp2 | #1 |
qms adhd | #1 |
adverse impact adhd | #1 |
adhd vntr | #1 |
s034 | #1 |
adhd increased | #1 |
hyperactivity body | #1 |
risk factor psud | #1 |
psud relatives | #1 |
relszs | #1 |
mitigates stimulant | #1 |
adhd adolescent | #1 |
antisocial disorders bpd | #1 |
school reliability | #1 |
disorder hyperactivity | #1 |
valid diagnosis | #1 |
2455 controls | #1 |
depression symptoms aggregation | #1 |
adhd prss adhd | #1 |
adherence xr | #1 |
adhdrs5 | #1 |
psud adhd probands | #1 |
adolescents concurrent adhd | #1 |
adhd fam | #1 |
dat1 untranslated regions | #1 |
symptoms versus impairment | #1 |
dependence controls | #1 |
stimulant therapy youths | #1 |
bipolar disorders psud | #1 |
fspds | #1 |
criteria 14 children | #1 |
growth delays weight | #1 |
rs9627183 | #1 |
sud bpdsud | #1 |
adhd concurrent sud | #1 |
studies attention | #1 |
biomarkers adhd | #1 |
social adjustment inventory | #1 |
neurocognitive marker | #1 |
association syp | #1 |
pdd subjects mania | #1 |
rf041 | #1 |
key conceptual issues | #1 |
youth bpi disorder | #1 |
copy organization | #1 |
neurocognitive functions suds | #1 |
association adhd | #1 |
adhd druggable genes | #1 |
ptsd familial disorders | #1 |
valid psychiatric disorder | #1 |
adhd efficacy outcome | #1 |
placebo ldx treatment | #1 |
bipolar disorder girls | #1 |
cdbpd | #1 |
executive functioning adults | #1 |
parents proband youth | #1 |
sud remittent adhd | #1 |
1350t | #1 |
distribution child | #1 |
adhd adverse impact | #1 |
slc6a4 gene risk | #1 |
children pdag parents | #1 |
stimulant treatment alcohol | #1 |
lateandmoderate | #1 |
adhd children ld | #1 |
affective symptoms children | #1 |
probands rates | #1 |
etiology disorder | #1 |
adhd baseline | #1 |
adhd maoa | #1 |
comt maoa interaction | #1 |
zmynd17 genes | #1 |
manic symptoms vcfs | #1 |
odd relatives | #1 |
relbps | #1 |
adhd children bpd | #1 |
adhd genetic variants | #1 |
learning disorders adhd | #1 |
dat110 6 | #1 |
neurocognitive dysfunctions | #1 |
connectivity executive control | #1 |
sodasmph | #1 |
interaction adhd severity | #1 |
vntr haplotype | #1 |
non‐random error | #1 |
twin adoption | #1 |
psud controls | #1 |
association behavioral inhibition | #1 |
studies adhd children | #1 |
“schizotypes | #1 |
adult samples model | #1 |
74±77 | #1 |
p20e04 | #1 |
diagnoses valid | #1 |
daily parent rating | #1 |
maoa adhd | #1 |
shared endophenotypes | #1 |
genetic variants adhd | #1 |
referred parents | #1 |
slc9a9 | #1 |
familial underpinnings | #1 |
ldx adult adhd | #1 |
20183 | #1 |
depression offspring variables | #1 |
association slc6a3 | #1 |
outcome adhd | #1 |
clinical features adhd | #1 |
proband youth bpd | #1 |
rs2449340 | #1 |
motor preference asthma | #1 |
896 cases | #1 |
cbclbp | #1 |
persistence disorder | #1 |
dopamine receptor polymorphism | #1 |
hyperactivity | #1 |
adhd adhd cases | #1 |
new diagnoses age | #1 |
diagnoses probands | #1 |
prescription stimulant nonmedical | #1 |
adhd gender | #1 |
cyp2d6 hypothesis | #1 |
children behavioral inhibition | #1 |
age 7repeat allele | #1 |
adhd gene | #1 |
2276ct | #1 |
adhd comorbid dbds | #1 |
rs552655 | #1 |
smaller total brain | #1 |
relatives adhd status | #1 |
adhd prss | #1 |
children general psychopathology | #1 |
ermph clinical response | #1 |
adhd desr probands | #1 |
adhd snps | #1 |
efficacy outcome adhd | #1 |
european treatment guideline | #1 |
parents behavioral disinhibition | #1 |
adhd diagnosed | #1 |
asd weaknesses | #1 |
dsmiiir dsmiv adhd | #1 |
molecular genetics network | #1 |
adhdi prenatal exposure | #1 |
onset mania | #1 |
suds neurocognitive functions | #1 |
n122 | #1 |
adhd | #1 |
efficacy outcome week | #1 |
cognitive endophenotypes adhd | #1 |
odd disruptive behavior | #1 |
bpprss | #1 |
prodromal overt psychosis | #1 |
rs9610449 | #1 |
c759t | #1 |
adhd genetic receptors | #1 |
51 genes | #1 |
snpssnpsa | #1 |
bpi sza | #1 |
expected height weight | #1 |
association dopamine receptors | #1 |
children ermph | #1 |
attention deficit | #1 |
highiq adults adhd | #1 |
disorders hypothesis | #1 |
risk comt gene | #1 |
rs7124601 | #1 |
adhd single nucleotide | #1 |
n55374 | #1 |
iiv shr | #1 |
association snap25 | #1 |
adhd symptoms crf | #1 |
conduct disorder probands | #1 |
ldx amses | #1 |
ldx size children | #1 |
differences medications | #1 |
mr006 | #1 |
40basepairrepeat | #1 |
nonreferred samples | #1 |
psychopharmacologic | #1 |
robust familiality | #1 |
masxr treatment | #1 |
anxiety disorders findings | #1 |
mgh studies | #1 |
deficits time | #1 |
levels dysfunction | #1 |
healthy cortical development | #1 |
genes etiology | #1 |
expressed emotion children | #1 |
dbds adhd | #1 |
neurocognitive traits | #1 |
reproducibility adolescent | #1 |
relatives diagnoses | #1 |
genetics adhd | #1 |
adhd scores | #1 |
pdd mania | #1 |
emotional symptoms adhd | #1 |
cigarette smoking metaanalysis | #1 |
time reproduction children | #1 |
adhde | #1 |
asthma motor preference | #1 |
distinct subtype | #1 |
subcortical volumes adhd | #1 |
matching fallacy | #1 |
inflation personal satisfaction | #1 |
youth adhd | #1 |
shlod | #1 |
temperamental risk factor | #1 |
concurrent adhd sud | #1 |
lifetime impairment | #1 |
lateonset adhd | #1 |
stimulant treatment profiles | #1 |
hyperactivity disorder | #1 |
schizotypal relatives | #1 |
hyperactivity comorbidity | #1 |
african‐american pedigrees | #1 |
maoa impulsivity | #1 |
rs3916970 | #1 |
adhd symptom counts | #1 |
adhd sample model | #1 |
adhd stronger connectivity | #1 |
efficacy medications | #1 |
alcohol dependence relatives | #1 |
elevated risk adhd | #1 |
regions age | #1 |
10repeats | #1 |
persistent adhd symptoms | #1 |
psychiatric risk vcfs | #1 |
evidence sud phenotypes | #1 |
highiq adults | #1 |
gender familial risk | #1 |
add parent report | #1 |
rorb bipolar disorder | #1 |
efds functional outcomes | #1 |
relatives bipolar | #1 |
endophenotypic construct | #1 |
adhd bipolar studies | #1 |
odd disorders follow | #1 |
sud adolescent patients | #1 |
training raters | #1 |
schizophrenia current knowledge | #1 |
aff add | #1 |
male adolescents adhdct | #1 |
hyperactivity child | #1 |
adhd baseline assessment | #1 |
trypotphan | #1 |
adhd learning | #1 |
masir | #1 |
suds nicotine dependence | #1 |
35191 controls | #1 |
adhd degree relatives | #1 |
familial links | #1 |
hyperactivity child humans | #1 |
haplotypes adhd | #1 |
siblings males | #1 |
sud nicotine dependence | #1 |
77e08 | #1 |
abnormalities adhd | #1 |
children antisocial disorders | #1 |
type adhd | #1 |
adhd module | #1 |
subjects adhd | #1 |
shr iiv | #1 |
mothers fam | #1 |
onset adult subjects | #1 |
adhd antisocial | #1 |
measurement invariance study | #1 |
bpi disorder children | #1 |
nonpsychotic relatives controls | #1 |
adhd euphoria | #1 |
adults stimulant sizes | #1 |
rs6000200 | #1 |
hamiltondepression | #1 |
adhd dyscalculia | #1 |
disorder | #1 |
snps quantitative phenotypes | #1 |
adhd smoking | #1 |
suds relatives | #1 |
clinical controls | #1 |
adolescent psychiatric cohort | #1 |
aggressive symptoms risk | #1 |
adhd highiq youths | #1 |
rare protective allele | #1 |
relatives alcohol dependence | #1 |
thermenos | #1 |
acting medications | #1 |
female individuals adhd | #1 |
rutters | #1 |
md parents | #1 |
interobserver agreement measures | #1 |
rs1633445 | #1 |
sexes bpi disorder | #1 |
type attention | #1 |
drd2 risk gene | #1 |
idir proteins siblings | #1 |
phenotype adhd | #1 |
vcfs manic symptoms | #1 |
142 combined subtype | #1 |
adhd psychiatric conditions | #1 |
schizophrenia familybased studies | #1 |
stimulants height | #1 |
endosomal genes asds | #1 |
scqscore | #1 |
18 items impairment | #1 |
adhd structural abnormalities | #1 |
adhd treatment treatment | #1 |
pdi impulsiveness | #1 |
scales risk | #1 |
15q13 deletions | #1 |
clinical interview mania | #1 |
adhd familial disorder | #1 |
mp adhd | #1 |
twin adoption studies | #1 |
cacng2 gene | #1 |
stimulant treatment | #1 |
braingenie | #1 |
nonreferred siblings probands | #1 |
9r allele | #1 |
cortical surface adhd | #1 |
relatives risk adhd | #1 |
impulsive symptoms | #1 |
bpdsud bpd | #1 |
covariates dopamine receptors | #1 |
h2053 | #1 |
placebo cgsq | #1 |
genetic overlap adhd | #1 |
stimulant treatment adults | #1 |
disorder attention | #1 |
years adhd | #1 |
association evidence schizophrenia | #1 |
putamen volume alterations | #1 |
positive peer affiliation | #1 |
probands comorbidity | #1 |
adhd screening | #1 |
neural network correlates | #1 |
adhd specific | #1 |
disorder relatives | #1 |
nonmental diseases | #1 |
pregnancy adhd | #1 |
suds genetic studies | #1 |
hyperactive impulsive symptoms | #1 |
bipolar mdd | #1 |
disorder meta | #1 |
female adhd | #1 |
stimulants abuse potential | #1 |
childhood adhd adulthood | #1 |
sensitive adhd | #1 |
14 children pdd | #1 |
exposure clinical features | #1 |
bpi disorder sexes | #1 |
adhd seconddegree relatives | #1 |
hyperactive impulsive | #1 |
rs11133767 | #1 |
mania pdd subjects | #1 |
inattention adhd | #1 |
p0499 | #1 |
adult adhd differences | #1 |
teenage parents individuals | #1 |
familybased studies association | #1 |
transmission adhd | #1 |
adhd candidate genes | #1 |
sexdifferentiated effects traits | #1 |
drugplacebo | #1 |
c2orf82 | #1 |
a409p | #1 |
cohorts age groups | #1 |
adhd african children | #1 |
sud parents | #1 |
adhd educational deficits | #1 |
prospective datasets | #1 |
bpd hypothesis | #1 |
adhd clinical obesity | #1 |
neuroanatomic predictors | #1 |
familial disorders adhd | #1 |
syp female adhd | #1 |
adhdtd | #1 |
morbidity adhd | #1 |
adhd total score | #1 |
childhood genetic background | #1 |
bpi disorder youth | #1 |
large controlled study | #1 |
sud phenotypes | #1 |
add pdics | #1 |
symptoms adult | #1 |
individuals adhd | #1 |
males overweight obesity | #1 |
subthreshold adhd subjects | #1 |
antisocial families | #1 |
adhd gwas | #1 |
transmission parents | #1 |
fhrscz | #1 |
risk substance disorders | #1 |
mania rates | #1 |
longitudinal outcome boys | #1 |
genetic correlations schizophrenia | #1 |
moderating effects patterns | #1 |
parental panic depression | #1 |
laboratory driving simulation | #1 |
adhd bipolar comorbidity | #1 |
persons rels | #1 |
adhd girls | #1 |
association psychiatric comorbidity | #1 |
adulthood genetic architecture | #1 |
nonreferred | #1 |
rs2272080 | #1 |
lifetime adhd | #1 |
stimulants childhood | #1 |
impulsiveness inattention | #1 |
maf⩾1 | #1 |
evidence stimulant treatment | #1 |
risk opioid dependence | #1 |
9 nhe9 | #1 |
adhd social class | #1 |
add antisocial disorders | #1 |
adhd probands relatives | #1 |
cbt intervention adolescents | #1 |
population screen | #1 |
neuroleptic nonresponse | #1 |
report adhd | #1 |
paediatric patients adhd | #1 |
adhd genetic correlation | #1 |
hyperactivity biomarkers aadhd | #1 |
2 familial factors | #1 |
adhd iiv | #1 |
convergent functional genomic | #1 |
gsprs adhd | #1 |
adhd clinical characteristics | #1 |
lod213 | #1 |
marijuana smoking metaanalysis | #1 |
inattentive hyperactive | #1 |
schizotaxia schizophrenia | #1 |
rs916455 | #1 |
tova api aklt01 | #1 |
discordant twin study | #1 |
hyperactivity disorder adults | #1 |
future dsm | #1 |
diagnostic continuity | #1 |
qelbree | #1 |
cbcldesr | #1 |
dbds adhddbds | #1 |
paternal overtransmission | #1 |
motheronly | #1 |
adhddbds | #1 |
parental probands | #1 |
nr3c1 stress exposure | #1 |
adhd background | #1 |
loci asd symptoms | #1 |
groundskeeper | #1 |
learning disabilities girls | #1 |
unaffected siblings volumes | #1 |
genomesignificance | #1 |
stress exposure connectivity | #1 |
nmu oral | #1 |
masir ldx | #1 |
bpd relatives | #1 |
trypotphan hydroxylase | #1 |
akt1 snp markers | #1 |
d15s1012 | #1 |
diagnosis bpi disorder | #1 |
siblings adhd probands | #1 |
adhd girls adhd | #1 |
adhd familial risk | #1 |
p27e05 | #1 |
referred samples | #1 |
disorder schizotaxia | #1 |
adhd clinical trial | #1 |
relatives bpi | #1 |
git1 adhd | #1 |
disorder follow | #1 |
female gender boys | #1 |
adults ldx sizes | #1 |
mania referred children | #1 |
selfreport adhd | #1 |
ldx sizes children | #1 |
adhd clinical | #1 |
adhd bpi disorder | #1 |
impaired sensorimotor timing | #1 |
prs rtv | #1 |
weaknesses comorbidity | #1 |
35191 | #1 |
hyperactivity cognition | #1 |
mr005 | #1 |
female humans inhibition | #1 |
adhd asd youth | #1 |
exposure parental adhd | #1 |
gene aggressive behavior | #1 |
adhd adult disorder | #1 |
12allele | #1 |
rs9325032 | #1 |
anxiousdepressed | #1 |
conduct disorder aspd | #1 |
prescription stimulant nmu | #1 |
behavioral disinhibition offspring | #1 |
adhd prs rtv | #1 |
co‐expression modules | #1 |
adult samples adhd | #1 |
smoking cessation controls | #1 |
adhd gsprs | #1 |
suggestive linkage signals | #1 |
adhd mp | #1 |
hyperactivity databases | #1 |
adhd desr | #1 |
bipolar adhd | #1 |
pinslbl | #1 |
adult persistence adhd | #1 |
5ht1b receptor gene | #1 |
combination scientific data | #1 |
re‐review | #1 |
relatives add probands | #1 |
1 relatives | #1 |
dna methylation adhd | #1 |
paliperidone monotherapy | #1 |
rs3746544 rs1051312 | #1 |
adhd asthma | #1 |
metaanalysis controlled study | #1 |
relatives bpi probands | #1 |
matter volumes volumes | #1 |
83097 | #1 |
rs1799835 | #1 |
snps drd4 gene | #1 |
rs11568324 | #1 |
age1542 | #1 |
dao gene schizophrenia | #1 |
regions lgi | #1 |
adhd oxidative stress | #1 |
adhd maternal smoking | #1 |
rs12843268 | #1 |
quantitative analyses treatment | #1 |
nmu nasal nmu | #1 |
sob adhd | #1 |
falconer3 | #1 |
mph controls | #1 |
neuropsychologic function schizophrenia | #1 |
shifting sands | #1 |
fhraff | #1 |
120 normal controls | #1 |
clinical correlates ocd | #1 |
mddprss | #1 |
bpd anx | #1 |
adults diagnosis | #1 |
adhd social disability | #1 |
affective psychosis hraff | #1 |
adhd female individuals | #1 |
adhd highly | #1 |
chi25762 | #1 |
adhd families | #2 |
ncrl wky | #2 |
ldsc genetic correlations | #2 |
parents disorder | #2 |
alleles attention | #2 |
structured diagnostic interviews | #2 |
6 17 years | #2 |
adhd impact | #2 |
informant source | #2 |
iii attention | #2 |
adhd choice | #2 |
schizotaxia discussion | #2 |
adhd lower | #2 |
adhd subjects | #2 |
ratio081 | #2 |
disease humans inhibition | #2 |
6‐year longitudinal study | #2 |
female probands | #2 |
screening diagnosis treatment | #2 |
adult samples | #2 |
persistent attention | #2 |
subthreshold diagnoses | #2 |
unipolar relatives | #2 |
rs40184 | #2 |
rs1801028 | #2 |
efds adults | #2 |
lallele homozygotes | #2 |
adhd neuropsychological deficits | #2 |
desr children | #2 |
families schizophrenia patients | #2 |
adhd ldx | #2 |
adhd growth | #2 |
youth meaningful | #2 |
maoa comt | #2 |
quetiapine monotherapy treatment | #2 |
diagnosis attention | #2 |
siblings youth | #2 |
default network schizophrenia | #2 |
sud bpd | #2 |
psychiatrically | #2 |
bias child child | #2 |
major depression findings | #2 |
consecutively referred children | #2 |
genetic transmission | #2 |
cbcljbd children | #2 |
antisocial disorders relatives | #2 |
add probands | #2 |
adhd objective | #2 |
adhdliability | #2 |
affective probands | #2 |
617 years | #2 |
cbcl clinical | #2 |
shared genetic background | #2 |
cpt oih | #2 |
disorder adults | #2 |
ncrl | #2 |
adhd genetics | #2 |
background attention | #2 |
adhd assessed | #2 |
stimulants adults | #2 |
childhoodonset adhd | #2 |
target features | #2 |
adhd comparison subjects | #2 |
childhood adolescent adhd | #2 |
bpd adhd | #2 |
galantamine hbr placebo | #2 |
qualitative literature review | #2 |
structure adult adhd | #2 |
disorder conclusions | #2 |
dsm adhd | #2 |
manic children | #2 |
disorder add | #2 |
psychotic mood disorder | #2 |
140 girls | #2 |
disorders adhd | #2 |
neuroleptic dose reduction | #2 |
boys maoa | #2 |
treatment sud patients | #2 |
adhd case subjects | #2 |
adhd surface area | #2 |
familial adhd | #2 |
pdd overlap | #2 |
adhd risk icv | #2 |
scales sex | #2 |
blind raters | #2 |
concurrent attention | #2 |
age onset distribution | #2 |
ldsc heritability | #2 |
aklt01 | #2 |
heterogeneity schizophrenia | #2 |
d2s410 | #2 |
5 loci adhd | #2 |
youth attention | #2 |
disorder impact | #2 |
bipolar disorder symptomatology | #2 |
adhd bipolar | #2 |
association meta analysis | #2 |
disorders suds | #2 |
adhd combined subtype | #2 |
versus controls | #2 |
methodological complexities | #2 |
disorder girls | #2 |
dimesylate treatment | #2 |
dsmiiir adhd | #2 |
neuropsychoanalytic treatment | #2 |
adhd neuropsychological tests | #2 |
qualitative review | #2 |
consortium neuroscience | #2 |
assessed structured | #2 |
relatives | #2 |
mirsky | #2 |
ppv hyperactivity diagnostic | #2 |
enigma adventure | #2 |
immune disorder | #2 |
comorbidity probands | #2 |
chromosomes inclusion | #2 |
subsyndromal manifestations | #2 |
n2455 | #2 |
youth rates | #2 |
spectrum phenotypes | #2 |
factors adhd | #2 |
mood disorders adhd | #2 |
7point | #2 |
jackknife procedure | #2 |
probands relatives | #2 |
girls adhd | #2 |
viloxazine extendedrelease | #2 |
child behavioral inhibition | #2 |
adhd major depression | #2 |
odd girls | #2 |
scales adolescent | #2 |
adhd suds | #2 |
executive function outcome | #2 |
subjects conduct disorder | #2 |
expert clinician | #2 |
key cognitive phenotypes | #2 |
adhd bpd | #2 |
comparative profile analysis | #2 |
relatives add | #2 |
comorbidity disorders comorbidity | #2 |
adhd lifespan | #2 |
n‐acetylcysteine treatment | #2 |
parental anxiety disorders | #2 |
adhd outcomes | #2 |
weaknesses youth | #2 |
comorbidity attention | #2 |
2q143 | #2 |
n328917 | #2 |
large controlled | #2 |
age onset distributions | #2 |
effects paternal smoking | #2 |
familial risk analysis | #2 |
activation trigger | #2 |
juvenile bipolar phenotype | #2 |
cacng2 genes | #2 |
deficit sustained attention | #2 |
life social adjustment | #2 |
diabetes disorders | #2 |
hyperactivity female humans | #2 |
youth selfreports | #2 |
referred youth | #2 |
conners adult adhd | #2 |
support genetic factors | #2 |
symptoms neuropsychological | #2 |
adhd psychiatric disorders | #2 |
adhdprss | #2 |
young adult years | #2 |
adhd birth | #2 |
drug abuse dependence | #2 |
hypothalamic abnormalities | #2 |
prior reports | #2 |
scale asrs | #2 |
risk panic disorder | #2 |
cbcl profile | #2 |
schizophrenia pedigrees | #2 |
role adhd | #2 |
disease humans receptors | #2 |
bsfq | #2 |
multicenter adhd | #2 |
sex differences adhd | #2 |
control subjects adhd | #2 |
parents major depression | #2 |
investigator ratings | #2 |
ermph children | #2 |
18 dsm | #2 |
polygenic resilience score | #2 |
stimulants adhd | #2 |
dysfunction offspring | #2 |
stin2vntr | #2 |
emf impairments | #2 |
elusive indicators | #2 |
problems adhd | #2 |
twin studies adhd | #2 |
morning behavior | #2 |
case subjects adhd | #2 |
n17666 | #2 |
trauma adhd | #2 |
hyperactivity attention deficit | #2 |
methylphenidate attention | #2 |
strong heritability | #2 |
clinically referred | #2 |
masxr | #2 |
disorder oppositional | #2 |
disorder background | #2 |
maternal smoking mothers | #2 |
overlap mania | #2 |
association mtbi | #2 |
comorbidity adhd | #2 |
somatosensory functioning | #2 |
current adult adhd | #2 |
adhdonly | #2 |
modest evidence | #2 |
specific haplotype | #2 |
disorder children | #2 |
schizophrenia genetic studies | #2 |
underlying bipolarity | #2 |
n3199 | #2 |
comorbid conduct problems | #2 |
comparison probands | #2 |
aggressive symptoms | #2 |
n11221 | #2 |
pediatrically | #2 |
rates adhd | #2 |
child comorbidity | #2 |
addicted | #2 |
stimulant therapy | #2 |
method subjects | #2 |
probands | #2 |
models adhd | #2 |
manic switches | #2 |
adhd african americans | #2 |
relatives adhd | #2 |
millennium consortium | #2 |
antisocial disorders | #2 |
opioid induced hyperalgesia | #2 |
≥210 | #2 |
variance adult | #2 |
comorbid aggression | #2 |
combinedtype | #2 |
risk factor adhd | #2 |
candidate genetic pathways | #2 |
status rating scales | #2 |
testretest reliability screener | #2 |
adhd report | #2 |
selfmedicating | #2 |
comorbid conduct disorder | #2 |
multigenic inheritance | #2 |
hypothetical task | #2 |
hyperactivity impulsiveness | #2 |
serum neuroleptic activity | #2 |
lgi regions | #2 |
asrs health organization | #2 |
adherence stimulants | #2 |
allele schizophrenia | #2 |
derived phenotypes | #2 |
unweighted screener asrs | #2 |
actively reducing | #2 |
schizophrenia parahippocampal gyrus | #2 |
structured diagnostic | #2 |
findings children | #2 |
wwwhapmaporg | #2 |
initial stimulant | #2 |
adhd risk factor | #2 |
cnvs copy variants | #2 |
adhd conduct | #2 |
deficits efds | #2 |
adhd mph response | #2 |
comorbidity disorder | #2 |
schizophrenia calcineurin | #2 |
scz data | #2 |
familybased studies | #2 |
p161e05 | #2 |
schizophrenia interactions | #2 |
psychiatric comorbidity | #2 |
correlates adhd | #2 |
male psychiatric | #2 |
patterns comorbidity | #2 |
comorbid oppositional defiant | #2 |
adhd physical conditions | #2 |
postcleavage | #2 |
s038 | #2 |
enigma adhd | #2 |
efficacy stimulants | #2 |
rs3746544 | #2 |
hyperactivity diagnostic | #2 |
schizotypy handedness | #2 |
subsequent substance | #2 |
deficit hyperactivity disorder | #2 |
adhd adults | #2 |
risk add | #2 |
checklist clinical | #2 |
internal distractibility | #2 |
adolescents substance disorder | #2 |
wky ncrl | #2 |
function deficits | #2 |
cbcl desr | #2 |
personal satisfaction | #2 |
oral prescription | #2 |
snp12snp2ctgn | #2 |
attentional control effects | #2 |
deficits executive | #2 |
familial trait | #2 |
adhd major | #2 |
hantac | #2 |
naltrexone adults | #2 |
adhd emotional symptoms | #2 |
items screener | #2 |
studies adderall | #2 |
qtl linkage adhd | #2 |
psychoactive substance disorders | #2 |
conjfdr005 | #2 |
stress adhd | #2 |
dsmiv subtypes | #2 |
parent rating | #2 |
reward‐related activation | #2 |
developmental subtype | #2 |
molecular genetics schizophrenia | #2 |
derived diagnosis | #2 |
factors attention | #2 |
eye vergence | #2 |
iii adhd | #2 |
relatives schizophrenic | #2 |
idiopathic adhd | #2 |
juvenile antisocial | #2 |
levels comorbidity | #2 |
galantamine hbr | #2 |
disorder inattentive | #2 |
bipolar disorder relatives | #2 |
deficits adults | #2 |
evidence adhd | #2 |
disorder adolescent | #2 |
neuropsychological function girls | #2 |
adhd autism symptoms | #2 |
psychotic relatives | #2 |
deficits sustained attention | #2 |
bipolar disorder sud | #2 |
hypothesis adhd | #2 |
cigarette smoking suds | #2 |
expanded symptom criteria | #2 |
work needed | #2 |
adhd odd | #2 |
disorders findings | #2 |
6 17 | #2 |
familial association | #2 |
pilot adult | #2 |
small literature | #2 |
adverse effects subjects | #2 |
proinflammatory expansion | #2 |
expanded versions | #2 |
genome‐wide association scan | #2 |
adhd risk gene | #2 |
nonpsychotic relatives | #2 |
adhd height | #2 |
chromosomes 6 14 | #2 |
disorder findings | #2 |
regions studies | #2 |
separation attention deficit | #2 |
d0·18 | #2 |
infancy complications | #2 |
10092 | #2 |
adra2a polymorphism | #2 |
stimulants | #2 |
comorbid conduct | #2 |
dsm subtypes | #2 |
checklist scales | #2 |
attention‐deficit hyperactivity | #2 |
subjects desr | #2 |
cognition youth | #2 |
wiatii | #2 |
adhd disability | #2 |
rs1800955 | #2 |
association data | #2 |
adhd relatives | #2 |
variants adhd | #2 |
wky nhsd | #2 |
adhd adhd patients | #2 |
adhd acc | #2 |
schizophrenia twin studies | #2 |
child comorbidity illness | #2 |
adhd combined | #2 |
systematized delusions | #2 |
subjects criteria | #2 |
rs6938431 | #2 |
adhd icv | #2 |
bmi adhd symptoms | #2 |
consecutively referred | #2 |
bidirectional overlap | #2 |
disorders similarities | #2 |
adhd comparison | #2 |
treatment childhood adhd | #2 |
nicotine substance | #2 |
g72 daao | #2 |
cbsk | #2 |
efds | #2 |
preventing schizophrenia | #2 |
adhd control subjects | #2 |
n2246 | #2 |
relatives simplex families | #2 |
rates bpd | #2 |
health organization asrs | #2 |
euphorigenic effects | #2 |
adults adhd | #2 |
morbidity dysfunction | #2 |
hrscz | #2 |
rates odd | #2 |
n1934 | #2 |
6p243 | #2 |
eye vergence responses | #2 |
bpd sud | #2 |
anx bipolar disorder | #2 |
clinically referred children | #2 |
d10s1432 | #2 |
tourette spectrum | #2 |
subjects adults | #2 |
risk female cases | #2 |
dsmjbd | #2 |
adhd genes | #2 |
genome‐wide association data | #2 |
adults attention | #2 |
amses | #2 |
adhd comorbid problems | #2 |
performancemeasures | #2 |
dsmiv adhd | #2 |
acpts | #2 |
adhd method | #2 |
actively reducing severity | #2 |
suggestive linkage loci | #2 |
adhd adhd children | #2 |
disorder studies | #2 |
wm deficits | #2 |
smoking probands | #3 |
teacher reports | #3 |
27 risk loci | #3 |
schizophrenia allele | #3 |
ermph | #3 |
schizoaffective bipolar disorder | #3 |
md adhd | #3 |
bipolar psychoses | #3 |
comt adhd | #3 |
cortical thickness cases | #3 |
longitudinal follow | #3 |
comt promoter | #3 |
comorbidities adhd | #3 |
ocd groups asd | #3 |
relatives bipolar disorder | #3 |
prenatal adversities | #3 |
adhd metaanalysis | #3 |
candidate gene studies | #3 |
qtl linkage | #3 |
sibling trait | #3 |
relationship adhd | #3 |
nmu prescription stimulants | #3 |
7repeat allele | #3 |
weight effects | #3 |
familial risk factors | #3 |
adhd emotional | #3 |
stimulants treatment | #3 |
13q222 | #3 |
risk panic | #3 |
model adhd | #3 |
adhd comorbid conditions | #3 |
nervous stimulants | #3 |
disease humans interviews | #3 |
familial nature | #3 |
genetics initiative | #3 |
morning school | #3 |
adhd psud | #3 |
comorbidity diagnosis | #3 |
childhood attention‐deficit | #3 |
508e7 | #3 |
clinically referred adults | #3 |
vulnerability indicators | #3 |
adhd mental disorders | #3 |
relatives proband groups | #3 |
adhd polygenic | #3 |
checklist cbcl | #3 |
adhd rare cnvs | #3 |
cgsq | #3 |
intron13 | #3 |
sexdifferentiated effects | #3 |
wonderlic personnel test | #3 |
social perception skills | #3 |
cbcl scales | #3 |
deficient emotional | #3 |
growth deficits | #3 |
adhd pairwise correlations | #3 |
major depression comorbidity | #3 |
impairment adhd | #3 |
interactions schizophrenia | #3 |
adult psychiatric outcomes | #3 |
risk factors sud | #3 |
sirolimus 12 months | #3 |
adhd mania | #3 |
rs6565113 | #3 |
topic adolescent | #3 |
adhd risk | #3 |
ldx amphetamine | #3 |
faraone reply | #3 |
chromosome 10q22 | #3 |
asd ocd groups | #3 |
parents panic disorder | #3 |
intra‐individual variability | #3 |
adhd stimulant medication | #3 |
subjects sud | #3 |
manic symptoms children | #3 |
asthma adhd | #3 |
dat1 | #3 |
dsmiiir diagnosis | #3 |
schizophrenic outpatients | #3 |
pdd adhd | #3 |
comorbidity panic disorder | #3 |
drd4 7 | #3 |
adhd common | #3 |
enigma global neuroscience | #3 |
youths ocd | #3 |
adolescent adhd | #3 |
cigarette smoking children | #3 |
atomoxetine response | #3 |
enigma wgs wgs | #3 |
educational deficits | #3 |
anxiety disorders parents | #3 |
smds scz | #3 |
adhd data | #3 |
amphetamines attention | #3 |
networks adhd | #3 |
psychopathologic conditions | #3 |
temperamental correlates | #3 |
adhd implications | #3 |
bipolar disease | #3 |
tic disorders adhd | #3 |
sud offspring | #3 |
npl scores | #3 |
notch4 schizophrenia | #3 |
schizophrenia neurocognitive performance | #3 |
defined adhd | #3 |
metadoxine extended release | #3 |
adhd bipolar disorder | #3 |
methylphenidate studies | #3 |
evidence genetic association | #3 |
“negativity | #3 |
gsprs | #3 |
schizotaxia | #3 |
sud youths | #3 |
psychiatric comorbidity adhd | #3 |
children mania | #3 |
genetic receptors serotonin | #3 |
association confounders | #3 |
control probands relatives | #3 |
common disorders brain | #3 |
syndromatic | #3 |
nicotine disorders | #3 |
schizophrenia schizotaxia | #3 |
experienced pain | #3 |
hyperactivity attention | #3 |
vcfsadhd | #3 |
adhd wm deficits | #3 |
conduct disorder adhd | #3 |
disorder conduct | #3 |
ptsd adhd | #3 |
7 repeat | #3 |
substances symptoms | #3 |
reln promoter | #3 |
european‐american | #3 |
snps haplotype | #3 |
hyperactivity bipolar | #3 |
morbidity risk | #3 |
adhdpi | #3 |
md females | #3 |
excess transmission | #3 |
alcohol adhd | #3 |
abstraction verbal memory | #3 |
studies square | #3 |
non500 | #3 |
brain methylation | #3 |
anxiety disorders authors | #3 |
similarities genetic etiology | #3 |
n5827 | #3 |
drug nicotine | #3 |
9rcarriers | #3 |
enuresis adhd | #3 |
disabilities male | #3 |
asrs v11 | #3 |
potential gene | #3 |
adhd mtbi | #3 |
psychotic behaviour | #3 |
n2271 | #3 |
mtbi studies | #3 |
dose response effects | #3 |
neurological polymorphism | #3 |
probands parental | #3 |
substance disorders adhd | #3 |
inattentive subtype | #3 |
n2323 | #3 |
simulated workplace laboratory | #3 |
remittent | #3 |
emotional dysregulation adhd | #3 |
cognition comorbidity | #3 |
learning disabilities adhd | #3 |
siblings young | #3 |
international adhd | #3 |
mania disorders | #3 |
highly heritable disorder | #3 |
resilience score | #3 |
67e07 | #3 |
parental substance disorders | #3 |
hyperactivity central | #3 |
neuropsychiatric disorders similarities | #3 |
controls 6 disorders | #3 |
observed age | #3 |
zakzanis | #3 |
disproportionate impairment | #3 |
disorders conclusions | #3 |
htr1e | #3 |
predisposition schizophrenia | #3 |
global neuroscience decade | #3 |
variance severity | #3 |
schizophrenia genotype | #3 |
adhd systematic review | #3 |
n1777 | #3 |
petronis | #3 |
desr | #3 |
caarsss | #3 |
response methylphenidate | #3 |
naltrexone methylphenidate | #3 |
structural imaging findings | #3 |
manic symptoms youth | #3 |
dmi addh | #3 |
sud children | #3 |
children vcfsadhd | #3 |
impact adhd | #3 |
adhd control | #3 |
children adhd | #3 |
pairwise correlations disorders | #3 |
parents panic | #3 |
lbw adhd | #3 |
adhd psychiatric comorbidity | #3 |
enigma neuroimaging genetics | #3 |
oprm1 variants | #3 |
adhd presence | #3 |
firstdegree relatives | #3 |
deficits height | #3 |
girls attention | #3 |
relatives persons | #3 |
disorder comorbid | #3 |
drd5 marker | #3 |
nonpsychotic relatives persons | #3 |
persistence psychiatric disorders | #3 |
lambdasib | #3 |
large battery | #3 |
adolescents mania | #3 |
anxiety behavioral inhibition | #3 |
cpt deficits | #3 |
bpd rates | #3 |
tsuang | #3 |
mania children | #3 |
adhd ptsd | #3 |
adhd mdd | #3 |
adhd combined type | #3 |
z280 | #3 |
impulsivity errors | #3 |
children adhd diagnosis | #3 |
treatment seeking patients | #4 |
cbcljbd phenotype | #4 |
asd mood disorders | #4 |
disorders attention | #4 |
roh risk | #4 |
humans lisdexamfetamine | #4 |
anxiety disorders mdd | #4 |
factors substance | #4 |
psc35 | #4 |
independent transmission | #4 |
cbclaps | #4 |
shr ncrl | #4 |
risk factors bpd | #4 |
receiver operator characteristic | #4 |
stimulantnaïve | #4 |
disorders panic | #4 |
hypescheme | #4 |
mhlod | #4 |
inattentive adhd | #4 |
inhibition anxiety | #4 |
subthreshold | #4 |
rels | #4 |
46222 | #4 |
controls basal ganglia | #4 |
preterm sample | #4 |
rs140700 | #4 |
findings risk | #4 |
expected height | #4 |
adhd impairments | #4 |
treatment stimulant medication | #4 |
increased neural responses | #4 |
primary substance abuse | #4 |
psychiatric gene discoveries | #4 |
height deficits | #4 |
adhd substance abuse | #4 |
parents bpd | #4 |
health female | #4 |
psychiatrically referred youth | #4 |
hemmings | #4 |
adolescent outcome | #4 |
subsequent substance disorders | #4 |
adolescent years | #4 |
deficits executive functioning | #4 |
bipolar disorder linkage | #4 |
adderall methylphenidate | #4 |
relatives normal controls | #4 |
anxiety disorders offspring | #4 |
4th international meeting | #4 |
child behavior checklist | #4 |
gxr adhd | #4 |
motor coordination problems | #4 |
snps intelligence | #4 |
global neuroscience | #4 |
depression parental depression | #4 |
reported findings | #4 |
adhd neuropsychological performance | #4 |
suds adolescents | #4 |
strattera | #4 |
report scale | #4 |
homogeneous subtypes | #4 |
pediatric mania | #4 |
maternal smoking alcohol | #4 |
offspring sud | #4 |
adhd youth | #4 |
metadoxine placebo | #4 |
rutters indicators | #4 |
families girls | #4 |
risk factors adhd | #4 |
snpbased | #4 |
children comorbid adhd | #4 |
developmental improvement | #4 |
fmri replication | #4 |
disorders comorbidity | #4 |
secondary psychotic symptoms | #4 |
support mechanism | #4 |
sud bpd sud | #4 |
chinese sample | #4 |
17q111q12 | #4 |
adhd brain regions | #4 |
bpd sud patients | #4 |
pord05 | #4 |
acting formulations | #4 |
adhd subgroups | #4 |
quantitative phenotype | #4 |
d4s1644 | #4 |
transporter genotypes | #4 |
remittent adhd | #4 |
poor motor performance | #4 |
selenbp1 schizophrenia | #4 |
presence adhd | #4 |
total score week | #4 |
4year followup | #4 |
comorbid aggression adhd | #4 |
odd adhd | #4 |
adults | #4 |
disease genome humans | #4 |
treatment adhd | #4 |
neuropsychological performance schizophrenia | #4 |
risk variants adhd | #4 |
maoa | #4 |
vulnerability schizophrenia | #4 |
parental panic | #4 |
schizophrenia genetic factors | #4 |
md individuals | #4 |
rate switching | #4 |
disorders neuropsychological | #4 |
adhd status | #4 |
angerirritability | #4 |
subjects schizotaxia | #4 |
adhd children mph | #4 |
impaired intellect | #4 |
mts growth | #4 |
enrichment adhd | #4 |
substance disorders suds | #4 |
reward dysfunction | #4 |
vcfs adhd | #4 |
objective studies | #4 |
reported adhd | #4 |
tests psychiatric | #4 |
safren | #4 |
rs3916968 | #4 |
adhd based | #4 |
bpd sud bpd | #4 |
time reproduction | #4 |
rs3916971 | #4 |
psychiatric comorbidity risk | #4 |
openlabel studies | #4 |
image sample | #4 |
achievement goal orientation | #4 |
comorbid psychiatric | #4 |
choice adhd | #4 |
adhd participants | #4 |
aggregation adhd | #4 |
comorbidity humans | #4 |
adhd md | #4 |
pavgrnk000417 | #4 |
rates psychiatric | #4 |
behavior checklist | #4 |
female probands relatives | #4 |
neuropsychoanalytic | #4 |
notch4 locus | #4 |
metaanalyzes | #4 |
growing literature | #4 |
adhd individuals | #4 |
attention adhd | #4 |
adhd pharmacogenetic studies | #4 |
scores adhd | #4 |
sd133 | #4 |
disorder objective | #4 |
phenotypes adhd | #4 |
risk gene schizophrenia | #4 |
cbcl | #4 |
adhd pdd | #4 |
lgi age | #4 |
nonoral routes administration | #4 |
gender children | #4 |
adhd adulthood | #4 |
adhd controls | #4 |
relatives controls | #4 |
enigmaadhd | #4 |
adhd pharmacotherapy | #4 |
vcfs sample | #4 |
psud | #4 |
differences adults | #4 |
handedness schizotypy | #4 |
familial vulnerability | #4 |
boys higher prevalence | #4 |
rs1079727 | #4 |
adhd association | #4 |
jbd | #4 |
adhd control children | #4 |
rs3785143 | #4 |
adhd symptom | #4 |
comorbid attention | #4 |
adhd etiology | #4 |
rutter | #4 |
onset adhd | #4 |
genetic heterogeneity schizophrenia | #4 |
adhd reported | #4 |
psychiatrically referred | #4 |
executive function deficits | #4 |
d4s2361 | #4 |
quantitative models | #4 |
functioning adhd | #4 |
panic disorder pregnancy | #4 |
distinct disorder | #4 |
lifetime dimensions | #4 |
addictive drug | #4 |
treatment adult adhd | #4 |
intelligence snps | #4 |
coordination problems | #4 |
large collaborative study | #5 |
adhd ld | #5 |
torture review | #5 |
referred children | #5 |
children ldx | #5 |
pathways association | #5 |
ppp3cc schizophrenia | #5 |
elevated rates | #5 |
puwma | #5 |
comorbid disorders | #5 |
diagnosis mania | #5 |
boys attention | #5 |
d22s683 | #5 |
cardinal symptom | #5 |
panic disorder parents | #5 |
grubb | #5 |
anxiety disorders anx | #5 |
serum neuroleptic | #5 |
highly heritable | #5 |
adhd tic disorders | #5 |
adhd cases | #5 |
etiopathologies | #5 |
interview psychological | #5 |
adult attention | #5 |
disorder parents | #5 |
3 probands | #5 |
adhd comorbid anxiety | #5 |
resilience project | #5 |
nt5dc1 | #5 |
ascertainment source | #5 |
disorder sud | #5 |
report screening | #5 |
psychiatric correlates | #5 |
parents psychiatric | #5 |
social disability | #5 |
nonmedical nmu | #5 |
children dbds | #5 |
initial responsiveness | #5 |
pdmd | #5 |
risk factors schizophrenia | #5 |
dsm age | #5 |
year prospective | #5 |
impaired parents humans | #5 |
intellectually capable adults | #5 |
wcst scores | #5 |
desistent | #5 |
inhibited children | #5 |
criteria schizotaxia | #5 |
referred sample | #5 |
adhd adult | #5 |
palauan | #5 |
youth vcfs | #5 |
oosterlaan | #5 |
3q13 | #5 |
neuropsychological risk | #5 |
severe scores | #5 |
sud | #5 |
2nd cohort | #5 |
kuntsi | #5 |
adult probands | #5 |
disorders follow | #5 |
relatives female probands | #5 |
adhd bupropion | #5 |
oppositional defiant disorder | #5 |
height weight | #5 |
proband risk | #5 |
referred youths | #5 |
parental adhd | #5 |
organization adult | #5 |
asrs screener | #5 |
psychiatric disorders study | #5 |
neuropsychiatric comorbidity | #5 |
mood disorders asd | #5 |
adhd nonaffected siblings | #5 |
desipramine placebo | #5 |
disorder anxiety | #5 |
child child behavior | #5 |
adolescence adhd | #5 |
conventional medications | #5 |
aagc | #5 |
disorder genetic | #5 |
adhd inattentive type | #5 |
sms intervention | #5 |
methylphenidate adults | #5 |
humans interview | #5 |
hyperactivity caregivers | #5 |
zmynd17 | #5 |
adhd treated | #5 |
multivariate endophenotypes | #5 |
growth dysregulation | #5 |
ncrl rats | #5 |
onset criterion | #5 |
auditory vigilance | #5 |
mania adhd | #5 |
memantine hydrochloride | #5 |
depression panic disorder | #5 |
inattentive symptoms | #5 |
major depression parents | #5 |
tass | #5 |
psychosis velocardiofacial syndrome | #5 |
shared haplotypes | #5 |
lifetime impact | #5 |
impairment baseline | #5 |
rs1799836 | #5 |
adolescent alleles | #5 |
disorders psychiatric | #5 |
pdd subjects | #5 |
effects adhd | #5 |
function adhd | #5 |
clinical obesity | #5 |
cbcl data | #5 |
pleiotropic effects disorders | #5 |
xr adults | #5 |
kiddieschedule | #5 |
female individuals | #5 |
psychosis scale | #5 |
disorder rating | #5 |
risk anxiety | #5 |
prembr | #5 |
unipolar mdd | #5 |
nonaffected siblings | #5 |
schizophrenia palau | #5 |
familial risk adhd | #5 |
impairment survey | #5 |
adhd response | #5 |
symptoms hyperactivity | #5 |
familial distribution | #5 |
genetic linkage schizophrenia | #5 |
adults adult | #5 |
hechtman | #5 |
bipolar disorder pedigrees | #5 |
adhd youths | #5 |
bipolar disorder bpd | #5 |
study genetic factors | #5 |
screener | #5 |
adhdlike symptoms | #5 |
scale adhd | #5 |
sex adhd | #5 |
iiv adhd | #5 |
parental sud | #5 |
mothers anxiety disorders | #5 |
combined subtype | #5 |
familial subtypes | #5 |
checklist child | #5 |
risk relatives | #5 |
hyperactivity clinical trials | #5 |
behavioral inhibition children | #5 |
dopamine risk | #5 |
maternal reports | #5 |
unfamiliar situations | #6 |
interpreting estimates | #6 |
males adhd | #6 |
premorbid cognitive ability | #6 |
chromosome 15 locus | #6 |
ascertained | #6 |
cbcljbd | #6 |
symptoms adhd | #6 |
adhd genetic factors | #6 |
behavioral inhibition | #6 |
criteria adhd | #6 |
p1e04 | #6 |
t518 | #6 |
risk attention | #6 |
psychopathology children | #6 |
dnajc9 | #6 |
nhe inhibitors | #6 |
tmcq | #6 |
followup studies | #6 |
adults disorder | #6 |
adhd increased risk | #6 |
familial loadings | #6 |
schizophrenia deficit | #6 |
loci autism | #6 |
adhdia | #6 |
disorder combined | #6 |
pediatric bpd | #6 |
groups adults | #6 |
psychiatric disorders prss | #6 |
oceanic palau | #6 |
parental major depression | #6 |
druggable genome | #6 |
nmu | #6 |
dopamine transporter gene | #6 |
value09 | #6 |
140 children | #6 |
neuroleptic activity | #6 |
risk sud | #6 |
depression panic | #6 |
teenage parenthood | #6 |
prevalence adult adhd | #6 |
bpdsud | #6 |
association studies schizophrenia | #6 |
relatives probands | #6 |
individual alleles | #6 |
pediatric bipolar | #6 |
genome‐wide | #6 |
hierarchical factor model | #6 |
liability schizophrenia | #6 |
niacin schizophrenia | #6 |
stimulant treatment children | #6 |
normal sexual dimorphism | #6 |
year recall | #6 |
4634 | #6 |
environmental adversity | #6 |
stimulant prescription | #6 |
pavgrnk | #6 |
adhd mood disorders | #6 |
genetic linkage genome | #6 |
hyperactivity disease models | #6 |
adhd compared | #6 |
adhd variability | #6 |
downward extension | #6 |
parents major | #6 |
total gray matter | #6 |
clinical features children | #6 |
life adults | #6 |
objective marker | #6 |
referred children adolescents | #6 |
altered neural connectivity | #6 |
schizophrenia g72 | #6 |
oppositional defiant | #6 |
clinical scales | #6 |
literature efficacy | #6 |
wm performance patients | #6 |
adhd mental retardation | #6 |
symptoms disorder | #6 |
placebo response response | #6 |
neuropsychological functioning | #6 |
paternal age schizophrenia | #6 |
referred adults | #6 |
differences cortical thickness | #6 |
mixed amphetamine | #6 |
children relatives | #6 |
cognition adults | #6 |
maniclike symptoms | #6 |
cognitive impairments adhd | #6 |
ppp3cb | #6 |
driving simulation | #6 |
benefitrisk ratio | #6 |
t515 | #6 |
dsm iii | #6 |
pseudocontrols | #6 |
adhd firstdegree relatives | #6 |
male odds | #6 |
fspd | #6 |
adhd women | #6 |
prior stimulant treatment | #6 |
anxiety disorder relatives | #6 |
large heterogeneous | #6 |
child delayed | #6 |
bpd comorbid | #6 |
hyperactivity child chromosomes | #6 |
schizophrenia premorbid | #6 |
cpg sites methylation | #6 |
adhd life | #6 |
disorders adolescent | #6 |
psychoactive substance | #6 |
disorders relatives | #6 |
enigma wgs | #6 |
combined condition | #6 |
irmph | #6 |
specific predictor | #6 |
schizophrenic probands | #6 |
scales psychometrics | #6 |
facial memory | #6 |
pediatric mood disorders | #6 |
bpd controls | #6 |
vulnerability indicator | #6 |
taan | #6 |
concurrent validation | #6 |
seidman | #6 |
gxr efficacy | #6 |
xp114p113 | #6 |
adhd tic | #6 |
adhd children adults | #6 |
schizophrenia spectrum schizophrenia | #6 |
psychiatric | #6 |
nonparanoid schizophrenia | #6 |
combined subtypes | #6 |
genetic child | #6 |
females adhd | #6 |
flush response | #7 |
palauans | #7 |
adhd improvement | #7 |
prevention schizophrenia | #7 |
relatives risk | #7 |
velo‐cardio‐facial | #7 |
drd5 | #7 |
long repeats | #7 |
childhood disorder | #7 |
mph adhd adults | #7 |
methylomics | #7 |
ldx treatment | #7 |
parents psychiatric disorders | #7 |
child impaired | #7 |
children bpd | #7 |
highrisk siblings | #7 |
children tourettes syndrome | #7 |
controls probands | #7 |
pmee | #7 |
coming years | #7 |
parents prevalence | #7 |
nmu prescription | #7 |
hyperactivity brain | #7 |
adhd symptoms | #7 |
development adhd | #7 |
exome chip analyses | #7 |
neuroimage study | #7 |
locus haplotypes | #7 |
pdag mdd | #7 |
chromosome workshop | #7 |
adhd criteria | #7 |
n1031 | #7 |
adhd asrs | #7 |
disorder substance | #7 |
candidate gene schizophrenia | #7 |
measures adhd | #7 |
markov chain analysis | #7 |
persistence anxiety disorders | #7 |
nalysis | #7 |
adhd emotional dysregulation | #7 |
genome‐wide association | #7 |
haplotype schizophrenia | #7 |
dependence rates | #7 |
implicating | #7 |
asd youth | #7 |
statistical measure | #7 |
members schizophrenia | #7 |
outpatient child | #7 |
relatives schizophrenic patients | #7 |
children learning disorders | #7 |
mdd pdag | #7 |
combined type adhd | #7 |
polygenic scores adhd | #7 |
conduct disorder girls | #7 |
adhdrs | #7 |
idir | #7 |
systematic chart review | #7 |
dimensional measures | #7 |
sensorimotor timing | #7 |
adhd persistence | #7 |
adhdct | #7 |
teachers boys | #7 |
confusability | #7 |
adhd overweight obesity | #7 |
nrp104 | #7 |
tomoxetine | #7 |
myosin5b | #7 |
spn812 | #7 |
qlesqsf | #7 |
exon15 | #7 |
odd | #7 |
attention task | #7 |
mph adhd | #7 |
neurocognitive performances | #7 |
kgas | #7 |
hraff | #7 |
adhd sud sud | #7 |
pediatric major depression | #7 |
adhd substance disorders | #7 |
asd asd youth | #7 |
association cdh13 | #7 |
swedish registry data | #7 |
boys adhd | #7 |
authors goal | #7 |
6 psychiatric disorders | #7 |
pdqr | #7 |
methylphenidate therapy | #7 |
adhd authors | #7 |
skin flush response | #7 |
studies dopamine | #7 |
seeking substance | #7 |
adhd boys girls | #7 |
bipolar unipolar disorders | #7 |
saica | #7 |
wonderlic | #7 |
parent reports | #7 |
snap25 adhd | #7 |
adhd symptoms association | #7 |
ancestry attention | #7 |
disorders probands | #7 |
pempirical | #8 |
notch4 | #8 |
pliszka | #8 |
schizophrenia members | #8 |
affairs cooperative | #8 |
biological relatives | #8 |
participants adhd | #8 |
probands risk | #8 |
attention | #8 |
familial aggregation adhd | #8 |
adhd rtv | #8 |
agreement measures | #8 |
cadhd | #8 |
chromosome schizophrenia | #8 |
stimulanttreated | #8 |
bpd disorders | #8 |
metaanalysis schizophrenia | #8 |
impaired motor performance | #8 |
mwq | #8 |
link adhd | #8 |
euphoria | #8 |
onset bpd | #8 |
schizophrenia polymorphisms | #8 |
differential utility | #8 |
adhd associations | #8 |
male multifactorial inheritance | #8 |
child diagnostic | #8 |
adhd inattentive | #8 |
rs3916965 | #8 |
behavioral inhibition risk | #8 |
shared familial effects | #8 |
treatment sirolimus | #8 |
treatment lead | #8 |
adhd symptom scores | #8 |
adhd stimulant | #8 |
studies provide | #8 |
diagnosed adhd | #8 |
unaffected siblings adhd | #8 |
therapeutic dilemmas | #8 |
presence autistic traits | #8 |
controls relatives | #8 |
gender effects | #8 |
rs3916966 | #8 |
prescription stimulant | #8 |
familybased association study | #8 |
substantial evidence | #8 |
negative symptoms scale | #8 |
nonpsychotic | #8 |
avoidant disorder | #8 |
ordered subsets | #8 |
sample youth | #8 |
attention deficit adhd | #8 |
autistic traits children | #8 |
adhd adolescence | #8 |
multigenerational pedigree | #8 |
disease humans polymorphism | #8 |
adhdhi | #8 |
human aggression | #8 |
analysis association | #8 |
polygenic associations | #8 |
behavior attention | #8 |
disorder probands | #8 |
biederman | #8 |
offspring trios | #8 |
disorders baseline | #8 |
indicators schizophrenia | #8 |
adhdcd | #8 |
symptoms impairment | #8 |
disorders families | #8 |
adhd manic symptoms | #8 |
psychiatric genomics | #8 |
n1314 | #8 |
mph adults | #8 |
hemideletion | #8 |
control adhd | #8 |
crossover comparison | #8 |
volumetric reductions | #8 |
nonverbal social | #8 |
adhd unaffected | #8 |
promising directions | #8 |
dimesylate ldx | #8 |
adhd remission | #8 |
diagnosis major depression | #8 |
10q223 | #8 |
behavioral inhibition anxiety | #8 |
subjects children | #8 |
adhd boys | #8 |
adhd dat1 | #8 |
aversion adhd | #8 |
symptoms behaviors | #8 |
impulsivity adhd | #8 |
pvalues005 | #8 |
abbreviated questionnaire | #8 |
childhood mania | #8 |
neuropsychologic function | #9 |
disorders sex interaction | #9 |
hhrr | #9 |
adhdi | #9 |
ecpbhs | #9 |
adderall | #9 |
aisrs | #9 |
taiwanese families | #9 |
symptoms mania | #9 |
ads individuals | #9 |
25e07 | #9 |
nuremberg code | #9 |
gwas psychiatric disorders | #9 |
serotonin genes | #9 |
alzheimer disease schizophrenia | #9 |
proband groups | #9 |
stimulant medication | #9 |
n41 | #9 |
pregnancy depression | #9 |
39 datasets | #9 |
hum genet | #9 |
festschrift | #9 |
nonreplications | #9 |
netherlands twin registry | #9 |
nonparanoids | #9 |
schizotaxic | #9 |
ldps | #9 |
lag sequential analysis | #9 |
mdd youth | #9 |
substantial risk | #9 |
hyperactivity automobile | #9 |
moderate sensitivity | #9 |
comparison girls | #9 |
male nuclear | #9 |
diagnostic efficiency | #9 |
schizophrenia resilience | #9 |
depression offspring | #9 |
inattentive | #9 |
hyperactivity humans | #9 |
deficit disruptive | #9 |
endophenotypic | #9 |
disruptive behavior disorders | #9 |
adhd enuresis | #9 |
haplotype snps | #9 |
childhood psychosis | #9 |
genes risk factors | #9 |
etiologically | #9 |
children assessed | #9 |
rpdr | #9 |
extendedrelease methylphenidate | #9 |
snp7 | #9 |
serotonin gene polymorphisms | #9 |
dao gene | #9 |
orosmph irmph | #9 |
adult report | #9 |
adult symptoms | #9 |
blindly | #9 |
subtypes adhd | #9 |
g×s interaction disorders | #9 |
comorbidity female | #9 |
addh | #9 |
adhd healthy | #9 |
sud bipolar disorder | #9 |
rs685012 | #9 |
rasd2 | #9 |
adhd article | #9 |
sustained attention schizophrenia | #9 |
adhd loci | #9 |
stimulants humans | #10 |
genetic vulnerability schizophrenia | #10 |
pthreshold | #10 |
risk md | #10 |
sexual dimorphisms | #10 |
childhood adhd symptoms | #10 |
adhd quality | #10 |
4th | #10 |
probands bpd | #10 |
new specialty | #10 |
anxiety disorders children | #10 |
stimulants child | #10 |
nephews | #10 |
cbclap | #10 |
systematic qualitative review | #10 |
drd4 | #10 |
normal sexual | #10 |
association dat1 | #10 |
shared neurobiology | #10 |
genes disorders | #10 |
psychiatric clinic | #10 |
severity adhd | #10 |
adult years | #10 |
small effects | #10 |
sleep problems adhd | #10 |
irmph orosmph | #10 |
adhd childhood | #10 |
untreated adhd | #10 |
genetics network | #10 |
case identification | #10 |
rorb | #10 |
rates abuse | #10 |
adhd difficulties | #10 |
amphetamine salts | #10 |
asd tourette syndrome | #10 |
gwas adhd | #10 |
groups boys | #10 |
young adult outcome | #10 |
reassessed | #10 |
evidence genetic | #10 |
comorbidity depressive | #10 |
ascertainment methods | #10 |
comorbidity | #10 |
dms1 | #10 |
bipolar disorder probands | #10 |
parent‐of‐origin effects | #10 |
adhd unaffected siblings | #10 |
image project | #10 |
slod | #10 |
disorder age | #10 |
adhd substance disorder | #10 |
linkage analyses | #10 |
comorbid odd | #10 |
aged attention | #10 |
psychiatric genetic studies | #10 |
panic depression | #10 |
caadid | #10 |
conduct disorder | #10 |
association death | #10 |
diminished risk | #10 |
nonpharmacologic treatments | #10 |
kruglyak | #10 |
d4 receptor gene | #10 |
comorbid bpd | #10 |
adhd sud | #10 |
noninhibited | #10 |
preschool depressive | #10 |
adulthood association | #10 |
preteen | #10 |
deficits adhd | #10 |
shr model | #11 |
differentiated genetic | #11 |
sample adults | #11 |
inattentive type | #11 |
release methylphenidate | #11 |
adhd substance | #11 |
paternal smoking | #11 |
adhd psychopathology | #11 |
gene adhd | #11 |
diagnosis adults | #11 |
children bipolar | #11 |
studies mtbi | #11 |
maternal antenatal anxiety | #11 |
disorders | #11 |
disease humans schizophrenia | #11 |
rs1137070 | #11 |
disorder pedigrees | #11 |
nosologists | #11 |
familybased association test | #11 |
panic disorder comorbidity | #11 |
n136 | #11 |
polymorphism 5 | #11 |
youth bpd | #11 |
serotonin genetic receptor | #11 |
differences parents | #11 |
ppp3cc | #11 |
major depression adhd | #11 |
adhd intellectual disability | #11 |
fbatpc | #11 |
neuropsychological test scores | #11 |
real progress | #11 |
dimesylate | #11 |
vcfs | #11 |
comorbidity patterns | #11 |
adhd onset | #11 |
defiant disorder | #11 |
psychiatric disorders youth | #11 |
achievement adolescent | #11 |
juvenile mania | #11 |
cardinal symptoms | #11 |
prodromal psychosis | #11 |
adhd female humans | #11 |
hyperactivity child cross | #11 |
disorders mothers | #11 |
shared familial | #11 |
adhd time | #11 |
study perspective | #11 |
children addh | #11 |
cutraits | #11 |
etiology pathophysiology | #11 |
pediatric bipolar disorder | #11 |
adult relatives | #11 |
lisdexamfetamine ldx | #11 |
preschool depressive disorder | #11 |
inhibition adhd | #11 |
ldx placebo | #11 |
hydrochloride attention | #11 |
nonadhd controls | #11 |
effects genes | #11 |
4372 | #11 |
growth delays | #11 |
rora rorb | #11 |
informativeness | #11 |
multiple domains | #11 |
deficits schizophrenia patients | #11 |
dopamine d5 receptors | #11 |
symptom subtype | #11 |
offspring bipolar parents | #11 |
female relatives | #11 |
markers adhd | #11 |
differences adhd | #11 |
adolescents adhd | #11 |
remission adhd | #11 |
attention deficit disorder | #11 |
agoraphobia anxiety | #11 |
impaired parents child | #12 |
epilepsy mothers | #12 |
multiplex schizophrenia | #12 |
variable age | #12 |
impaired parents | #12 |
adhd dopamine | #12 |
obesity adhd | #12 |
lossavoidance | #12 |
scales treatment | #12 |
digital treatment | #12 |
systematized | #12 |
psychiatric genetics | #12 |
common disorders | #12 |
youths bpd | #12 |
adhd symptoms adults | #12 |
effects time | #12 |
adhd core symptoms | #12 |
salts extended | #12 |
n1397 | #12 |
assessment adhd | #12 |
sec23ip | #12 |
sud patients adhd | #12 |
twins humans models | #12 |
nonoral | #12 |
adolescent adult age | #12 |
psychotic mood disorders | #12 |
impulsivity children | #12 |
kappa coefficients | #12 |
early psychosis study | #12 |
response atomoxetine | #12 |
sexually dimorphic effects | #12 |
adhd age | #12 |
functional impairments | #12 |
cbcl children | #12 |
genes methylation | #12 |
defiant | #12 |
comorbid disorder | #12 |
obesity risk alleles | #12 |
unaffected sibs | #12 |
studies relatives | #12 |
rs947267 | #12 |
hawi | #12 |
deficits attention | #12 |
amfetamine | #12 |
nhe9 | #12 |
disorder subjects | #12 |
unaffected siblings individuals | #12 |
test wcst | #12 |
ksadse | #12 |
convergent functional | #12 |
perceived motor competence | #12 |
comorbidity diagnostic | #12 |
juvenile bipolar | #12 |
neurocognitive measures | #12 |
adult outcome | #12 |
rs778293 | #12 |
thalamic activation | #12 |
disorder adult | #12 |
treatment paliperidone | #12 |
dat1 polymorphism | #12 |
sud adhd | #12 |
psychotic behavior | #12 |
onelevel | #12 |
stimulant medication children | #12 |
psychiatric clinics | #12 |
pleiotropic mechanisms | #12 |
cnvs risk | #12 |
girls relationship | #12 |
probands siblings | #12 |
striatal sensitivity | #12 |
covid19 restrictions children | #12 |
common psychiatric | #12 |
metan | #12 |
adhd offspring | #12 |
sample consisted | #12 |
treatment attention | #12 |
40–48 | #12 |
symptom rating | #12 |
necrotic death | #13 |
robust effects | #13 |
taiwanese sample | #13 |
morbidity risks | #13 |
specific hypotheses | #13 |
familial risk schizophrenia | #13 |
psychometrics reproducibility | #13 |
symptoms attention | #13 |
scale studies | #13 |
velocardiofacial syndrome vcfs | #13 |
risk mood | #13 |
girls | #13 |
late onset | #13 |
persistence remission | #13 |
diagnostic concepts | #13 |
adderall mph | #13 |
environment adolescent | #13 |
methods subjects | #13 |
ravg | #13 |
rates comorbidity | #13 |
disorder childhood | #13 |
overanxious | #13 |
chi12 | #13 |
adhd diagnosis | #13 |
bpd offspring | #13 |
disorders child | #13 |
adhdodd | #13 |
psychometric measure | #13 |
genomewide significance | #13 |
disorder youth | #13 |
risk parents | #13 |
adverseevents | #13 |
iiv | #13 |
adhd alcohol | #13 |
convergent functional genomics | #13 |
nonoral routes | #13 |
longallele | #13 |
psychiatric risk | #13 |
pkcm | #13 |
psychotic mood | #13 |
label studies | #13 |
adhd alterations | #13 |
disorders sud | #13 |
humans methylphenidate | #13 |
studies bipolar | #13 |
pair 6 chromosomes | #13 |
permutation testing | #13 |
male samples | #13 |
colorado springs | #13 |
transdermal methylphenidate | #13 |
diagnostic threshold | #13 |
cognitive impulsivity | #13 |
adhd cognitive | #13 |
response inhibition adolescents | #13 |
weight bmi | #13 |
114 years | #13 |
bipolar probands | #14 |
siblings probands | #14 |
early precursors | #14 |
prss mdd | #14 |
siblings cases | #14 |
mph adderall | #14 |
teachers reports | #14 |
adhd symptoms adulthood | #14 |
adhd phenotype | #14 |
wraadds | #14 |
sud patients | #14 |
geschwind | #14 |
adhd brain | #14 |
nimh genetics | #14 |
disorder child | #14 |
cautiously | #14 |
quetiapine bipolar disorder | #14 |
factors schizophrenia | #14 |
genes schizophrenia | #14 |
associations adhd | #14 |
economic psychology | #14 |
social school | #14 |
children bipolar disorder | #14 |
comorbid condition | #14 |
children stimulants | #14 |
children criteria | #14 |
older adults adhd | #14 |
n643 | #14 |
hillside | #14 |
studies adults | #14 |
stimulant abuse | #14 |
ocd scz | #14 |
familial disorder | #14 |
unaffected siblings controls | #14 |
mixed amphetamine salts | #14 |
cnvs park2 | #14 |
selfcontained | #14 |
disorders comorbid | #14 |
relatives male probands | #14 |
disorder odd | #14 |
genetic studies schizophrenia | #14 |
aadhd | #14 |
worldwide prevalence | #14 |
diagnosis mdd | #14 |
lisdexamfetamine dimesylate ldx | #14 |
suds | #14 |
attention executive | #14 |
symptoms psychiatric disorders | #14 |
lphn3 adhd | #14 |
emotional impulsivity | #14 |
subcortical brain volume | #14 |
differential heritability | #14 |
common disorder | #14 |
paediatric bipolar disorder | #15 |
sackett | #15 |
agents attention | #15 |
association schizophrenia | #15 |
study design features | #15 |
metabolic syndrome obesity | #15 |
schizophrenia families | #15 |
adhd functional connectivity | #15 |
symptom count | #15 |
adhd diagnostic | #15 |
rs2652511 | #15 |
methylation gene expression | #15 |
interaction genotype | #15 |
treatment xr | #15 |
genderdifferences | #15 |
velocardiofacial | #15 |
ocd comorbid adhd | #15 |
executive function theory | #15 |
chi2 | #15 |
seconddegree relatives | #15 |
poor perception | #15 |
risk substance | #15 |
mphmlr | #15 |
adults substance disorders | #15 |
substance disorder patients | #15 |
adhd performance | #15 |
persons schizophrenia | #15 |
psychiatric interviews | #15 |
49 children | #15 |
male mood | #15 |
bipolar schizoaffective disorder | #15 |
nhsd | #15 |
zranb2 | #15 |
gxr children | #15 |
male relatives | #15 |
daily living administration | #15 |
healthy comparison subjects | #15 |
snps methylation | #15 |
symptoms adulthood | #15 |
adhd treatment | #15 |
adhd study | #15 |
disord | #15 |
disorder evidence | #15 |
pregnancy risk factor | #15 |
tests psychomotor | #15 |
asd mdd | #15 |
diagnostic interviews | #15 |
card sorting | #15 |
4669 | #15 |
wfirsp | #15 |
behavior disorders | #15 |
cbclpbd | #15 |
prodromal symptoms psychosis | #15 |
d10s1423 | #15 |
adhd disorders | #15 |
youths adhd | #16 |
informant assessment | #16 |
linkage findings | #16 |
adhd symptom severity | #16 |
special classes | #16 |
adhd obesity | #16 |
drug disorder | #16 |
dexedrine | #16 |
control participants participants | #16 |
factual factor analysis | #16 |
pervasive developmental disorder | #16 |
familial relationship | #16 |
“difficulty | #16 |
rdoc framework | #16 |
risk psychotic disorders | #16 |
delayed action | #16 |
n424 | #16 |
dbds | #16 |
ntac | #16 |
scz risk | #16 |
hyperkinetic disorders | #16 |
geneenvironment interaction | #16 |
brainbody | #16 |
adhd diagnoses | #16 |
regional cortical thickness | #16 |
onset anticipation | #16 |
cprsr | #16 |
multiple test | #16 |
longitudinal assessments | #16 |
growth children | #16 |
parents anxiety disorders | #16 |
adhd anxiety symptoms | #16 |
condfdr | #17 |
hyperactivity attitude | #17 |
bipolar disorder subjects | #17 |
depression md | #17 |
a161t | #17 |
5071 | #17 |
ocd age | #17 |
persistent adhd | #17 |
ldx children | #17 |
psychology schizotypal | #17 |
resultsfirst | #17 |
young offspring | #17 |
pediatric samples | #17 |
larger sample | #17 |
asd ocd | #17 |
diagnostic statistical | #17 |
study adhd | #17 |
substance disorders sud | #17 |
childhood predictors | #17 |
nonparametric linkage | #17 |
association scan | #17 |
random forest regression | #17 |
prevalence adhd | #17 |
assessment positive symptoms | #17 |
pediatric disorder | #17 |
response inhibition network | #17 |
prospective follow | #17 |
rbfox1 | #17 |
accn2 | #17 |
multiple anxiety disorders | #17 |
medication type | #17 |
factors siblings | #17 |
driving behaviors | #17 |
adulthood adhd | #17 |
combined type | #17 |
mania | #17 |
neuropsychiatric evaluation | #17 |
association markers | #17 |
parents adhd | #17 |
relation adhd | #17 |
disability adhd | #17 |
studies psychiatric | #17 |
schizophrenia psychosis | #17 |
method participants | #17 |
samples children | #17 |
considerable overlap | #17 |
adhd sud patients | #18 |
dcdq | #18 |
neuropsychologic | #18 |
childhood traumas | #18 |
schizophrenia patients relatives | #18 |
adhd groups | #18 |
preschool diagnostic | #18 |
bipolar choice trial | #18 |
children vcfs | #18 |
schizophrenia dtnbp1 | #18 |
operationalized | #18 |
illness twins | #18 |
4286 | #18 |
single nucleotide severity | #18 |
anxiety mdd | #18 |
poor tolerability | #18 |
marijuana age | #18 |
adhd cannabis | #18 |
behavior scale | #18 |
meet criteria | #18 |
relatives control subjects | #18 |
hrr 95 | #18 |
bipolar major | #18 |
risk disorders | #18 |
potential contributor | #18 |
kcnj4 | #18 |
transporter gene | #18 |
low dose naltrexone | #18 |
linkage regions | #18 |
symptom overlap | #18 |
psuds | #18 |
stimulant | #18 |
depression genetic risk | #18 |
primary substance | #18 |
fullsiblings | #18 |
minisatellite repeats | #18 |
lisdexamfetamine dimesylate | #18 |
unaffected siblings | #18 |
conduct disorder children | #18 |
unemotionality | #18 |
prolonged therapy | #18 |
adhd severity | #18 |
mcgue | #19 |
hyperconnectivity | #19 |
medication trials | #19 |
mental health human | #19 |
disconfirmations | #19 |
candidate loci | #19 |
scz ocd | #19 |
action preparations | #19 |
improvement symptoms | #19 |
symptoms adolescent | #19 |
addicted patients | #19 |
psychosocial features | #19 |
euphoric effects | #19 |
adhd young adults | #19 |
nature nurture | #19 |
disorders adults | #19 |
assessing outcome | #19 |
adolescent age onset | #19 |
comorbidity rates | #19 |
lod1 | #19 |
adolescent age | #19 |
adhd neurodevelopmental | #19 |
substance adhd | #19 |
casecontrol sample | #19 |
verbal memory task | #19 |
rs3918342 | #19 |
familial transmission | #19 |
outcome attention | #20 |
linkage scans | #20 |
pedigree selection | #20 |
manual mental | #20 |
mflynn | #20 |
inhibition children | #20 |
nonpsychotic siblings | #20 |
adolescent | #20 |
deficits children | #20 |
disorders polymorphism | #20 |
human ortholog | #20 |
parents risk | #20 |
notch4 gene | #20 |
slc6a2 | #20 |
sibpair | #20 |
dicap | #20 |
kiddie | #20 |
prenatal exposure nicotine | #20 |
parent origin | #20 |
illness female humans | #20 |
ratings adhd | #20 |
biological families | #20 |
neuropsychologically | #20 |
schizophrenia attention | #20 |
response curve | #20 |
controlled pilot study | #20 |
neuroleptic dose | #20 |
rbfox1 gene | #20 |
neuropsychological function | #20 |
gsma | #20 |
humanhap550v3 | #20 |
depression adhd | #20 |
transmission ratio distortion | #20 |
schizophrenia taiwan | #21 |
monoamine oxidase maoa | #21 |
children comorbid | #21 |
male probands | #21 |
11year followup | #21 |
humans linkage | #21 |
prospective longitudinal | #21 |
cacng2 | #21 |
comorbid adhd | #21 |
prenatal exposure alcohol | #21 |
psychiatric symptoms patients | #21 |
bipolar pedigrees | #21 |
prevalent cases | #21 |
sodium hydrogen exchanger | #21 |
linkage chromosomes | #21 |
treatment growth | #21 |
childhood conduct disorder | #21 |
risk offspring | #21 |
schizotypals | #21 |
schizophrenia disease humans | #21 |
schizophrenia united | #21 |
prescription stimulants | #21 |
life enjoyment | #21 |
genehunterplus | #21 |
children pdd | #21 |
chronic tics | #21 |
rat shr | #21 |
gender comparisons | #21 |
methods age | #21 |
palau | #21 |
rs778294 | #21 |
agler | #21 |
motor problems | #21 |
niacin skin | #22 |
preliminary reliability | #22 |
ldx | #22 |
overtransmission | #22 |
bpd subjects | #22 |
syndrome vcfs | #22 |
familiality | #22 |
adhd susceptibility | #22 |
disruptive | #22 |
amphetamine methylphenidate | #22 |
youth bipolar | #22 |
polygenic overlap | #22 |
diagnostic interview | #22 |
youth mdd | #22 |
stimulants children | #22 |
schizophrenia pgc | #22 |
controls | #22 |
pre‐school | #22 |
adhd impulsivity | #22 |
study methodology | #22 |
10p | #22 |
adhd rating scale | #22 |
genetic phenotype | #22 |
children attention | #22 |
6 disorders | #22 |
neuropsychological profiles | #22 |
disorders major | #22 |
adhd anxiety | #22 |
adhd stimulants | #22 |
amygdala structure | #22 |
adderall xr | #22 |
rg022 | #22 |
neurocognitive performance schizophrenia | #22 |
depression treatment patients | #22 |
association prs | #22 |
partial replication | #22 |
n449 | #23 |
adhd symptoms childhood | #23 |
mdd anxiety disorders | #23 |
handful | #23 |
neuroleptic withdrawal | #23 |
scq asd | #23 |
asd scq | #23 |
rs464049 | #23 |
comprehensively | #23 |
propylamines | #23 |
interview dsm | #23 |
executive functions efs | #23 |
wide linkage | #23 |
snapiv | #23 |
twins genetic predisposition | #23 |
kotkin | #23 |
adolescents bpd | #23 |
wechsler scales | #23 |
notch4 receptors | #23 |
anxious mothers | #23 |
siblings | #23 |
serotonin receptor gene | #23 |
syp | #23 |
interacting molecules | #23 |
intrinsic curvature | #23 |
heterogeneity genetic | #23 |
metadoxine | #23 |
male individuals | #23 |
diagnostician | #23 |
disequilibrium male | #23 |
oppositional | #23 |
genetic investigation | #23 |
phenotype definition | #23 |
risk studies | #23 |
chromosomes 6 | #24 |
children meeting | #24 |
mental control | #24 |
nonstimulant | #24 |
receptor d4 | #24 |
adhd characteristics | #24 |
female humans illness | #24 |
child female humans | #24 |
dsmiiir criteria | #24 |
lithium bipolar disorder | #24 |
stress exposure | #24 |
15q13 | #24 |
deficits | #24 |
adra2a | #24 |
aggression anxiety | #24 |
refilled | #24 |
stroop task performance | #24 |
guanfacine extended release | #24 |
neural activation patterns | #24 |
symptoms psychosis | #24 |
conduct problems adhd | #24 |
statistical manual | #24 |
ocd asd | #24 |
intelligence schizophrenia | #24 |
actigraphy studies | #24 |
quantitative phenotypes | #24 |
sassr | #24 |
snorting | #24 |
0535 | #24 |
genome‐wide linkage scans | #24 |
amrs | #24 |
expected growth | #24 |
age regions | #24 |
adhd comorbidities | #24 |
nieces | #24 |
young relatives | #25 |
clinical interviews | #25 |
conners parent | #25 |
efficacy atomoxetine | #25 |
symptom subtypes | #25 |
–environment interactions | #25 |
school failure | #25 |
wkht | #25 |
splicing regulator | #25 |
or194 | #25 |
biased transmission | #25 |
anticipation schizophrenia | #25 |
unique profile | #25 |
decreased volume | #25 |
major affective disorders | #25 |
slc6a3 gene | #25 |
maternal criticism | #25 |
d22s283 | #25 |
behavioral disinhibition | #25 |
baseline assessment | #25 |
psychiatric nosology | #25 |
copy variants schizophrenia | #25 |
vietnam twin registry | #25 |
exposure adhd | #25 |
dapple | #25 |
task patients | #25 |
nudt3 | #25 |
understanding adhd | #25 |
dyscalculia | #25 |
bipolar choice | #25 |
psychiatric disorders children | #25 |
association snps | #25 |
liker | #25 |
psychometrically | #25 |
neurocognitive predictors | #25 |
screening scale | #25 |
twins humans | #26 |
efpc | #26 |
psychometric measures | #26 |
label study | #26 |
core symptoms adhd | #26 |
rs3730358 | #26 |
adhd mothers | #26 |
neurodevelopmental genes | #26 |
adults symptoms | #26 |
wm microstructure | #26 |
htr1d | #26 |
gender risk | #26 |
bipolar phenotype | #26 |
controls adhd | #26 |
n81 | #26 |
inrich | #26 |
major depression md | #26 |
association allele | #26 |
maob gene | #26 |
selfmonitor | #26 |
adrenergic uptake | #26 |
alcohol drug abuse | #26 |
social impairment | #26 |
add | #26 |
orosmethylphenidate | #26 |
affair | #26 |
structured interviews | #26 |
voxel based morphometry | #26 |
prenatal health | #26 |
screening diagnosis | #26 |
behavioral disorder | #26 |
agreement raters | #26 |
nonmedical prescription stimulants | #26 |
schizophrenia genetic | #27 |
aff | #27 |
consecutively | #27 |
asherson | #27 |
bipolar disorder comorbidity | #27 |
greater severity | #27 |
potential confounds | #27 |
t102c polymorphism | #27 |
offspring risk | #27 |
intelligence male | #27 |
based association | #27 |
international meeting | #27 |
ptsd adults | #27 |
cnvs adhd | #27 |
childreniv | #27 |
osterrieth | #27 |
association signals | #27 |
genetic susceptibility schizophrenia | #27 |
d22s278 | #27 |
rate remission | #27 |
hyperactivity disorder adhd | #27 |
mdd asd | #27 |
disorders executive | #27 |
weaker effects | #27 |
treatment atomoxetine | #27 |
parent teacher | #28 |
ocd disorders | #28 |
raters | #28 |
disorder compared | #28 |
vigilance performance | #28 |
symptom reports | #28 |
schizophrenia onset | #28 |
emotional dysregulation | #28 |
child clinical | #28 |
cortical gyrification | #28 |
subjects bpd | #28 |
polysomnography actigraphy | #28 |
symptoms inattention | #28 |
assessment negative symptoms | #28 |
dopamine transporter binding | #28 |
clinical correlates | #28 |
6179 | #28 |
snp18 | #28 |
image study | #28 |
adhd differences | #28 |
rest task | #28 |
genomewide studies | #28 |
sustained attention deficits | #28 |
slc6a3 | #28 |
new genetics | #28 |
maternal adhd | #28 |
guze | #28 |
dopamine receptor d4 | #28 |
preliminary findings | #28 |
male methylphenidate | #28 |
families schizophrenia | #28 |
metaalgorithm | #28 |
adults study | #28 |
genetic etiology | #28 |
persons bipolar disorder | #28 |
adhd autism | #28 |
medication misuse | #29 |
bipolar disorder youth | #29 |
adhd patients controls | #29 |
offspring parents | #29 |
misuse diversion | #29 |
african‐american | #29 |
disorder bipolar | #29 |
childhood diagnosis | #29 |
inattention hyperactivity impulsivity | #29 |
hyperactivity impulsivity | #29 |
psychosocial dysfunction | #29 |
attention‐deficit | #29 |
infants weight | #29 |
male polymorphism | #29 |
childhood antecedents | #29 |
studies genes | #29 |
dsmiiir | #29 |
disorders offspring | #29 |
parents bipolar disorder | #29 |
kcnn3 | #29 |
shared genetic basis | #29 |
comorbidity ptsd | #29 |
etiological heterogeneity | #29 |
medication usage | #29 |
hyperactive symptoms | #30 |
relatives age | #30 |
antisocial behavior asb | #30 |
adhd child | #30 |
association paternal age | #30 |
parental predictors | #30 |
structural brain features | #30 |
specific psychopathology | #30 |
caarsinv | #30 |
problems attention | #30 |
nimh | #30 |
treatment adolescents | #30 |
nonaffected | #30 |
genetic perspective | #30 |
bmi growth | #30 |
comorbid | #30 |
diagnosticians | #30 |
nicotine pregnancy | #30 |
robust statistical methods | #30 |
individual studies | #30 |
juvenile bipolar disorder | #30 |
growth childhood | #30 |
reanalyzed | #31 |
sex effects | #31 |
lodscore | #31 |
kif16b | #31 |
neuropsychologic deficits | #31 |
depression genetic | #31 |
discriminates | #31 |
n305 | #31 |
charles river | #31 |
impulsivity inattention | #31 |
twin concordance | #31 |
rgs4 schizophrenia | #31 |
extant literature | #31 |
95 adhd | #31 |
potential endophenotypes | #31 |
bpd risk | #31 |
neuroimage | #31 |
nonadhd | #31 |
genotype haplotypes | #31 |
prs adhd | #31 |
variable tandem | #31 |
methylphenidate | #31 |
smoking substance | #31 |
schizophrenia affective psychosis | #32 |
subfields hippocampus | #32 |
70–80 | #32 |
bipolar disorder bpi | #32 |
gender | #32 |
attentiondeficit | #32 |
aggression attention | #32 |
psychosis youth | #32 |
impulsecontrol | #32 |
kremen | #32 |
anterior insular | #32 |
repeat length | #32 |
psychiatric genetic | #32 |
adhd adolescents | #32 |
rs206936 | #32 |
psdq | #32 |
slc6a4 | #32 |
wiscr | #32 |
child psychiatric | #32 |
randomized crossover study | #32 |
anxiety disorders | #32 |
10p13 | #32 |
psychiatric disorders | #32 |
asd symptoms children | #32 |
studies schizophrenia | #32 |
parents child | #32 |
studies adolescent | #32 |
comorbidity cross | #33 |
subcortical brain | #33 |
psychiatric sample | #33 |
association genes | #33 |
maternal smoking pregnancy | #33 |
mood anxiety | #33 |
frontopolar | #33 |
ld adhd | #33 |
original study | #33 |
autism symptoms | #33 |
val allele | #33 |
children risk | #33 |
pharmacotherapy trials | #33 |
10repeat allele | #33 |
neural reward processing | #33 |
youth bipolar disorder | #33 |
briefa | #33 |
wfirs | #33 |
adhd evidence | #33 |
single snps | #33 |
adhd patients | #33 |
qsf | #33 |
twins factor analysis | #33 |
disorder symptom | #33 |
quetiapine monotherapy | #33 |
aspd bpd | #33 |
rhobtb3 | #33 |
psychiatric status | #33 |
prior findings | #33 |
animal model adhd | #33 |
current adhd | #33 |
rs1130214 | #33 |
neuropsychiatric sle | #33 |
neuropsychological deficits | #33 |
psychological tests | #34 |
young adults adhd | #34 |
disorders mood | #34 |
risk psychiatric disorders | #34 |
cognition interaction | #34 |
disorders diagnostic | #34 |
grm5 | #34 |
dsm5 dsmiv | #34 |
harvard | #34 |
disorder traits | #34 |
inattention | #34 |
treatment sud | #34 |
structural brain asymmetries | #34 |
linkage studies | #34 |
md risk | #34 |
candidate gene polymorphisms | #34 |
pharmacotherapy adhd | #34 |
emerging consensus | #34 |
gxr | #34 |
snp4 | #34 |
social anxiety children | #34 |
treatment memantine | #34 |
adhd rating | #35 |
htr1b | #35 |
#35 | |
lifetime rates | #35 |
bipolar disorder offspring | #35 |
participants bpd | #35 |
schizophrenia relatives | #35 |
familial risk | #35 |
bipolar spectrum disorders | #35 |
humans intelligence | #35 |
recall patients | #35 |
n64 | #35 |
schizophrenia schizotypy | #35 |
catechol‐o‐methyltransferase | #35 |
plink | #35 |
sample description | #35 |
n265 | #35 |
choice impulsivity | #35 |
schizophrenia gene | #35 |
adhd sleep problems | #35 |
risk females | #35 |
complex figure | #35 |
lithium quetiapine | #35 |
hyperactive disorder | #35 |
retrospective recall | #36 |
stimulant medications | #36 |
95 siblings | #36 |
n185 | #36 |
gypc | #36 |
overanxious disorder | #36 |
siblings controls | #36 |
term neuropsychological | #36 |
orosmph | #36 |
neurocognitive markers | #36 |
adhd drug | #36 |
annett | #36 |
groups adhd | #36 |
schizophrenia genes | #36 |
intracranial volume icv | #36 |
adult antisocial | #36 |
infant gender | #36 |
suny | #36 |
disorder bpd | #36 |
d6s274 | #36 |
structure psychopathology | #36 |
nocebo response | #36 |
young adult females | #36 |
neurotransmissions | #36 |
adhd control groups | #36 |
comorbidity children | #36 |
offspring association | #37 |
slc22a16 | #37 |
combined sample | #37 |
studies comorbidity | #37 |
disorder severity | #37 |
n278 | #37 |
tests schizophrenia | #37 |
odd dimensions | #37 |
genetics | #37 |
rs5 | #37 |
mapping genomic loci | #37 |
parents adhd children | #37 |
adhd asd | #37 |
predictive utility | #37 |
lisdexamfetamine | #37 |
symptom criteria | #37 |
functioning adults | #37 |
delayedaction preparations | #37 |
dat1 gene | #37 |
child behavioral | #37 |
methylphenidate treatment | #38 |
dsm criteria | #38 |
boys | #38 |
family‐based | #38 |
adhd problems | #38 |
unfamiliar | #38 |
rs2391191 | #38 |
polymorphism gene | #38 |
pediatric adhd | #38 |
kiddie schedule | #38 |
genetic risk schizophrenia | #38 |
height children | #38 |
genome‐wide search | #38 |
pik4ca | #38 |
d15s1360 | #38 |
school age children | #38 |
familial risk depression | #38 |
16 genes | #38 |
behavioral traits | #39 |
female cases | #39 |
washu | #39 |
ocd adhd | #39 |
mlod | #39 |
nonparanoid | #39 |
mdd ocd | #39 |
asthma systematic review | #39 |
structural brain abnormalities | #39 |
mood stabilization | #39 |
dsm5 criteria | #39 |
manic symptoms | #39 |
pharmacologic treatment | #39 |
wisconsin card | #39 |
test association | #39 |
increased risk adhd | #39 |
adhd behavior | #39 |
suggestive | #39 |
git1 | #39 |
antisocial traits | #39 |
iii personality | #39 |
onset children | #39 |
markers genetic | #39 |
familial effects | #40 |
genome scan | #40 |
bipolars | #40 |
cardiovascular adverse effects | #40 |
genetics schizophrenia | #40 |
rs2283265 | #40 |
brainspan | #40 |
chromosome 10p | #40 |
diagnosis bipolar disorder | #40 |
genetic studies | #40 |
rare copy variants | #40 |
reln gene | #40 |
onset | #40 |
dsmiv criteria | #40 |
anx | #40 |
heinrichs | #40 |
gxe | #40 |
fhrs | #41 |
sibpairs | #41 |
schizophrenia severity illness | #41 |
parent‐of‐origin | #41 |
methylphenidate response | #41 |
male parents | #41 |
sirolimus patients | #41 |
normal comparison subjects | #41 |
pediatric subjects | #41 |
methodological advances | #41 |
effects growth | #41 |
bdnf adhd | #41 |
neuropsychiatr | #41 |
psychosocial adversity | #41 |
chromosomes 6q | #41 |
adhd deficits | #42 |
child female | #42 |
schizophrenia disorders | #42 |
individual items | #42 |
fiveyear followup | #42 |
male panic | #42 |
gwas meta | #42 |
n262 | #42 |
tic disorders | #42 |
diagnostic comorbidity | #42 |
sorting test | #42 |
serotonergic pathway | #42 |
dtnbp1 schizophrenia | #42 |
disorder social | #42 |
schizophrenia | #42 |
massachusetts general | #43 |
candidate endophenotype | #43 |
mri study | #43 |
practitioner review | #43 |
children enuresis | #43 |
snp1 | #43 |
neuropsychological tasks | #43 |
brain scans | #43 |
disorder prevalence | #43 |
n242 | #43 |
digs | #43 |
p023 | #43 |
adhd prs | #43 |
neuropsychological differences | #43 |
simplex families | #43 |
n232 | #43 |
n176 | #43 |
youngadult | #43 |
p094 | #43 |
adhd depression | #43 |
sidp | #44 |
adolescents attention | #44 |
n140 | #44 |
odds ratio association | #44 |
asd adults | #44 |
nosologic | #44 |
treatment adult | #44 |
multidimensionality | #44 |
secondborns | #44 |
immediaterelease | #44 |
prior studies | #44 |
dopamine d5 | #44 |
mental disorders diseases | #44 |
pharmacogenetic studies | #45 |
genetic underpinnings | #45 |
pooled size | #45 |
suggestive associations | #45 |
inflation rate | #45 |
offspring adhd | #45 |
illness stress | #45 |
controls subjects | #45 |
schizophrenia genome | #45 |
risk schizophrenia | #45 |
tcerg1l | #45 |
volume reductions | #45 |
cep85l | #45 |
snpbased heritability | #45 |
behavior rating | #45 |
wnl | #45 |
adhd parents | #45 |
institute mental | #45 |
altered brain activation | #45 |
baseline adhd | #45 |
genetic loading | #45 |
prevalence psychiatric | #45 |
uncaring | #45 |
risk reduction strategies | #45 |
substance disorder | #45 |
10year followup | #46 |
cbt intervention | #46 |
sex bias | #46 |
converging evidence | #46 |
12 months treatment | #46 |
neuropsychological performance | #46 |
adhd effects | #46 |
lyons | #46 |
referral bias | #46 |
previous findings | #46 |
response mph | #46 |
nat genet | #46 |
gender influences | #46 |
stronger connectivity | #46 |
natural reward | #46 |
n164 | #46 |
familial coaggregation | #46 |
machine learning study | #46 |
childhood disorders | #47 |
loci chromosomes | #47 |
or125 | #47 |
desipramine dmi | #47 |
psychiatric status rating | #47 |
comt | #47 |
pooled odds ratio | #47 |
association bipolar disorder | #47 |
disorders studies | #47 |
oppositional symptoms | #47 |
trauma risk | #47 |
schizophrenia alleles | #47 |
meehl | #47 |
parents depression | #47 |
velocardiofacial syndrome | #47 |
ocd mdd | #47 |
compromised | #47 |
n280 | #47 |
genetic study | #47 |
shared polygenic risk | #47 |
abstract objective | #47 |
baiap2 | #47 |
adhd prevalence | #48 |
association test | #48 |
n103 | #48 |
nullhypothesis | #48 |
mpp3 | #48 |
n27 | #48 |
adhd dyslexia | #48 |
scientific foundation | #48 |
shared heritability | #48 |
disorder case | #48 |
rtv | #48 |
1711 | #48 |
revised | #48 |
effects gender | #48 |
disorder cognitive | #49 |
serotonin plasma | #49 |
schizophrenia cognition | #49 |
hyperactivity autism | #49 |
anxa7 | #49 |
familial loading | #49 |
snap‐25 | #49 |
volume differences | #49 |
nurture | #49 |
rs2494732 | #49 |
negative schizotypy | #49 |
inbred wky rats | #49 |
drug holidays | #49 |
weak evidence | #49 |
mental disorders children | #49 |
vdm | #50 |
early onset schizophrenia | #50 |
pair 6 | #50 |
rocf | #50 |
studies biomarkers | #50 |
impulsivity symptoms | #50 |
extended pedigrees | #50 |
wiat | #50 |
maoauvntr | #50 |
geneenvironment interactions | #50 |
life outcomes | #50 |
parent teacher ratings | #50 |
intergenerational effects | #50 |
caseness | #50 |
wais | #50 |
proteins polymorphism | #50 |
genomic relationships | #50 |
n168 | #50 |
dsmiv dsm5 | #50 |
adhd knowledge | #51 |
substantial role | #51 |
adults ocd | #51 |
bpd | #51 |
epilepsy adhd | #51 |
gender association | #51 |
1542 | #51 |
common psychiatric disorders | #51 |
manovas | #51 |
compelling | #51 |
peer affiliation | #51 |
disorders children | #51 |
male personality | #51 |
psychology adult | #51 |
youth asd | #52 |
gray matter alterations | #52 |
intracranial volume | #52 |
adra1a | #52 |
growth height | #52 |
chronic schizophrenia patients | #52 |
major depression | #52 |
combined adhd | #52 |
oros methylphenidate | #52 |
selenbp1 | #52 |
schizophrenia controls | #52 |
schizophrenia sex | #52 |
a218c | #52 |
bipolar disorder children | #52 |
metaanalysis association | #52 |
asdadhd | #52 |
n138 | #53 |
smoking schizophrenia | #53 |
mania depression | #53 |
scales schizophrenia | #53 |
schizophrenia adolescent | #53 |
extended‐release | #53 |
tourettes disorder | #53 |
dopamine plasma | #53 |
risktaking behavior | #53 |
placebo children | #53 |
parahippocampal gyrus | #53 |
adoption study | #53 |
risk analysis | #53 |
snps candidate genes | #53 |
psychopathology | #53 |
adhdc | #53 |
ppm1h | #53 |
jackknife | #54 |
bpd children | #54 |
unphased | #54 |
pregnancy time | #54 |
genetic reproducibility | #54 |
onset bipolar | #54 |
alcohol drug | #54 |
ablim1 | #54 |
psychlit | #54 |
dnms | #54 |
schizophrenia psychotic disorders | #54 |
chromosome 6p | #54 |
risk study | #54 |
gene interaction | #55 |
children diagnosis | #55 |
neuropsychological studies | #55 |
emotional lability | #55 |
flat affect | #55 |
disorders prevalence | #55 |
endophenotype | #55 |
sample children | #55 |
mid adolescence | #55 |
viloxazine | #55 |
disorders risk | #55 |
childhood trauma exposure | #55 |
child behavior | #55 |
1252 | #55 |
tova | #55 |
longitudinal case | #55 |
tics children | #56 |
entry points | #56 |
extendedrelease | #56 |
hyperactive | #56 |
cotwin | #56 |
disorder agoraphobia | #56 |
degree relatives | #56 |
alcohol substance | #56 |
pair chromosomes | #56 |
n43 | #56 |
subfield | #56 |
children siblings | #56 |
schizophrenia offspring | #56 |
etdt | #57 |
barkley | #57 |
model attention | #57 |
oddsratio | #57 |
zdhhc8 | #57 |
atomoxetine hydrochloride | #57 |
apol | #57 |
brain structure function | #57 |
rating inventory | #57 |
interregional profiles differences | #57 |
methylphenidate hydrochloride | #57 |
shared genetic etiology | #57 |
dbq | #58 |
childhood young adulthood | #58 |
comorbid psychiatric disorders | #58 |
adhd atomoxetine | #58 |
single snp | #58 |
repeat alleles | #58 |
100 children | #58 |
analysis schizophrenia | #58 |
controls children | #58 |
association comt | #58 |
function schizophrenia | #58 |
controlled study | #58 |
children | #58 |
heritable receptors | #58 |
tests attention | #58 |
vntr polymorphisms | #58 |
compelling evidence | #58 |
conners | #58 |
schizophrenia smoking | #59 |
mdd adhd | #59 |
rtn4r | #59 |
mdd children | #59 |
risk siblings | #59 |
risk psychiatric | #59 |
neuroleptic | #59 |
comt schizophrenia | #59 |
disorders including | #60 |
executive functioning | #60 |
abuse dependence | #60 |
duval | #60 |
reported associations | #60 |
3 domains | #60 |
inattention hyperactivity | #60 |
generalize | #60 |
disruptive behavior disorder | #60 |
lphn3 | #60 |
functional remission | #60 |
uninhibited | #61 |
disorders asd | #61 |
uncles | #61 |
disruptive behavior | #61 |
13q32 | #61 |
homogeneous subgroups | #61 |
oih | #61 |
comparison subjects | #61 |
dysregulation profile | #61 |
study adults | #61 |
study adherence | #61 |
cronbachs alpha | #61 |
unipolars | #61 |
wide scan | #61 |
maternal psychopathology | #62 |
4 year | #62 |
symptoms | #62 |
mph treatment | #62 |
inhibition memory | #62 |
schizophrenia human | #62 |
substantial heritability | #62 |
1537 | #62 |
tdts | #62 |
factors anxiety | #62 |
relatives schizophrenia | #62 |
bipolar youth | #62 |
polygenic risk schizophrenia | #62 |
treatments adhd | #63 |
behavioral dysregulation | #63 |
neurocognitive | #63 |
n179 | #63 |
ksads | #63 |
schizophrenia schizophrenic | #63 |
risk severity | #63 |
accounted | #63 |
stability time | #63 |
disorders bipolar | #63 |
structured interview | #63 |
rating scales | #64 |
males association | #64 |
40 countries | #64 |
treatment desipramine | #64 |
prefrontal dysfunction | #64 |
qlesq | #64 |
methylphenidate mph | #64 |
child | #64 |
risk trauma | #64 |
endosomal | #64 |
phacking | #64 |
europeanamerican | #64 |
linkage | #64 |
methylphenidate adhd | #64 |
diagnostic utility | #64 |
methylation cpg sites | #64 |
adhd 95 | #64 |
children mph | #64 |
childhood onset | #64 |
prior work | #65 |
zcchc4 | #65 |
occurrence adhd | #65 |
net gene | #65 |
schizophrenic | #65 |
small sample size | #65 |
neuropsychological impairments | #65 |
etiology schizophrenia | #65 |
emo | #65 |
function female | #65 |
emotional regulation | #65 |
adhd epilepsy | #65 |
male siblings | #65 |
marry | #65 |
controls siblings | #65 |
disorders genetic | #65 |
temperamental | #65 |
comorbid diagnosis | #65 |
oxidase gene | #65 |
disorder chromosome | #66 |
adhd dcd | #66 |
extended release | #66 |
vswm | #66 |
children mental retardation | #66 |
ci105 | #66 |
tic disorder | #66 |
tourettes syndrome | #66 |
attention hyperactivity | #66 |
simple phobia | #66 |
afternoons | #66 |
cbcldp | #66 |
study studies | #66 |
behavioral genetic | #66 |
neuropsychological profile | #66 |
global ratings | #66 |
nonrighthandedness | #67 |
subjects | #67 |
substance disorder sud | #67 |
patients bipolar disorders | #67 |
variance attention | #67 |
questionnaires treatment | #67 |
entire sample | #67 |
label trial | #67 |
findings association | #67 |
mental diseases | #67 |
treatment quetiapine | #67 |
n217 | #67 |
parents teachers | #67 |
grade retention | #67 |
risk bipolar | #67 |
chronic tic disorder | #67 |
conceptual issues | #68 |
qms | #68 |
hypofrontality | #68 |
naturalistic | #68 |
snparray | #68 |
delay aversion | #68 |
offspring | #68 |
brain gene | #68 |
chronological age | #69 |
clarifying | #69 |
humans schizophrenia | #69 |
impulsivity hyperactivity | #69 |
physical anhedonia | #69 |
illicit substances | #69 |
stress response genes | #69 |
panic disorder | #69 |
polymorphism schizophrenia | #69 |
symptom checklist | #69 |
low adherence | #69 |
ctgn | #69 |
scale assessment | #69 |
people adhd | #69 |
regulatory enzymes | #69 |
oros mph | #70 |
core adhd symptoms | #70 |
neuropsychological consequences | #70 |
nonrandom mating | #70 |
latrophilin | #70 |
new diagnoses | #70 |
npl | #70 |
linkage scan | #70 |
smoking children | #70 |
a2bp1 | #70 |
subsequent diagnosis | #70 |
interactions genes | #70 |
adhd behaviors | #71 |
neuroimaging genetics | #71 |
genes role | #71 |
adhd anxiety disorders | #71 |
genetic | #71 |
mspi polymorphism | #71 |
objective examine | #71 |
treated children | #71 |
vergence | #71 |
learning disorders | #72 |
digital intervention | #72 |
methodological issues | #72 |
digital health intervention | #72 |
genetic receptors | #72 |
school functioning | #72 |
molecular genetic | #72 |
boys age | #72 |
ocd subjects | #72 |
kagan | #73 |
adult | #73 |
3372 | #73 |
logodds | #73 |
disorders childhood | #73 |
adhd subtype | #73 |
candidate endophenotypes | #73 |
adhd medications | #73 |
youth | #73 |
anxiety adhd | #73 |
etiological | #73 |
poison control centers | #73 |
patients rest | #73 |
relapse depression | #73 |
schizophrenia genetics | #73 |
cellular models | #73 |
cortical abnormalities | #73 |
preferential transmission | #74 |
transmission disequilibrium | #74 |
pfkfb2 | #74 |
based diagnosis | #74 |
allele association | #74 |
age schizophrenia | #74 |
reaction time variability | #74 |
desipramine | #74 |
neale | #75 |
linkage schizophrenia | #75 |
child china | #75 |
efficacy outcome | #75 |
antisocial | #75 |
mind wandering | #75 |
weight body mass | #75 |
impairment children | #75 |
drd4 gene | #75 |
referred | #75 |
risk sample | #75 |
onset anxiety | #75 |
adhd traits | #75 |
akl | #75 |
slc1a1 | #75 |
hyperactivity adhd | #75 |
disorders brain | #76 |
depression pregnancy | #76 |
adhd total | #76 |
yates | #76 |
child depressive | #76 |
child humans | #76 |
positive schizotypy | #76 |
nondeficit | #76 |
chronic tic | #76 |
schizophrenia young | #76 |
centers disease control | #76 |
wcst performance | #77 |
lod score | #77 |
cortex schizophrenia | #77 |
atomoxetine children | #77 |
childhood adhd | #77 |
performance adhd | #77 |
psychological male | #77 |
performance schizophrenia | #77 |
disorders female | #78 |
bipolar disorder adhd | #78 |
bpi | #78 |
rare copy | #78 |
women antidepressants | #78 |
pharmacologic treatments | #78 |
adhd impairment | #78 |
local gyrification | #78 |
predixcan | #78 |
age adhd | #79 |
additive effects | #79 |
obesity metabolic syndrome | #79 |
n46 | #79 |
anxiety separation | #79 |
nosological | #79 |
disorder panic | #79 |
student athletes | #79 |
patients adhd | #79 |
studies relationship | #79 |
retrospective assessment | #79 |
cardinal | #79 |
schizophrenic patients | #79 |
genetic linkage studies | #79 |
pregnancy mothers | #79 |
siblings schizophrenia | #80 |
clinical interview | #80 |
adhd drugs | #80 |
linkage chromosome | #80 |
adhd rats | #80 |
total brain | #80 |
maternal smoking | #80 |
disliking | #81 |
subcortical brain volumes | #81 |
major diagnostic | #81 |
body mass diabetes | #81 |
treatment adults | #81 |
children parents | #81 |
interregional profiles | #81 |
hacking | #81 |
endophenotypes | #81 |
pathophysiology adhd | #81 |
bipolar disorder | #81 |
differences age | #81 |
eyhs | #81 |
oral routes | #81 |
comorbidity disorders | #82 |
square distribution | #82 |
comorbidity survey | #82 |
behavior assessment | #82 |
association maternal smoking | #82 |
genes pathways | #82 |
impaired quality life | #82 |
symptoms diagnosis | #82 |
cumulative evidence | #82 |
gene schizophrenia | #82 |
auditory verbal | #82 |
frontopolar cortex | #82 |
adults asd | #82 |
multifactorial inheritance | #83 |
illness | #83 |
tests risk | #83 |
unreliability | #83 |
disorders anxiety | #83 |
adult form | #83 |
neurocognitive functioning | #83 |
paterson | #83 |
substance disorders | #83 |
oros | #83 |
management adhd | #83 |
adhd adhd symptoms | #84 |
21 months | #84 |
women adhd | #84 |
15q133 | #84 |
complex disorder | #84 |
adhdrsiv | #85 |
atomoxetine | #85 |
european samples | #85 |
recycling endosome | #85 |
wide significance | #85 |
monitoring response | #85 |
hyperkinetic disorder | #85 |
buprenorphine maintenance | #85 |
genomics consortium | #85 |
adhd assessment | #85 |
linkage loci | #85 |
brain asymmetry | #85 |
humans risk | #85 |
9r | #85 |
adhd subtypes | #85 |
paranoid | #86 |
siblings children | #86 |
humans inhibition | #86 |
pord | #86 |
parents | #86 |
child conduct | #86 |
affective psychosis | #86 |
findings implications | #86 |
synaptosomal protein | #87 |
bipolar spectrum disorder | #87 |
ptsd trauma | #87 |
comparison children | #87 |
3utr | #87 |
bipolar | #87 |
putamen volume | #87 |
n203 | #87 |
risk alleles | #87 |
bonferroni correction | #88 |
drug effects | #88 |
hyperkinetic | #88 |
druggable | #88 |
comorbid psychopathology | #88 |
common risk | #88 |
caars | #89 |
2455 | #89 |
empirically | #89 |
chrna2 | #89 |
auditory attention | #89 |
comprehensive identification | #89 |
22 studies | #89 |
euphoric | #89 |
machine learning analysis | #89 |
prenatal nicotine exposure | #89 |
metaanalytic review | #89 |
nucleotide schizophrenia | #89 |
attention deficit hyperactivity | #90 |
snps haplotypes | #90 |
1month | #90 |
linkage genome | #90 |
verbal ability | #90 |
242 | #90 |
antidepressants pregnancy | #90 |
watt | #90 |
association metaanalysis | #90 |
male neuropsychological | #90 |
pervasive | #90 |
cortical brain | #91 |
naturalistic study | #91 |
adhd males | #91 |
identified studies | #91 |
complicates | #91 |
adhd efficacy | #91 |
adhd treatments | #91 |
parental socioeconomic status | #91 |
callousness | #91 |
assertion | #91 |
wcst | #91 |
documenting | #92 |
adults schizophrenia | #92 |
raise | #92 |
candidate gene | #92 |
h2snp | #92 |
studies sex | #92 |
studies association | #92 |
treatment mania | #92 |
referral consultation | #93 |
rate adult | #93 |
controls participants | #93 |
narrowly | #93 |
lifetime cannabis | #93 |
standardized differences | #93 |
ymrs | #93 |
hfasd | #94 |
hyperactivity autistic | #94 |
underachievement | #94 |
gprc5b | #94 |
sustained attention | #94 |
performance variability | #94 |
gottman | #94 |
social development | #94 |
adhd measures | #94 |
cdh13 | #94 |
aldh1l1 | #94 |
growing body | #94 |
brain case | #94 |
executive | #95 |
asd study | #95 |
total brain volume | #95 |
cadps2 | #95 |
minisatellite | #95 |
infa | #95 |
studies differences | #95 |
adolescents bipolar | #95 |
mdd bip | #95 |
phenotype polymorphism | #96 |
chromosome 9q34 | #96 |
scq | #96 |
nxph1 | #96 |
uvntr | #96 |
nominally | #96 |
behavior rating inventory | #96 |
hcadherin | #97 |
adolescent onset | #97 |
children tics | #97 |
studies asthma | #97 |
genome‐wide association study | #97 |
7q36 | #97 |
low cardiorespiratory fitness | #97 |
oppositionality | #98 |
wdpcp | #98 |
bipolar disorder risk | #98 |
hyperactivity brazil | #98 |
induced hyperalgesia | #98 |
massachusetts general hospital | #98 |
single nucleotide receptor | #98 |
concerta | #98 |
driving behavior | #98 |
linkage study | #98 |
syn2 | #98 |
identically | #98 |
nonfamilial | #98 |
methodssubjects | #99 |
substrains | #99 |
xp114 | #99 |
nonspecificity | #99 |
disease genetics | #99 |
medication effects | #99 |
neurodevelopmental processes | #99 |
metaanalysis trials | #99 |
adhd role | #99 |
psychoactive | #99 |
abuse potential | #99 |
motor timing | #99 |
disorder diagnosis | #99 |
chd6 | #99 |
obesity abdominal obesity | #100 |
clinical effects | #100 |
terror | #100 |
hippocampal subfield volumes | #100 |
12year | #100 |
adhd methylphenidate | #100 |
reticence | #100 |
pelham | #100 |
slc6a4 gene | #101 |
tsls | #101 |
genomewide | #101 |
roh | #101 |
depression pregnant women | #101 |
genetic risk scores | #101 |
cosegregation | #101 |
diagnostic boundaries | #101 |
schizophrenia psychotic | #101 |
advanced paternal age | #101 |
empirical test | #101 |
torture | #101 |
upsit | #101 |
harlan | #101 |
neurocognitive impairments | #101 |
addictive drugs | #101 |
functional pathways | #102 |
inhibition psychological | #102 |
individuals aud | #102 |
sob | #102 |
male neuropsychological tests | #102 |
parents offspring | #102 |
klf13 | #102 |
treatment seeking | #102 |
disorder psychiatric | #102 |
pgc | #103 |
clinical picture | #103 |
patients 12 months | #103 |
symptom profile | #103 |
schizophrenia mood disorders | #103 |
genome wide association | #103 |
ocd children | #103 |
touchstone | #103 |
genetic pedigree polymorphism | #103 |
tourette disorder | #104 |
genomic region | #104 |
individual sites | #104 |
schizophrenia metaanalysis | #104 |
controlled studies | #104 |
genetic mechanism | #104 |
motor competence | #104 |
1934 | #104 |
dsmiv diagnosis | #105 |
schizophrenia probands | #105 |
adhd review | #105 |
academic problems | #105 |
current article | #105 |
school dropout | #105 |
neuropsychological dysfunction | #105 |
drug dyskinesia | #105 |
cogs | #106 |
children methylphenidate | #106 |
humans lod | #106 |
children odd | #106 |
functional correlates | #107 |
lenticular | #107 |
chronic tic disorders | #107 |
λs | #107 |
consecutive sample | #107 |
sequential analysis | #107 |
matter volumes | #107 |
oral methylphenidate | #107 |
disorder female | #107 |
growth outcomes | #107 |
ldn | #107 |
daao | #107 |
mothers adhd | #107 |
adolescents bipolar disorder | #107 |
proband | #108 |
aged psychiatric | #108 |
site differences | #108 |
association cigarette smoking | #108 |
918 | #108 |
maternal warmth | #108 |
antimanic agents | #108 |
nesarc | #108 |
origin effects | #108 |
symptoms childhood | #108 |
pediatric psychopharmacology | #108 |
pervasive developmental | #108 |
n197 | #108 |
afni | #108 |
risk bipolar disorder | #109 |
psychosis proneness | #109 |
irrespective | #109 |
depression bipolar | #109 |
adhd medication | #109 |
total scores | #109 |
longitudinal trajectories | #109 |
neuroleptic medication | #109 |
worthy | #109 |
gabra6 | #109 |
adult adhd symptoms | #110 |
markers genome | #110 |
adhd parent | #110 |
linkage association | #110 |
rat models | #110 |
enlistment | #110 |
symptom ratings | #111 |
affective psychoses | #111 |
affective symptoms | #111 |
n107 | #111 |
selective reporting | #111 |
dao | #111 |
5httlpr genotype | #111 |
dimorphisms | #111 |
unmedicated | #112 |
impact exposure | #112 |
dopamine d4 receptors | #112 |
childhood risk factors | #112 |
pediatric obsessive | #112 |
substantial proportion | #112 |
bipolar parents | #112 |
independent studies | #112 |
factors social | #112 |
brain gene expression | #112 |
xr | #113 |
neuropsychological functions | #113 |
cronbach | #113 |
male prevalence | #113 |
functional neuroanatomy | #114 |
comorbid anxiety | #114 |
analysis statistical | #114 |
omim | #114 |
n34 | #115 |
genet | #115 |
liability | #115 |
schizophrenia severity | #115 |
nuclear families | #115 |
endorsed | #115 |
–r | #115 |
formulating | #116 |
diseases twins | #116 |
wm abnormalities | #116 |
schizophrenic psychology | #116 |
neuropsychological | #116 |
neurocognitive endophenotypes | #117 |
unipolar | #117 |
current symptoms | #117 |
quality life outcomes | #117 |
trait impulsivity | #117 |
z29 | #117 |
coordinated analysis | #117 |
polygenic association | #117 |
prenatal smoking | #117 |
prevention science | #118 |
grandiosity | #118 |
spm2 | #118 |
grandfathers | #118 |
definitively | #118 |
major female | #118 |
academic functioning | #118 |
satisfaction questionnaire | #118 |
large study | #118 |
genetic receptor serotonin | #118 |
midadolescence | #119 |
naa ratio | #119 |
efd | #119 |
dopaminergic genes | #119 |
method data | #119 |
schizophrenia linkage | #119 |
differences children | #120 |
misunderstandings | #120 |
t01 | #120 |
subfield volumes | #121 |
remittance | #121 |
disorder autism | #121 |
neurocognitive deficits | #121 |
aunts | #121 |
n108 | #121 |
cgibp | #121 |
new avenues | #121 |
pabs | #122 |
msit | #122 |
disregard | #122 |
adhd comorbidity | #122 |
v11 | #122 |
schizoaffective | #122 |
urvs | #122 |
levels adhd | #122 |
structural brain alterations | #122 |
anxious | #122 |
disorder depressive | #122 |
brain alterations | #122 |
psychopathology symptoms | #122 |
refute | #122 |
male risk | #122 |
neuropsychiatric disorders | #122 |
adhd ocd | #123 |
adcy2 | #123 |
wechsler | #123 |
age initiation | #123 |
clinical status | #123 |
chr psychosis | #123 |
p097 | #124 |
trios | #124 |
attention regulation | #124 |
twothirds | #124 |
laboratory observations | #124 |
wechsler intelligence scale | #124 |
longitudinal sample | #124 |
maximum lod score | #124 |
9q34 | #124 |
treatment subjects | #124 |
drug placebo | #124 |
g×s interaction | #124 |
patients chronic schizophrenia | #125 |
machine learning prediction | #125 |
caregiver strain | #125 |
psychosis individuals | #125 |
segregation analysis | #125 |
disorder risk | #125 |
anxiety problems | #125 |
odd conduct disorder | #126 |
positive negative symptoms | #126 |
biological parents | #126 |
memory adhd | #126 |
developmental aspects | #126 |
complex genetics | #126 |
parent version | #126 |
familial influences | #126 |
drug disorders | #126 |
taiwanese population | #127 |
drd2 | #127 |
psychiatric diagnoses | #127 |
stevenson | #127 |
attention child | #127 |
adult alleles | #127 |
genes | #127 |
disinhibited | #127 |
aged 6 | #128 |
neuropsychological measures | #128 |
familial | #129 |
intactness | #129 |
n102 | #129 |
implicate | #129 |
behavioral outcome | #129 |
personality assessment | #129 |
opiate antagonists | #129 |
families | #130 |
1990a | #130 |
adhd inattention | #130 |
retrospective data analysis | #130 |
moderating effects | #131 |
strong evidence | #131 |
differed | #131 |
kinesthesia | #131 |
register study | #131 |
bip mdd | #131 |
snps | #131 |
adolescents ocd | #131 |
mood anxiety disorders | #131 |
incapacitation | #131 |
pair 15 chromosomes | #131 |
animals attention | #131 |
late adolescents | #132 |
n79 | #132 |
child cognition | #132 |
hkd | #132 |
entire brain | #132 |
sodas | #132 |
learning disabilities | #132 |
p074 | #132 |
male prospective | #132 |
large european cohort | #132 |
childhood anxiety disorders | #132 |
linkage humans | #132 |
mph | #133 |
onset bipolar disorder | #133 |
heroin dependence | #133 |
children adults | #134 |
disorders social | #134 |
vntr | #134 |
preliminary examination | #134 |
association analyses | #135 |
social deficits | #135 |
male massachusetts | #135 |
adolescents young | #136 |
firstborns | #136 |
tspan8 | #136 |
olfactory identification | #136 |
risk factors smoking | #136 |
social environments | #136 |
relied | #136 |
sorcs3 | #136 |
psychological male memory | #137 |
schizophrenia affective disorders | #137 |
adolescent bipolar | #137 |
longitudinal evidence | #137 |
studies examined | #137 |
association asthma | #137 |
memantine treatment | #137 |
gaming | #137 |
expressed emotion | #137 |
asds | #138 |
evidence association | #138 |
control individuals | #138 |
biomarkers diagnosis | #138 |
mtor activation | #138 |
6q | #138 |
symptoms disorders | #139 |
n129 | #139 |
fhr | #139 |
meet | #139 |
mgh | #139 |
neuropsychiatric | #139 |
schizophrenia studies | #139 |
intriguing | #140 |
parental anxiety | #140 |
schizotypal traits | #140 |
n115 | #140 |
prss | #141 |
haplotype block | #141 |
disorder comorbidity | #141 |
genetic vulnerability | #141 |
emotional symptoms | #141 |
5ht1b receptors | #142 |
22q112 deletion syndrome | #142 |
disorders psychotic | #142 |
covid19 restrictions | #142 |
neurotrophic | #142 |
disorders personality | #142 |
peripheral biomarkers | #143 |
conduct | #143 |
risk factors obesity | #143 |
molecular genetics | #143 |
hydrogen exchangers | #143 |
fetal movement | #143 |
blind study | #144 |
statistical female humans | #144 |
child psychopathology | #144 |
diagnostic procedure | #144 |
humans linear | #144 |
g72 | #144 |
rfg | #144 |
agents tricyclic | #144 |
elston | #144 |
diagnosed attention | #144 |
affs | #145 |
genome‐wide association studies | #145 |
common genetic variants | #145 |
major psychoses | #145 |
n105 | #145 |
drug alcohol | #145 |
studies depressive | #145 |
early initiation | #145 |
individual symptoms | #145 |
p00018 | #145 |
genetic heterogeneity | #145 |
pcb exposure | #145 |
oppositional behavior | #146 |
atypicality | #146 |
intelligence quotient | #146 |
prenatal nicotine | #146 |
twin studies | #146 |
adult psychopathology | #146 |
warranted | #146 |
genders | #146 |
lras | #147 |
comprising | #147 |
intraindividual variability | #147 |
abbreviated | #147 |
p0016 | #147 |
histrionic | #147 |
cognitive variables | #148 |
adolescent young | #148 |
basc | #148 |
single locus | #148 |
sabp | #148 |
schizotypy | #149 |
adhd symptoms children | #149 |
risk mdd | #149 |
cdrsr | #149 |
parental substance | #149 |
brain correlates | #149 |
highlighting | #150 |
sud treatment | #150 |
categorical | #150 |
adhd relationship | #150 |
chrnb2 | #150 |
nonmedical | #150 |
impulsive | #150 |
synaptic biology | #151 |
higher burden | #151 |
consisted | #151 |
schizophrenia diagnosis | #152 |
functional impairment | #152 |
undegraded | #152 |
metaanalytic | #152 |
copy variants cnvs | #152 |
large sample | #152 |
linkage disequilibrium mapping | #152 |
httlpr | #152 |
atxn1 | #152 |
parent report | #152 |
autistic traits | #152 |
placebo subjects | #152 |
implicates | #152 |
diagnostic systems | #152 |
xq21 | #152 |
increases risk | #152 |
genomewide linkage | #153 |
alcohol conditions | #153 |
humans learning | #153 |
marginally | #153 |
editions | #153 |
schizophrenia deficits | #153 |
caucasian children | #153 |
5 httlpr | #153 |
schizophrenia bipolar disorder | #153 |
demoralization | #153 |
exposure maternal | #154 |
dsm | #154 |
disorder phenotype | #154 |
wisc | #154 |
emphasizing | #154 |
schizophrenia magnetic resonance | #154 |
atomoxetine placebo | #154 |
clarification | #155 |
ncsr | #155 |
year follow | #155 |
snpheritability | #155 |
genomewide scan | #155 |
humans polymorphism | #155 |
n84 | #156 |
600000 | #156 |
tests male | #156 |
genetic risk | #156 |
interpersonal functioning | #156 |
prospective controlled study | #156 |
enigma consortium | #157 |
panic disorder agoraphobia | #157 |
dopamine d4 | #157 |
new knowledge | #157 |
ppp2r2b | #158 |
clinical diagnostic | #158 |
htr2c | #158 |
myo5b | #158 |
genetic linkage | #158 |
sledai | #158 |
greatest | #158 |
oprm1 | #158 |
drd4 genotype | #158 |
adolescents | #158 |
primary setting | #158 |
cognitive tempo | #158 |
nonpersistent | #159 |
adult human brain | #159 |
quetiapine treatment | #159 |
selfratings | #159 |
patients substance | #159 |
dav | #159 |
teachers parents | #159 |
separation anxiety disorder | #160 |
smds | #160 |
humans impulsive | #160 |
medial temporal | #160 |
age onset | #160 |
hyperactivity disorders | #161 |
schizophrenia bipolar | #161 |
population samples | #161 |
adult adhd patients | #161 |
behavioral difficulties | #161 |
genetic component | #161 |
tic symptoms | #161 |
rats wky | #162 |
empirical tests | #162 |
disorder clinical | #162 |
disorder depression | #162 |
cooccurring disorders | #162 |
ksadspl | #162 |
140 | #162 |
5htt | #163 |
neuropsychological tests | #163 |
neurobiology | #163 |
sample | #163 |
paternal age | #163 |
dsmiv | #163 |
dn cells | #163 |
complex phenotype | #164 |
anxiety attention | #164 |
impairments | #164 |
illness schizophrenia | #164 |
familial liability | #164 |
diagnostic status | #164 |
risk subsequent | #165 |
neurocognitive performance | #165 |
boys girls | #165 |
washington university | #165 |
years children | #165 |
earlyonset schizophrenia | #166 |
12–14 | #166 |
domain criteria | #166 |
receptor gene | #166 |
antidepressant therapy | #166 |
linkage genetic | #166 |
symptom reduction | #166 |
cotwins | #166 |
alcohol disorders aud | #166 |
shared environment | #166 |
genetic influence | #166 |
association obesity | #167 |
ipsych | #167 |
moderates | #167 |
polygenic architecture | #168 |
leonard | #168 |
wisciii | #168 |
neurocognitive functions | #168 |
children 6 years | #168 |
duration illness | #169 |
n111 | #169 |
genetic association analysis | #169 |
perseverations | #169 |
multifactorial | #169 |
matter microstructure | #169 |
international congress | #169 |
cfg | #170 |
anxiety child | #170 |
single nucleotide schizophrenia | #170 |
disorders young | #170 |
risk gene | #170 |
arrb2 | #170 |
pharmacodynamic properties | #170 |
conditional probability | #170 |
traumas | #170 |
lgi | #170 |
functional laterality humans | #171 |
genesets | #171 |
child psychiatry | #171 |
n91 | #171 |
immune disorders | #172 |
inattention impulsivity | #172 |
treatment studies | #172 |
disorders study | #173 |
enuresis | #173 |
interpersonal sensitivity | #173 |
gabbr1 | #174 |
male mental | #174 |
tics | #175 |
large samples | #175 |
subsyndromal | #175 |
mph placebo | #176 |
confounds | #176 |
development schizophrenia | #176 |
hyperactive children | #177 |
ascertainment | #177 |
kraepelin | #177 |
disorders sex | #177 |
independent datasets | #177 |
confounded | #177 |
patients opioid | #177 |
suicide death | #177 |
n78 | #178 |
strong genetic component | #178 |
parent rated | #178 |
cortical surface | #178 |
behaviorally | #179 |
gene interactions | #179 |
pregnancy children | #179 |
genetic confounding | #179 |
strongest evidence | #179 |
underpinnings | #179 |
atomoxetine atx | #179 |
copy variants | #180 |
cvlt | #180 |
connectivity networks | #180 |
nagelkerke | #180 |
unemotional traits | #181 |
combinatory | #181 |
perceptual disorders | #181 |
mothers pregnancy | #181 |
scz bip | #182 |
htr4 | #182 |
control participants | #182 |
structured | #182 |
271 | #182 |
phenocopies | #182 |
mechanistic target | #183 |
rating | #183 |
studies gwas | #183 |
genotype humans | #183 |
psychometric testing | #183 |
effects atomoxetine | #184 |
based morphometry | #184 |
wei | #184 |
reading difficulties | #184 |
allison | #185 |
pdd | #185 |
genome human | #185 |
phenocopy | #185 |
reward sensitivity | #185 |
long acting | #185 |
n‐acetylcysteine | #185 |
predominately | #186 |
hyperactivity symptoms | #186 |
218 | #186 |
biomarker studies | #186 |
statistical female | #186 |
schizophrenia major depression | #187 |
schizophrenia evidence | #187 |
risperidone placebo | #187 |
stratifying | #187 |
autocorrelation | #188 |
blood biomarkers | #188 |
parahippocampus | #188 |
depression treatment | #188 |
3 untranslated region | #188 |
enigma | #188 |
bna | #189 |
genetic correlations | #189 |
differential association | #189 |
undertreatment | #189 |
linkage evidence | #190 |
childhood | #190 |
medication adhd | #190 |
scwt | #190 |
functioning children | #190 |
greater activation | #191 |
mph children | #191 |
psychiatric phenotypes | #191 |
social dysfunction | #191 |
clarify | #191 |
schedule female | #191 |
dopamine genes | #191 |
fsiq | #191 |
implicated | #191 |
mood disorder | #191 |
iasp | #192 |
association response | #192 |
612 years | #192 |
inconsistent findings | #194 |
joseph | #194 |
freedman | #194 |
sza | #195 |
polymorphisms snps | #195 |
cognitive endophenotypes | #195 |
placebo p001 | #195 |
clinical global | #195 |
perinatal complications | #197 |
dependence symptoms | #197 |
neural substrates | #197 |
overactivity | #197 |
arhgef9 | #197 |
wm performance | #197 |
ptk2b | #198 |
g×s | #198 |
mdd scz | #198 |
developmentally | #198 |
lifetime diagnosis | #198 |
snps schizophrenia | #198 |
male phenotype | #199 |
childhood symptoms | #199 |
raises | #199 |
asic1a | #199 |
bsd | #199 |
specific genes | #199 |
male | #199 |
asd adhd | #200 |
childhood attention | #200 |
neuropsychological battery | #200 |
mri data | #200 |
disruptive disorders | #200 |
small samples | #200 |
parents schizophrenia | #201 |
catecholomethyltransferase | #201 |
disorder humans | #201 |
functional genomics | #201 |
pain tolerance | #202 |
cognitive flexibility | #202 |
unaffected | #203 |
genetic liability | #203 |
control association | #203 |
neuropsychological correlates | #203 |
pdq | #203 |
childhood adulthood | #203 |
stopsignal task | #203 |
extend | #204 |
concurrent validity | #204 |
schizophreniform | #204 |
attentional control | #204 |
microsatellite marker | #204 |
adolescent psychiatry | #204 |
respond | #204 |
nonshared | #206 |
genes risk | #206 |
uptodate | #206 |
selfdirectedness | #206 |
sluggish cognitive tempo | #207 |
method drug | #207 |
prolactin levels | #208 |
parental alcohol | #208 |
prkg1 | #208 |
susceptibility schizophrenia | #208 |
baseline follow | #209 |
variable expression | #209 |
clinical benefits | #209 |
acds | #210 |
60mg | #210 |
5year followup | #210 |
n96 | #210 |
park2 | #210 |
maudsley | #210 |
correspondence | #210 |
vntr polymorphism | #211 |
predisposition disease | #211 |
greater risk | #211 |
apoe4 allele | #212 |
hkdc1 | #212 |
adult patients adhd | #212 |
ps005 | #212 |
dimensional models | #212 |
grm7 | #212 |
stroop task | #212 |
negative outcomes | #213 |
sampling strategy | #213 |
sought | #213 |
trauma ptsd | #213 |
replication studies | #213 |
continuous performance test | #214 |
rare cnvs | #214 |
schizophrenia chinese | #214 |
cvltii | #214 |
humans neuropsychological | #214 |
suggestive evidence | #214 |
disorders models | #214 |
adult cognition | #215 |
lifetime version | #215 |
male mental disorders | #215 |
bilag | #215 |
vivo correlation | #216 |
functional mri study | #216 |
antisocial personality | #217 |
glr | #217 |
male schizophrenia | #217 |
chromosome 15 | #217 |
parental | #218 |
trim31 | #218 |
gene based | #218 |
panic | #218 |
hippocampal subfield | #218 |
polygenic | #219 |
study selection | #219 |
misunderstood | #219 |
snpa | #220 |
normal controls | #220 |
drug double | #220 |
symptoms adults | #221 |
studies cognition | #221 |
irritable mood | #221 |
telephone interview | #221 |
parental psychopathology | #221 |
triangularis | #221 |
patient engagement | #222 |
childhoodonset | #222 |
score male | #222 |
n76 | #222 |
diagnoses | #222 |
methyltransferase comt | #222 |
study findings | #223 |
revisited | #223 |
learning disability | #223 |
sensing ion | #224 |
gria2 | #224 |
axis disorders | #224 |
effective treatments | #224 |
adhd sleep | #224 |
abnormalities schizophrenia | #224 |
default network | #225 |
coordination disorder | #225 |
bipolar spectrum | #225 |
hk3 | #226 |
children placebo | #226 |
inattentiveness | #226 |
subfields | #226 |
disorder study | #227 |
scales psychotic | #227 |
dependent variables | #227 |
subcortical regions | #227 |
unemotional | #227 |
criteria diagnosis | #227 |
individual variability | #227 |
comorbid anxiety disorders | #228 |
male twins | #228 |
age subjects | #228 |
control based | #228 |
atomoxetine treatment | #228 |
equally | #229 |
structural abnormalities | #229 |
birth complications | #229 |
overlapped | #229 |
psychiatric outcomes | #230 |
international multicenter | #231 |
heritable | #231 |
commission errors | #231 |
4years | #231 |
risk indicators | #231 |
hyperactivity behavior | #232 |
serotonin transporter gene | #232 |
differences prevalence | #232 |
study sample | #234 |
candidate genes | #234 |
worse performance | #234 |
probabilistic forecasts | #235 |
disorder medication | #235 |
discriminating | #235 |
shr wky rats | #236 |
route administration | #238 |
agoraphobia | #238 |
reliably | #238 |
fifty years | #238 |
placebo response | #238 |
allelic heterogeneity | #239 |
pdag | #240 |
nosology | #240 |
acid oxidase | #240 |
scientific data | #240 |
patients siblings | #240 |
healthy siblings | #240 |
adolescent offspring | #241 |
disorder asd | #241 |
symptoms quality | #241 |
adequately | #241 |
doubleblind | #241 |
sodium hydrogen | #242 |
psychiatric comorbidities | #242 |
joint analysis | #242 |
reward processing | #242 |
neurodevelopmental model | #242 |
impulsive choice | #242 |
onset obsessive | #243 |
female | #243 |
aggressive behaviors | #243 |
patients relatives | #243 |
valid | #243 |
n74 | #244 |
giftedness | #244 |
interregional | #245 |
paliperidone | #245 |
population differences | #245 |
disorder ptsd | #245 |
5ht2a receptor | #245 |
adversity | #245 |
expression genetic | #246 |
cadm2 | #246 |
community controls | #246 |
dsmivtr | #246 |
812 | #247 |
motor performance | #247 |
studies associations | #248 |
chinese families | #248 |
cigarette smoking | #248 |
epigenetic studies | #248 |
developmental disorder | #249 |
childs | #251 |
behavioral characteristics | #251 |
hypoactivation | #252 |
german patients | #252 |
intellect | #253 |
female subjects | #253 |
iqs | #253 |
genomewide association | #253 |
tourette | #253 |
studies metaanalysis | #254 |
kappas | #254 |
schizophrenia adult | #254 |
study schizophrenia | #254 |
benzodiazepine | #254 |
cpt performance | #254 |
conduct problems | #255 |
shared genetic | #256 |
biochemical studies | #256 |
cacna1c gene | #256 |
larsson | #256 |
carlson | #257 |
children adhd symptoms | #257 |
endorsement | #259 |
parental depression | #259 |
year study | #259 |
piq | #260 |
n61 | #260 |
diagnosis | #261 |
anxiety depressive disorders | #261 |
dexamphetamine | #261 |
pharmacotherapy | #261 |
22q11ds | #263 |
sex factors | #263 |
genomewide linkage scan | #263 |
obsessive compulsive disorder | #263 |
selfreports | #263 |
fluid intelligence | #263 |
disorder personality | #264 |
distinct subtypes | #264 |
conceptualized | #264 |
confirm | #264 |
attention problems | #264 |
adverse health | #264 |
long term outcomes | #265 |
5090 | #266 |
schizophrenia cases | #266 |
ptsd risk | #266 |
new models | #266 |
diagnostic validity | #266 |
scz mdd | #267 |
phenotype schizophrenia | #267 |
diagnosis schizophrenia | #268 |
genetic approaches | #268 |
neuropsychological impairment | #268 |
strong support | #268 |
diagnostic process | #269 |
test scores | #269 |
years baseline | #269 |
largest | #270 |
segregate | #270 |
age effects | #270 |
withdrawn | #270 |
phlda1 | #270 |
sibling pairs | #271 |
genetic overlap | #271 |
circadian genes | #271 |
social adversity | #271 |
symptoms assessed | #271 |
adult psychiatric | #271 |
diagnostic issues | #272 |
structural brain | #272 |
rora | #273 |
444 | #273 |
alcohol smoking | #273 |
statistics topic | #273 |
age | #273 |
szs | #273 |
4year | #273 |
schizophrenia siblings | #273 |
search terms | #273 |
22 years | #274 |
sleep behavior | #274 |
surgency | #275 |
maf1 | #275 |
reading disability | #275 |
underlie | #275 |
familial schizophrenia | #276 |
missingness | #276 |
t102c | #276 |
2q | #276 |
adhd healthy controls | #277 |
nicotinic schizophrenia | #277 |
growing evidence | #277 |
adolescent risk | #277 |
mania symptoms | #277 |
clinical setting | #278 |
manual | #278 |
nr3c1 | #278 |
early psychosis | #278 |
synaptosomal | #278 |
nicotine dependence | #279 |
ocd | #279 |
silico approach | #279 |
intelligence scale | #279 |
polygenic risk | #280 |
rating scale | #280 |
child parent | #280 |
remitted | #280 |
cognition female | #280 |
brain volumes | #280 |
n47 | #280 |
acting | #280 |
abuser | #280 |
disorders adult | #281 |
psychotic bipolar | #281 |
phenotyped | #281 |
individuals | #281 |
premature death | #281 |
collaborative analysis | #282 |
onset ocd | #282 |
reading problems | #282 |
response inhibition | #282 |
5ht1b | #282 |
antisocial behaviors | #283 |
continue | #283 |
titrated | #283 |
velo | #283 |
aspd | #284 |
gria3 | #285 |
quantitative traits | #285 |
3untranslated region | #285 |
neuroanatomical | #285 |
normal variation | #285 |
neoffi | #285 |
siblings patients | #286 |
quantitative analyses | #286 |
scale children | #286 |
explication | #286 |
swanson | #286 |
clues | #286 |
effects age | #287 |
schizophrenia abnormalities | #288 |
deficit schizophrenia | #288 |
postmortem brain | #289 |
bmisds | #289 |
22q112 | #290 |
psychiatric traits | #290 |
pediatric ocd | #290 |
disease haplotypes | #290 |
publication bias | #291 |
subcortical volumes | #291 |
low serum levels | #291 |
substrain | #292 |
modest | #293 |
groups children | #293 |
subjective responses | #294 |
salary | #294 |
cognition disorders | #294 |
hypertensive rat | #294 |
european populations | #295 |
interference control | #295 |
dtnbp1 | #295 |
risk factors children | #295 |
post‐traumatic stress disorder | #295 |
adverse impact | #295 |
psychosis schizophrenia | #295 |
ldsc | #296 |
continuous performance | #296 |
executive functions | #296 |
obesity overweight | #297 |
anxiety disorder | #297 |
asd traits | #297 |
early onset | #297 |
discriminated | #298 |
diagnostic approach | #298 |
reanalysis | #298 |
negative symptom | #299 |
predisposition | #299 |
cortical thickness | #300 |
qvalues | #300 |
effects stress | #300 |
roc analysis | #301 |
cognitive measures | #301 |
psychiatric hospitalization | #301 |
published literature | #302 |
states adolescent | #302 |
intrasubject variability | #302 |
emotional problems | #302 |
prefrontal function | #302 |
permuted | #303 |
height body | #303 |
psychometrics | #303 |
795 | #304 |
psychiatric conditions | #304 |
interviewers | #305 |
manifest | #305 |
ats | #305 |
affective disorders | #305 |
aggressive behavior | #305 |
case subjects | #305 |
dsm5 | #305 |
early morning | #306 |
dopamine transporter | #306 |
n62 | #307 |
learning disorder | #307 |
general psychopathology | #308 |
gene environment | #309 |
omission errors | #309 |
spencer | #309 |
myh9 | #309 |
membrane transport | #309 |
documented | #309 |
perseveration | #309 |
genetic schizophrenia | #310 |
memory wm | #310 |
efficacy treatment | #310 |
motor domain | #310 |
adolescent aggression | #310 |
life social support | #310 |
rdoc | #311 |
stroop test | #312 |
gender age | #312 |
childhood adolescence | #312 |
mainstays | #312 |
npsr1 | #313 |
mapping female | #313 |
underscore | #314 |
genetic analyses | #314 |
bedtimes | #315 |
risk estimation | #315 |
asb | #317 |
replicated | #317 |
dorsolateral prefrontal cortex | #317 |
demonstrable | #318 |
schizophrenia review | #318 |
5ht2c | #319 |
individual genes | #319 |
n55 | #319 |
adolescent adrenergic | #320 |
addictive disorders | #321 |
shared genetic influences | #321 |
intelligence tests | #321 |
gene | #321 |
robins | #322 |
humans longitudinal | #322 |
bipolar type | #322 |
risperidone treatment | #322 |
127 | #322 |
abusers | #323 |
time variability | #323 |
nolan | #324 |
guanfacine | #324 |
conceptual models | #324 |
manic | #325 |
yielded | #326 |
sex characteristics | #326 |
neonatal abstinence syndrome | #326 |
status female | #327 |
spurious | #327 |
xq26 | #327 |
impaired | #327 |
comprised | #328 |
etiologic | #328 |
8q | #329 |
disorders pervasive | #329 |
metaanalyses | #330 |
sexdifferences | #330 |
overrepresented | #330 |
drug response | #331 |
scores patients | #331 |
htr2a | #331 |
women schizophrenia | #332 |
naltrexone | #333 |
familial factors | #333 |
txndc5 | #333 |
expression brain | #333 |
cognitive dysfunctions | #334 |
obesity diabetes | #334 |
multiple comparisons | #334 |
mood disorders | #335 |
forthcoming | #335 |
adler | #335 |
24weeks | #335 |
humans mental | #336 |
rey | #336 |
methylphenidate placebo | #336 |
persist | #336 |
inferior parietal lobule | #336 |
neuropsychological test | #337 |
777 | #337 |
mobp | #337 |
tph2 | #337 |
asd individuals | #337 |
disentangle | #338 |
psychopathological | #339 |
evening | #339 |
patients attention | #339 |
replications | #339 |
disorder ocd | #340 |
exclusion criteria | #340 |
evidence linkage | #340 |
pnmt | #340 |
consistently | #340 |
placebo effects | #341 |
intelligence | #341 |
encompassing | #341 |
treatment bipolar | #341 |
phobic | #342 |
bipolarity | #342 |
visual memory | #342 |
maoa genotype | #342 |
neuroimaging studies | #342 |
multicenter analysis | #342 |
mood problems | #344 |
schizoaffective disorder | #344 |
frontal pole | #344 |
comorbid diagnoses | #344 |
tbv | #344 |
integrated analysis | #344 |
catechol methyltransferase | #345 |
casecontrol studies | #345 |
systematically | #345 |
864 | #346 |
gifts | #346 |
study genotype | #347 |
confused | #347 |
mdd bpd | #347 |
converging | #348 |
psychotic | #348 |
tic severity | #348 |
schizotypal personality disorder | #349 |
collaborative study | #349 |
temporal processing | #349 |
aetiological | #350 |
methylphenidate atomoxetine | #350 |
adolescent anxiety | #350 |
suspiciousness | #351 |
disequilibrium | #352 |
receptor genes | #352 |
adults children | #352 |
distractibility | #352 |
impairing | #353 |
disease genome | #353 |
reln | #354 |
gabra1 | #354 |
child attention | #354 |
brain atlas | #354 |
genetic environmental | #354 |
substantial | #354 |
maob | #354 |
disorders middle | #354 |
executive attention | #354 |
male adolescent | #355 |
rgs4 | #355 |
prodh | #355 |
dsmiii | #355 |
phobic disorders | #356 |
schizophrenia data | #356 |
heterogeneous disorder | #356 |
measures attention | #357 |
chrna7 | #357 |
children anxiety disorders | #357 |
gottesman | #358 |
maternal cigarette smoking | #359 |
deviant | #359 |
psychiatric symptoms | #359 |
disorder patients | #359 |
persists | #359 |
symptom scores | #360 |
linkage analysis | #360 |
n54 | #361 |
neuroleptic treatment | #361 |
chromosomal regions | #361 |
social adjustment | #362 |
dorsolateral prefrontal | #363 |
genetic findings | #364 |
tid | #365 |
paralimbic | #365 |
core symptoms | #366 |
confirmation | #366 |
elevated risk | #366 |
771 | #367 |
pediatric populations | #367 |
memory load | #367 |
bpd mdd | #368 |
comparison groups | #368 |
study entry | #368 |
risk psychopathology | #368 |
young adulthood | #369 |
differential involvement | #369 |
702 | #369 |
hyperactivityimpulsivity | #369 |
representativeness | #370 |
differential susceptibility | #370 |
nervousness | #370 |
current concepts | #371 |
damphetamine | #371 |
schizophrenia risk | #371 |
endorse | #372 |
comt gene | #372 |
prevention strategies | #372 |
replicate | #372 |
5httlpr | #373 |
genomewide association studies | #373 |
executive function | #373 |
snp heritability | #374 |
small sample | #374 |
driving performance | #374 |
dozens | #375 |
wide analysis | #375 |
scz | #375 |
916 | #375 |
medication children | #376 |
teenage | #376 |
emphases | #376 |
sas | #377 |
genetic architecture | #377 |
memory short | #377 |
data studies | #377 |
child adolescent | #377 |
children medication | #377 |
children adolescents | #378 |
schizotypal personality | #378 |
impression | #378 |
control adults | #379 |
marriages | #379 |
opd | #380 |
ht1b | #380 |
youths | #380 |
converged | #380 |
pearson | #380 |
disorder diagnostic | #381 |
culmination | #381 |
invaluable | #381 |
receptors dopamine | #381 |
relevant articles | #381 |
general cognitive ability | #381 |
methylphenidate children | #381 |
overlap | #381 |
adolescent patients | #382 |
chisquare | #382 |
carefully | #383 |
antimanic | #383 |
psychopharmacological treatment | #383 |
psychopathologies | #383 |
researched | #384 |
summary statistics | #384 |
gad2 | #385 |
7r | #385 |
treatment children | #386 |
multigenerational | #386 |
18p | #386 |
chinese subjects | #387 |
neural activation | #387 |
npas2 | #388 |
evenings | #388 |
versa | #388 |
contrasted | #388 |
childhood depression | #389 |
adhd symptomatology | #389 |
brain circuits | #390 |
perinatal morbidity | #390 |
lefthandedness | #390 |
disorder symptoms | #390 |
studies children | #390 |
handedness | #390 |
genetic predisposition | #391 |
interaction genetic | #391 |
lambert | #392 |
schizophrenia susceptibility | #392 |
comorbid substance | #392 |
p54 | #393 |
substance users | #394 |
genes expression | #394 |
function humans | #395 |
dopamine norepinephrine | #395 |
hippocampal subfields | #395 |
adolescents adults | #396 |
disorders schizophrenia | #397 |
fbat | #397 |
mental health children | #397 |
3methoxy4hydroxyphenylglycol | #397 |
psychometric | #397 |
schizophrenia disorder | #397 |
clinical risk psychosis | #398 |
spm8 | #398 |
earlier onset | #398 |
wandering | #398 |
neuropsychological testing | #400 |
control sample | #401 |
core symptom | #402 |
inattention symptoms | #402 |
academic outcomes | #402 |
suffocation | #402 |
relations male | #403 |
implications findings | #403 |
inconsistencies | #403 |
hyperparameter | #405 |
psychostimulants | #405 |
diagnosis children | #406 |
n52 | #406 |
vntrs | #406 |
neuropsychiatric conditions | #406 |
parahippocampal | #406 |
attending | #407 |
cognitive inhibition | #408 |
childhood risk | #408 |
behavior genetics | #409 |
communitybased | #409 |
0038 | #409 |
distinct subsets | #410 |
substance | #410 |
children studies | #411 |
dextroamphetamine | #411 |
twin study | #411 |
impulsive behavior | #411 |
reading comprehension | #411 |
consistent evidence | #412 |
interview | #412 |
childhood anxiety | #412 |
tourette syndrome | #412 |
neanderthal | #412 |
psychotic disorders | #412 |
apoe4 | #412 |
moderated | #413 |
systematic literature search | #413 |
anticipation | #413 |
reviewing | #414 |
performance tests | #414 |
151 | #414 |
volition | #415 |
polymorphism snp | #415 |
genetic receptor | #416 |
schizotypal | #416 |
elucidating | #416 |
functional effects | #417 |
effects brain | #417 |
adolescent psychiatric | #418 |
adult intelligence | #418 |
conferred | #418 |
deletion syndrome | #419 |
srsa | #419 |
questionnaires adolescent | #419 |
genetic association | #419 |
daily doses | #420 |
kdm4a | #420 |
antidepressive agents | #420 |
dopamine d4 receptor | #420 |
sexes | #421 |
modestly | #421 |
adult subjects | #421 |
cdis | #422 |
operating characteristic | #422 |
iccs | #422 |
drug dependence | #422 |
tricyclic | #423 |
medicated | #423 |
reliability validity | #423 |
gcta | #424 |
characteristic curve | #424 |
discovery sample | #425 |
subtests | #425 |
transport proteins | #425 |
cardiff | #426 |
parent ratings | #426 |
attain | #427 |
hum | #427 |
spectrum disorders | #428 |
diversion | #428 |
brain volume | #428 |
persistent symptoms | #429 |
male obsessive | #430 |
disentangling | #431 |
personality development | #431 |
teacher | #432 |
operating characteristics | #432 |
uniquely | #433 |
peps | #434 |
wistarkyoto | #435 |
frequency genotype | #436 |
perceptual organization | #436 |
cprs | #436 |
12q | #436 |
1433 | #436 |
disorder brain | #437 |
relatives patients | #437 |
lower scores | #437 |
grin2a | #437 |
srs2 | #438 |
adolescent psychopathology | #438 |
visual learning | #438 |
correlation coefficients | #438 |
impulsiveness | #438 |
toddlerhood | #438 |
nominal | #439 |
genetic genetic predisposition | #439 |
risk psychosis | #439 |
digit span | #439 |
22q112ds | #439 |
snps association | #440 |
major risk factor | #440 |
aged neuropsychological | #440 |
method female | #440 |
corroborated | #441 |
gmo | #441 |
trex | #441 |
white matter microstructure | #441 |
allelic association | #441 |
post hoc analysis | #441 |
meaningful | #441 |
disorders autism | #442 |
adult analysis | #442 |
logistic regression model | #442 |
planum temporale | #442 |
female functional | #442 |
virtual histology | #442 |
n80 | #443 |
differential female | #444 |
conferring | #444 |
disorders surveys | #444 |
emphasize | #444 |
10 year | #444 |
pcdh10 | #445 |
862 | #446 |
ntrk3 | #446 |
534 | #446 |
nucleotide receptors | #446 |
statistic | #446 |
holland | #447 |
behavior child | #448 |
originally | #448 |
genome wide | #448 |
motor coordination | #448 |
expressiveness | #449 |
earlier age | #449 |
risk variants | #450 |
early response | #450 |
wistar kyoto | #450 |
sex | #451 |
exceptions | #451 |
brain abnormalities | #452 |
clinical expression | #452 |
prevalence correlates | #452 |
subsequent risk | #452 |
children adolescent | #456 |
chat | #456 |
zscores | #457 |
psychiatry | #457 |
79 | #457 |
masse | #458 |
preliminary study | #458 |
independently | #458 |
structural magnetic | #458 |
22q112 deletion | #460 |
522 | #460 |
psychotic disorders schizophrenia | #460 |
lander | #460 |
genetic correlation | #460 |
polygenic risk score | #460 |
smoking pregnancy | #461 |
hyperkinesis | #461 |
jw | #462 |
d4 | #463 |
neuroanatomy | #465 |
pregnancy complications | #465 |
life treatment | #465 |
decrements | #465 |
affection | #465 |
runs | #466 |
control rates | #466 |
gene sets | #466 |
anxiety depressive | #467 |
mini | #467 |
inbred wky | #467 |
bpad | #468 |
subjects patients | #469 |
genetic effects | #470 |
disorders treatment | #470 |
patient adherence | #470 |
cacna1c | #470 |
remission relapse | #471 |
receiver operating | #471 |
risk allele | #472 |
psychology adolescent | #472 |
response remission | #473 |
chrna4 | #473 |
norepinephrine transporter | #474 |
environmental risk factors | #474 |
plp1 | #474 |
cautious | #476 |
developmental coordination | #476 |
opioid addiction | #476 |
multiple measures | #477 |
obesity children | #477 |
broader | #478 |
5th | #479 |
multiplex families | #479 |
dysthymia | #479 |
humans | #480 |
adds | #480 |
symptom | #480 |
genetic risk variants | #480 |
diagnostic categories | #481 |
semistructured | #481 |
cortex child | #481 |
maternal anxiety | #482 |
data extraction | #482 |
genotyped | #482 |
etiology | #483 |
arithmetic | #483 |
nfil3 | #484 |
conception | #484 |
sml | #484 |
treatment methylphenidate | #484 |
verbal learning | #484 |
adulthood | #485 |
756 | #485 |
agents bipolar | #485 |
epidemiologically | #486 |
baseline age | #486 |
outcome variables | #486 |
evaluates | #487 |
adult anxiety | #487 |
symptom dimensions | #487 |
123 | #487 |
spontaneity | #488 |
female adolescents | #489 |
unpublished | #489 |
longterm effects | #489 |
genetic disorders | #489 |
neuropsychiatric disorder | #490 |
shared environmental | #490 |
administration schedule | #490 |
schizophrenia autism | #490 |
common variant | #492 |
schizophrenia age | #492 |
smoking prevention | #492 |
pnds | #493 |
overlapping | #493 |
frequency genetic | #495 |
antisocial personality disorder | #495 |
late adolescence | #495 |
anxiety | #497 |
schizophrenia patients | #497 |
restlessness | #497 |
separation anxiety | #497 |
psychobiology | #497 |
pair human | #497 |
bonferroni | #498 |
longitudinal studies | #498 |
candidate | #499 |
daoa | #499 |
addressed | #499 |
genetic mechanisms | #499 |
placebos | #499 |
case reports | #500 |
identifying | #500 |
comt val158met polymorphism | #500 |
nocebo | #501 |
rat strains | #501 |
d4 receptors | #501 |
additional evidence | #503 |
865 | #503 |
verbal memory | #503 |
circadian clock genes | #505 |
child executive | #505 |
fallacy | #506 |
n26 | #506 |
subscale | #506 |
continued | #507 |
cooperativeness | #507 |
reflecting | #508 |
tobacco disorder | #508 |
developing schizophrenia | #509 |
delay discounting | #509 |
agg | #510 |
educational status | #511 |
dichotomous | #511 |
shared | #511 |
95 death | #512 |
identifiable | #512 |
p80 | #512 |
obsessive compulsive | #512 |
risk haplotype | #513 |
lod | #513 |
coaggregation | #514 |
disproportionate | #514 |
morning | #515 |
disorders depression | #515 |
phis | #515 |
assessments | #515 |
total sample | #516 |
normal control | #516 |
cognitive traits | #517 |
n39 | #517 |
contributing | #517 |
15q | #518 |
missing link | #519 |
fn1 | #520 |
pbat | #520 |
environmental influences | #520 |
gyrus cinguli | #521 |
dichotic | #521 |
specificity ppv | #521 |
selfreport | #522 |
polymorphism single | #522 |
social class | #522 |
disorder obsessive | #522 |
attention memory | #523 |
dibenzothiazepines | #523 |
dmi | #524 |
phg | #524 |
adult bipolar | #524 |
assortative | #524 |
dedication | #524 |
sciencedirect | #525 |
disorder treatment | #525 |
pacific island | #525 |
clinical diagnoses | #525 |
covariates | #525 |
affiliations | #526 |
functioning | #527 |
criminality | #527 |
persistence | #527 |
adverse life events | #528 |
adolescent children | #528 |
depression anxiety disorders | #528 |
symptomatic remission | #528 |
design study | #528 |
flnc | #529 |
parental reports | #529 |
community samples | #529 |
compulsive disorder | #529 |
abrupt | #529 |
ruled | #529 |
control children | #530 |
tagsnps | #530 |
increased burden | #531 |
strongest | #531 |
medications | #531 |
existing studies | #532 |
n40 | #532 |
autism schizophrenia | #532 |
clinical sample | #533 |
subjects age | #533 |
analyses conducted | #534 |
temperament character | #534 |
asd | #535 |
selective review | #535 |
intercorrelations | #535 |
parsing | #537 |
global impression | #537 |
child adhd | #538 |
autistic symptoms | #538 |
models genetic | #538 |
d4 receptor | #539 |
personality factors | #541 |
milder | #541 |
lobe humans | #542 |
single nucleotide | #543 |
disease genotype | #543 |
taiwanese | #543 |
severe symptoms | #544 |
independent samples | #544 |
complexities | #544 |
ld | #545 |
population sample | #545 |
choice behavior | #546 |
cognitive impairments | #546 |
genetic influences | #547 |
functional variant | #548 |
healthy control subjects | #548 |
computer program | #548 |
oral route | #549 |
risk children | #549 |
dichotomized | #549 |
behavior male | #549 |
patients schizophrenia | #549 |
clash | #549 |
schizophrenia study | #549 |
nonclinical sample | #549 |
genetic pathways | #550 |
fam | #550 |
765 | #550 |
case control | #551 |
define | #551 |
motor inhibition | #551 |
ideally | #551 |
performance test | #552 |
major diagnosis | #552 |
n29 | #553 |
verbal | #553 |
preadolescent | #554 |
suggests | #555 |
release oral | #555 |
viewed | #555 |
prs schizophrenia | #555 |
spectrum disorder | #556 |
phenotypic features | #556 |
child anxiety | #557 |
nogo task | #557 |
neuropsychiatric diseases | #557 |
africanamerican | #558 |
neurodevelopmental | #558 |
equivocal | #558 |
justify | #559 |
response variability | #560 |
gray matter volumes | #560 |
higher rate | #561 |
profoundly | #563 |
caregivers children | #563 |
risk smoking | #565 |
adolescents risk | #565 |
risky behaviors | #566 |
twins female | #566 |
intermediate phenotypes | #566 |
patients sud | #566 |
4th edition | #566 |
3050 | #567 |
haplotype | #567 |
neurocognitive impairment | #567 |
unaffected relatives | #568 |
replication study | #569 |
10−8 | #570 |
onsets | #570 |
environment interaction | #570 |
diverging | #570 |
keywords | #571 |
birthday | #571 |
risk genes | #571 |
dose reduction | #573 |
irritability | #574 |
obesity body mass | #574 |
white matter abnormalities | #574 |
inbred shr | #575 |
questionnaires adult | #575 |
asd diagnosis | #576 |
spaced | #576 |
gyri | #576 |
chromosomes human | #577 |
parent | #577 |
medical genetics | #577 |
individually | #577 |
schizophrenia sample | #577 |
finetuning | #578 |
82 | #578 |
impulsivity | #578 |
symptoms children | #579 |
subsample | #579 |
5httlpr polymorphism | #580 |
development anxiety | #580 |
preschool age | #580 |
cold pressor test | #580 |
haplotype analysis | #581 |
rdc | #582 |
psychiatric association | #582 |
apol1 | #582 |
drd1 | #582 |
3rd | #583 |
delinquent behavior | #583 |
hk1 | #584 |
new approaches | #584 |
separately | #585 |
fine mapping | #585 |
data children | #585 |
neuroanatomical correlates | #586 |
traumatized | #587 |
examine | #588 |
compared controls | #588 |
nback task | #588 |
defaultmode network | #588 |
138 | #589 |
haplotypes humans | #590 |
40mg | #591 |
patients comorbid | #591 |
estonian | #591 |
behavior adult | #591 |
criticism | #593 |
2005 | #594 |
concordant | #594 |
brain child | #595 |
cognition schizophrenia | #596 |
overrepresentation | #596 |
snap25 | #597 |
nonpharmacologic | #597 |
discounted | #597 |
generalizable | #597 |
899 | #598 |
new directions | #598 |
affymetrix | #598 |
differences brain | #600 |
genetic factors | #601 |
specific phobia | #603 |
clinical settings | #604 |
diagnosing | #604 |
diagnostic specificity | #604 |
performance children | #606 |
disorganized | #606 |
clinician | #606 |
cognitive outcomes | #606 |
social environment | #607 |
personality traits | #607 |
sizeable | #608 |
4 6 | #608 |
small fraction | #608 |
executive dysfunctions | #609 |
true | #609 |
antisocial behavior | #609 |
gold standard | #609 |
polygenic risk scores | #610 |
functional outcomes | #610 |
informant | #611 |
pleiotropic | #612 |
complex disorders | #612 |
chromosome 6 | #613 |
grandmothers | #614 |
schizophrenia brain | #614 |
educational achievement | #614 |
curve analysis | #615 |
behavior disorder | #615 |
disease etiology | #615 |
snp markers | #615 |
memory deficits | #616 |
genetic epidemiology | #616 |
prevalence severity | #616 |
tscores | #617 |
genome scans | #617 |
african children | #618 |
genetic associations | #618 |
val158met | #618 |
differ | #618 |
correcting | #619 |
digeorge | #619 |
vigilance | #620 |
genetic markers | #620 |
md | #621 |
antisocial behaviour | #621 |
confer | #622 |
adverse health outcomes | #623 |
juvenile delinquency | #624 |
receptor serotonin | #624 |
executive control | #625 |
misconceptions | #625 |
executive dysfunction | #625 |
mood stabilizers | #626 |
seeks | #627 |
hrr | #627 |
attentional deficits | #627 |
fibromyalgia | #629 |
child gender | #629 |
treatment disorder | #629 |
schizophrenia findings | #630 |
reject | #631 |
deficits schizophrenia | #631 |
teacher ratings | #632 |
needed | #633 |
girls boys | #634 |
genetic basis | #635 |
tiny | #637 |
generalisability | #638 |
icv | #638 |
obsessivecompulsive disorder | #638 |
disease genotype humans | #639 |
longitudinal | #640 |
adult outcomes | #641 |
ranks | #641 |
advertisement | #641 |
illness duration | #642 |
inconsistent | #643 |
gateway | #643 |
expression genes | #644 |
premorbid | #645 |
twin pairs | #645 |
subjects schizophrenia | #646 |
functioning autism | #646 |
exacerbate | #647 |
methodological | #648 |
17 years | #649 |
galantamine | #650 |
gene association | #652 |
avoidant | #652 |
treatment effects | #652 |
128 | #653 |
hyperactivity inattention | #653 |
physical conditions | #653 |
federation | #654 |
stroop | #654 |
intergenerational transmission | #655 |
reward anticipation | #656 |
random allocation rats | #656 |
bipolar disorder schizophrenia | #656 |
studies evidence | #657 |
groups compared | #658 |
impairment | #658 |
psychosocial treatment | #658 |
boldness | #658 |
volumes | #659 |
hypomanic | #659 |
association exposure | #660 |
core feature | #661 |
poorer performance | #661 |
structural alterations | #662 |
peer relations | #662 |
referrals | #662 |
lowlevel | #665 |
permission | #665 |
digeorge syndrome | #665 |
subcortical | #666 |
dacc | #666 |
psychiatric illnesses | #667 |
mood | #668 |
swedish population | #669 |
prominent | #669 |
phenotypic expression | #672 |
neurobiological | #675 |
time children | #676 |
impulsive behaviors | #677 |
disorders memory | #678 |
unselected | #678 |
sleep difficulties | #679 |
129 | #679 |
middle childhood | #680 |
psychopathological symptoms | #680 |
mental disorders humans | #680 |
gene frequency | #681 |
neurotic | #681 |
quetiapine | #682 |
trait | #682 |
semantic fluency | #682 |
soviet union | #682 |
severe phenotype | #683 |
scales | #685 |
east asian | #685 |
remitting | #685 |
p0019 | #687 |
chromosomal region | #688 |
17q | #688 |
children groups | #688 |
postmortem brains | #689 |
younger children | #689 |
fibromyalgia patients | #689 |
average age | #694 |
tcas | #694 |
disorder schizophrenia | #694 |
testretest reliability | #695 |
parcellation | #696 |
cortical surface area | #696 |
participants | #696 |
5years | #697 |
4–5 | #697 |
pharmacokinetic profile | #697 |
relevant studies | #699 |
122 | #699 |
drug abuse | #699 |
effects methylphenidate | #700 |
quota | #701 |
adult mental | #701 |
nonrandom | #701 |
illness surveys | #701 |
pleiotropic effects | #704 |
treatmentnaïve | #704 |
gwa studies | #704 |
follow studies | #705 |
pathogenesis schizophrenia | #706 |
preschool years | #706 |
adaptive functioning | #706 |
autism spectrum | #708 |
school settings | #709 |
p009 | #709 |
children diagnosed | #710 |
informative | #713 |
chronic schizophrenia | #713 |
maternal report | #714 |
eric | #714 |
prs | #714 |
dysphoric | #714 |
misuse | #714 |
disorders substance | #715 |
728 | #715 |
stress disorder | #715 |
ethanol consumption | #715 |
641 | #716 |
3 weeks | #716 |
contradictory | #717 |
groundwork | #719 |
abstraction | #719 |
meta‐analysis | #720 |
multiple genes | #721 |
clinical population | #721 |
household income | #722 |
recurrence risk | #722 |
memory | #723 |
cognitive load | #724 |
proponents | #725 |
cinguli | #725 |
common snps | #726 |
gender dysphoria | #726 |
male adolescents | #726 |
lateonset | #726 |
attention deficits | #727 |
schizophrenics | #727 |
dizygotic | #728 |
statistical | #728 |
assortative mating | #729 |
structured clinical interview | #729 |
786 | #730 |
fmri study | #730 |
metabotropic glutamate | #731 |
prevention programs | #732 |
correlates | #733 |
voxel based | #733 |
git | #733 |
finding | #734 |
phenotypic heterogeneity | #734 |
wky | #735 |
gyrification | #737 |
health intervention | #737 |
life cycle | #737 |
opioid dependence | #738 |
substancerelated disorders | #738 |
inflation | #739 |
polygenic score | #739 |
validating | #740 |
rapid cycling | #741 |
refill | #742 |
caudate | #742 |
boston | #742 |
time task | #743 |
comparators | #744 |
amphetamines | #744 |
topic twins | #745 |
soviet | #745 |
bupropion | #745 |
compulsive | #746 |
neuropsychological status | #746 |
manifested | #747 |
child interaction | #748 |
duplications | #748 |
adrb1 | #749 |
examining | #750 |
934 | #750 |
fulfilling | #752 |
twins dizygotic | #752 |
molecular genetic analysis | #754 |
347 | #754 |
post hoc | #755 |
comt val158met | #755 |
neuroleptics | #756 |
bipolar depression | #756 |
recalled | #756 |
mental disorders | #756 |
nhe | #757 |
schizophrenia scz | #757 |
disease haplotypes humans | #759 |
renewal | #760 |
sads | #761 |
variation genome | #762 |
artifact | #763 |
workday | #764 |
matter abnormalities | #764 |
humans logistic | #765 |
likelihoods | #765 |
autism asd | #766 |
people schizophrenia | #767 |
substance misuse | #768 |
disinhibition | #769 |
comt polymorphism | #772 |
emerged | #772 |
performance patients | #774 |
parent reported | #776 |
birth rates | #776 |
behavioral phenotypes | #777 |
human pair | #777 |
depressive | #777 |
phenotypes | #778 |
deletion polymorphism | #779 |
euthymic | #779 |
schizophrenia relationship | #780 |
weaknesses | #780 |
risky behavior | #780 |
inheritance | #781 |
iowa gambling task | #782 |
wky rats | #782 |
fourth edition | #783 |
questioning | #783 |
combined analysis | #783 |
mega | #784 |
emerging roles | #784 |
reformulation | #785 |
teaes | #785 |
faced | #786 |
pbd | #787 |
963 | #787 |
adolescence | #787 |
niacin | #788 |
child temperament | #789 |
medial temporal lobe | #790 |
cgi | #791 |
behavioral | #791 |
spelling | #791 |
subtypes | #792 |
individuals schizophrenia | #793 |
clinical criteria | #793 |
motivations | #794 |
symptom burden | #794 |
association polymorphisms | #794 |
caveats | #796 |
delinquent | #796 |
separate | #797 |
363 | #800 |
additional studies | #800 |
genomic regions | #802 |
dopamine d1 receptors | #803 |
prenatal exposure | #803 |
randomized clinical trials | #804 |
stimulant drugs | #804 |
clinically | #805 |
superior frontal | #805 |
dysfunction | #805 |
dorsolateral | #806 |
male memory | #806 |
latent classes | #806 |
novelty seeking | #806 |
developmental perspective | #807 |
lobule | #808 |
hdrs | #809 |
ucla | #810 |
dopamine function | #810 |
preschool female humans | #811 |
adjusting | #811 |
phonemic | #811 |
dopamine serotonin | #811 |
blind | #813 |
coadministration | #815 |
declarative | #816 |
mhpg | #816 |
quantitative measures | #817 |
lasting | #817 |
cfb | #817 |
tryptophan hydroxylase | #817 |
breakthroughs | #817 |
memory attention | #818 |
substance dependence | #818 |
single gene | #818 |
epigenetic factors | #818 |
meeting | #820 |
cortical development | #820 |
rated | #821 |
counties | #821 |
patients psychotic disorders | #821 |
switches | #822 |
hme | #822 |
parental report | #824 |
transcriptomic analysis | #824 |
prefrontal regions | #824 |
rare coding variants | #825 |
common genetic | #825 |
adolescents asd | #827 |
humans models | #827 |
s100a6 | #828 |
treatment interventions | #829 |
timeframe | #830 |
multipoint | #830 |
prevalent | #831 |
multiple testing | #831 |
lifetime prevalence | #831 |
conduct disorders | #832 |
association tests | #832 |
liabilities | #833 |
college students | #834 |
n60 | #837 |
gray | #837 |
sleep disorder | #837 |
aversion | #838 |
inbred shr rats | #838 |
matter humans | #838 |
prescription | #839 |
obstetric complications | #839 |
symptom profiles | #839 |
neurocognition | #841 |
parenthood | #842 |
sporadic cases | #843 |
participants completed | #843 |
biological basis | #844 |
consensus statement | #844 |
facial emotion recognition | #845 |
n35 | #846 |
dnm | #847 |
exception | #847 |
gwas summary | #848 |
dysregulated | #848 |
dgcr8 | #848 |
factor model | #851 |
prefrontal | #855 |
putative | #857 |
nonsignificant | #857 |
heightened risk | #858 |
estimated prevalence | #858 |
schizophrenia healthy | #858 |
putamen | #858 |
6p | #859 |
nineteen | #859 |
preschool | #861 |
handbook | #862 |
heterogeneity | #863 |
delayed effects | #865 |
seventy | #866 |
global assessment | #866 |
glossary | #866 |
crosssectional studies | #867 |
nnt | #869 |
mental | #869 |
hypothesized | #869 |
neurobiological basis | #870 |
specialized | #872 |
753 | #873 |
perseverative errors | #874 |
pediatric | #874 |
shr rats | #874 |
existing evidence | #875 |
comorbidity depression | #875 |
hypotheses | #876 |
manova | #876 |
positive symptoms | #876 |
genetic counseling | #876 |
test performance | #877 |
externalizing disorders | #879 |
gender differences | #879 |
sizes | #881 |
memory functions | #882 |
association genetic | #883 |
altered | #884 |
12p | #886 |
psychedelics | #886 |
171 | #887 |
dynamism | #888 |
delayed | #890 |
cpts | #891 |
obsessive | #893 |
n95 | #893 |
n17 | #893 |
decade | #894 |
bonn | #894 |
veterans affairs | #895 |
480 | #897 |
164 | #898 |
cortical thinning | #902 |
biological psychiatry | #903 |
anterior cingulate | #903 |
aptitude | #904 |
bipolar illness | #904 |
reinforcer | #904 |
weight body | #904 |
genetic contribution | #904 |
sibling | #904 |
visit | #905 |
psychosocial functioning | #906 |
late childhood | #906 |
826 | #906 |
adult aggression | #907 |
standardized difference | #909 |
morphometric | #910 |
symptom control | #911 |
ggc | #911 |
psychosocial | #912 |
amygdala reactivity | #912 |
pedigrees | #912 |
complications pregnancy | #913 |
visuospatial memory | #913 |
versions | #914 |
underlying pathophysiology | #914 |
association age | #916 |
disorder specific | #917 |
school performance | #917 |
cousins | #918 |
sleep children | #920 |
177 | #923 |
pharmacogenetic | #924 |
screening tool | #924 |
dysthymic | #925 |
vulnerability | #925 |
wide | #926 |
dividing | #927 |
developmental trajectories | #927 |
affective disorder | #928 |
participating | #930 |
nucleotide | #930 |
cpg sites | #930 |
heroin addiction | #933 |
permutation | #933 |
194 | #933 |
20mg | #934 |
d5 | #935 |
adolescence young adulthood | #935 |
smoking risk | #936 |
environment interactions | #936 |
3040 | #937 |
diagnostic | #938 |
female genotype | #938 |
study designs | #938 |
irrs | #940 |
robustly | #940 |
severe form | #941 |
critics | #941 |
tdt | #943 |
gwas | #946 |
brain regions | #946 |
22q | #948 |
sles | #948 |
risk developing | #949 |
albeit | #950 |
fetal exposure | #950 |
subtest | #952 |
relapsers | #954 |
amphetamine | #954 |
personality disorder | #954 |
behavioral treatment | #955 |
effects sex | #956 |
prompted | #956 |
112 | #959 |
qam | #960 |
clinical disorders | #960 |
cytoarchitecture | #962 |
children epilepsy | #963 |
female frontal | #963 |
clinical assessment | #963 |
scores | #965 |
tandem repeat | #965 |
dopamine uptake | #965 |
cgis | #965 |
body height | #966 |
scarce | #966 |
heritability estimates | #967 |
splicing factor | #968 |
cuneus | #968 |
freesurfer | #969 |
pharmacological treatment | #970 |
schizophrenia association | #970 |
mtbi | #970 |
examined | #970 |
medication treatment | #971 |
aggression | #972 |
risky sexual behavior | #972 |
262 | #973 |
chromosome mapping | #974 |
diva | #975 |
autism spectrum disorder | #976 |
fluphenazine | #977 |
vmat2 | #978 |
resolve | #978 |
psychosis risk | #978 |
neurodevelopmental disorder | #980 |
2–4 | #980 |
459 | #982 |
pertaining | #982 |
educational | #982 |
seriousness | #985 |
logistic regression models | #986 |
symptoms age | #986 |
alleles | #986 |
patients sle | #987 |
difficulties | #988 |
ranked | #990 |
small proportion | #990 |
tci | #990 |
depressed mothers | #991 |
polymorphism genetic | #994 |
pathway analysis | #995 |
temporal stability | #996 |
colleagues | #996 |
internal consistency | #997 |
comorbid conditions | #998 |
keystone | #999 |
diathesis | #999 |
detoxification | #999 |
adolescent analysis | #1000 |
child child | #1001 |
stata | #1003 |
interviews | #1003 |
comparative efficacy | #1004 |
haplotypes | #1006 |
daughter | #1007 |
preschool cohort | #1007 |
0016 | #1007 |
confounding factors | #1007 |
long‐term outcome | #1007 |
allele | #1007 |
norms | #1008 |
structural mri | #1008 |
multiplex | #1009 |
risk alcohol | #1009 |
qualifications | #1009 |
posttraumatic stress disorder | #1009 |
discriminant | #1010 |
genes environment | #1012 |
ltc | #1014 |
7 years | #1014 |
metabotropic | #1020 |
maturational | #1020 |
conclusive | #1021 |
risk prediction | #1024 |
relates | #1024 |
insufficient | #1026 |
004 | #1027 |
pharmacotherapies | #1027 |
persistent | #1028 |
obsessive – | #1028 |
pharmacologic | #1029 |
weiss | #1030 |
analytic | #1031 |
wwwclinicaltrialsgov | #1031 |
frontostriatal | #1031 |
symptoms child | #1032 |
patients panic disorder | #1032 |
73 | #1034 |
preface | #1034 |
– compulsive | #1034 |
predicted | #1034 |
negative symptoms | #1035 |
rodent models | #1035 |
total score | #1035 |
brain disorders | #1035 |
exploratory analyses | #1037 |
eventual | #1037 |
major depressive episode | #1039 |
general framework | #1040 |
serotonin | #1041 |
general intelligence | #1041 |
twin | #1043 |
gaf | #1044 |
mental health treatment | #1044 |
heightened | #1045 |
relate | #1045 |
antecedents | #1046 |
inv | #1046 |
ffi | #1050 |
late gestation | #1051 |
subtle | #1052 |
onset schizophrenia | #1052 |
benzodiazepines | #1053 |
disorders post | #1054 |
school age | #1055 |
psychiatric morbidity | #1056 |
vice | #1056 |
major humans | #1058 |
nogo | #1058 |
obscure | #1060 |
youth report | #1060 |
adolescence adulthood | #1061 |
bipolar disorders | #1062 |
199 | #1063 |
illicit | #1063 |
genes involved | #1063 |
memory disorders | #1064 |
europe female | #1065 |
paediatric patients | #1065 |
childhood trauma | #1068 |
pooled | #1068 |
awakenings | #1068 |
heritability | #1068 |
paranoia | #1068 |
negative impact | #1069 |
emotional | #1069 |
memantine | #1069 |
word reading | #1070 |
memory impairments | #1070 |
human genetics | #1070 |
reading ability | #1071 |
genetic model | #1071 |
social problems | #1071 |
single nucleotide receptors | #1071 |
controlled clinical | #1071 |
risk scores | #1071 |
character inventory | #1072 |
4q | #1072 |
validity | #1073 |
associations | #1073 |
obesity risk | #1074 |
studying | #1075 |
3′utr | #1075 |
general hospital | #1076 |
mapping chromosomes | #1077 |
schizophrenia spectrum disorders | #1078 |
exposure delayed | #1080 |
transdiagnostic | #1080 |
schizophrenia social | #1082 |
adult antipsychotic | #1082 |
anxiety children | #1083 |
contiguous | #1084 |
onset psychosis | #1086 |
autoreceptors | #1086 |
psds | #1086 |
european continental | #1088 |
alcohol marijuana | #1089 |
distinctive | #1090 |
subtype | #1090 |
polygenic scores | #1092 |
development disorders | #1092 |
obsessivecompulsive disorder ocd | #1093 |
gifted | #1094 |
irritable | #1096 |
semistructured interview | #1096 |
scientific literature | #1096 |
smoking | #1099 |
metaanalysis | #1102 |
external validity | #1103 |
daughters | #1103 |
future work | #1103 |
cnvs | #1104 |
odds | #1106 |
10 weeks | #1107 |
psychosis | #1107 |
diagnostic groups | #1107 |
bip | #1108 |
emotional behavioral | #1108 |
psychoses | #1110 |
experimental test | #1110 |
prioritized | #1110 |
share | #1111 |
10−5 | #1111 |
male children | #1112 |
depressive disorder | #1113 |
new developments | #1114 |
effects children | #1116 |
discusses | #1117 |
schizophrenia subjects | #1119 |
psychotropic | #1121 |
children anxiety | #1122 |
exchangers | #1123 |
632 | #1123 |
556 | #1124 |
coexisting | #1125 |
mts | #1125 |
projects | #1127 |
dysthymic disorder | #1128 |
similarities | #1128 |
enriched | #1128 |
quantifies | #1128 |
investigator | #1129 |
weighting | #1130 |
adult alcoholism | #1130 |
attention performance | #1134 |
n28 | #1134 |
psychiatric diagnosis | #1135 |
birth outcomes | #1136 |
independent sample | #1136 |
laterality humans | #1138 |
blood pressure response | #1138 |
susceptibility loci | #1139 |
social phobia | #1142 |
clinical samples | #1142 |
signal task | #1144 |
prodromal | #1145 |
cognitive domains | #1145 |
early adolescent | #1145 |
demographic factors | #1146 |
normal volunteers | #1147 |
emotionality | #1147 |
measurement invariance | #1147 |
refine | #1149 |
discounting | #1150 |
humans intellectual | #1150 |
children association | #1150 |
discriminability | #1150 |
quick | #1152 |
continents | #1152 |
developmental model | #1152 |
normals | #1153 |
refinements | #1153 |
generalizability | #1153 |
sensory gating | #1154 |
alspac | #1154 |
clinical profiles | #1154 |
differential humans | #1160 |
uncorrected | #1160 |
ht2c | #1160 |
phenotype | #1161 |
” “ | #1163 |
review findings | #1163 |
phobia | #1164 |
studies data | #1164 |
neurocognitive function | #1165 |
deteriorated | #1166 |
clinical groups | #1166 |
affective | #1166 |
congress | #1167 |
catecholaminergic | #1168 |
medication status | #1169 |
social outcomes | #1170 |
292 | #1171 |
quality measures | #1174 |
mspi | #1175 |
gwas data | #1176 |
cohen | #1176 |
bpd patients | #1176 |
nicotine exposure | #1177 |
genetic risk factors | #1177 |
clinical validation | #1178 |
male subjects | #1178 |
study gwas | #1179 |
childhood exposure | #1182 |
reward | #1182 |
cinguli humans | #1182 |
persisting | #1182 |
nonverbal | #1183 |
addressing | #1184 |
triads | #1184 |
paradox | #1184 |
standardized | #1187 |
functional polymorphisms | #1188 |
hydrochloride | #1189 |
dysbindin | #1189 |
64 | #1190 |
child preschool | #1192 |
psychology | #1193 |
assess | #1194 |
parenting behavior | #1197 |
compulsivity | #1198 |
onequarter | #1198 |
addictions | #1198 |
wm | #1199 |
placebo | #1199 |
230 | #1200 |
asian continental | #1200 |
wisconsin | #1201 |
morbidity | #1202 |
systematic search | #1204 |
sib | #1204 |
millennium | #1207 |
externalizing symptoms | #1209 |
problems children | #1209 |
nationwide cohort study | #1209 |
neuropsychology | #1210 |
conceptualizations | #1210 |
p004 | #1211 |
term treatment | #1215 |
sample sizes | #1218 |
male mass | #1219 |
underlying | #1220 |
lbw | #1220 |
antecedent | #1221 |
prospects | #1222 |
child cognitive | #1222 |
study role | #1224 |
profile | #1226 |
approximated | #1227 |
partly | #1227 |
0011 | #1229 |
subgroup | #1232 |
refining | #1232 |
molecular alterations | #1232 |
poster | #1233 |
pregnancy prenatal | #1234 |
health organization | #1234 |
gprotein | #1235 |
children ages | #1235 |
shortcomings | #1237 |
educational attainment | #1239 |
brain structure | #1242 |
tandem repeats | #1242 |
interpersonal relations | #1244 |
short form | #1245 |
enjoyment | #1247 |
risk asthma | #1247 |
avenues | #1247 |
kf | #1247 |
cidi | #1248 |
psychosocial outcomes | #1248 |
cpg islands | #1249 |
delineate | #1251 |
roc | #1251 |
debilitating | #1252 |
alcohol disorders | #1255 |
serotonin transporter | #1256 |
risk ratio | #1256 |
summarize | #1256 |
goal | #1257 |
dysfunctions | #1257 |
nervous | #1257 |
onset depression | #1259 |
combine | #1260 |
consensus statements | #1263 |
characterize | #1266 |
onset age | #1267 |
likewise | #1270 |
logistic regression analyses | #1271 |
child mental | #1273 |
statistical methods | #1274 |
entire | #1277 |
developmental pathways | #1277 |
386 | #1277 |
n24 | #1278 |
04 | #1281 |
study evidence | #1281 |
paternal | #1282 |
priori | #1282 |
behavior adolescent | #1283 |
increased rates | #1283 |
neuroimaging | #1283 |
hopes | #1283 |
variance | #1284 |
spontaneously hypertensive | #1285 |
general cognitive | #1286 |
087 | #1286 |
somatic complaints | #1288 |
male nerve | #1288 |
orbitofrontal | #1288 |
warmth | #1289 |
aspect | #1289 |
dual psychiatry | #1291 |
1hmrs | #1291 |
posttraumatic | #1291 |
unmyelinated | #1291 |
quantitative trait | #1292 |
misclassification | #1292 |
clomipramine | #1292 |
animal conditioning | #1292 |
negative emotion | #1295 |
pvalue | #1297 |
136 | #1297 |
chromosomes | #1298 |
cures | #1301 |
atx | #1303 |
935 | #1305 |
1520 | #1305 |
cortical volume | #1306 |
prediction accuracy | #1309 |
sgas | #1309 |
extant | #1310 |
vin | #1310 |
risperidone | #1311 |
arrests | #1312 |
motor speed | #1313 |
factor analyses | #1313 |
criteria | #1314 |
76 | #1315 |
factors smoking | #1316 |
class analysis | #1317 |
minds | #1317 |
adolescents children | #1318 |
current findings | #1320 |
hypothetical | #1321 |
predictability | #1322 |
parents adolescents | #1323 |
short | #1323 |
polymorphism | #1324 |
hypothesis | #1325 |
response treatment | #1327 |
confusion | #1330 |
influencing | #1330 |
defining | #1331 |
measures | #1334 |
polysubstance | #1334 |
253 | #1335 |
psychopharmacology | #1335 |
authors | #1336 |
genetic background | #1336 |
nonuse | #1337 |
fronto | #1338 |
obsessive–compulsive disorder | #1338 |
clinical phenotypes | #1342 |
longterm outcome | #1342 |
542 | #1344 |
registry data | #1344 |
explaining | #1345 |
llysine | #1345 |
interpretation statistical | #1349 |
compared children | #1353 |
early adulthood | #1353 |
psychoticism | #1355 |
loci genetic | #1356 |
cocaine abuse | #1356 |
diagnostic tool | #1356 |
simon | #1357 |
variabilities | #1357 |
flush | #1357 |
seekers | #1358 |
gene discovery | #1359 |
antidepressive | #1359 |
broad spectrum | #1361 |
middle frontal gyrus | #1362 |
mammalian target | #1362 |
intergenerational | #1365 |
abcd | #1367 |
uptake inhibitors | #1369 |
neuronal development | #1369 |
school teachers | #1369 |
unexplored | #1369 |
reliance | #1370 |
intellectual functioning | #1371 |
observer variation | #1374 |
covert | #1377 |
larger | #1378 |
pallidum | #1380 |
inositol | #1382 |
ghr | #1385 |
new onset | #1386 |
thought disorder | #1386 |
highlighted | #1386 |
dimensional approach | #1389 |
prodrome | #1391 |
familial aggregation | #1391 |
6 years | #1391 |
treatment depression | #1391 |
illicit drugs | #1393 |
vendors | #1394 |
rats shr | #1395 |
satisfying | #1395 |
manuscripts | #1395 |
thalamic | #1395 |
racial | #1398 |
timely | #1399 |
emotional stimuli | #1399 |
suggesting | #1400 |
lability | #1400 |
17 | #1402 |
blinded | #1403 |
sufficient | #1403 |
brain region | #1404 |
hippocampal volumes | #1405 |
placebo treatment | #1407 |
hama | #1408 |
create | #1409 |
preparations | #1410 |
personality inventory | #1412 |
1998 | #1413 |
shyness | #1414 |
issue | #1414 |
independent | #1415 |
impressions | #1416 |
prepubertal children | #1416 |
332 | #1417 |
logical | #1419 |
carry | #1419 |
humans memory | #1421 |
discoveries | #1422 |
parents children | #1422 |
exploratory factor analysis | #1423 |
greater | #1426 |
dosed | #1427 |
linkage disequilibrium | #1430 |
taps | #1431 |
163 | #1431 |
interaction effects | #1432 |
cognitive profiles | #1432 |
affairs | #1434 |
social perception | #1436 |
publication adult analysis | #1438 |
bche | #1439 |
academic | #1443 |
holidays | #1444 |
personality | #1447 |
psychotic illness | #1448 |
443 | #1448 |
chp | #1449 |
hydroxylase | #1450 |
prevalence obesity | #1450 |
ratings | #1451 |
height | #1453 |
78 | #1453 |
ewas | #1453 |
square | #1453 |
population stratification | #1454 |
hypermethylation | #1454 |
switching | #1455 |
replicability | #1457 |
dorsal striatum | #1457 |
collaborations | #1457 |
generalized anxiety | #1458 |
comparisons | #1459 |
severe depression | #1462 |
biological pathways | #1463 |
stronger | #1463 |
treatment duration | #1464 |
principal | #1467 |
discordant | #1467 |
untranslated | #1468 |
partial remission | #1468 |
valuable | #1468 |
groups differences | #1469 |
hippocampi | #1469 |
contrast effects | #1472 |
openlabel | #1474 |
statistically | #1474 |
cognition patients | #1474 |
amygdala volume | #1477 |
risk relapse | #1479 |
conducted | #1480 |
medication | #1481 |
cortex dlpfc | #1487 |
prodromal symptoms | #1488 |
issues | #1489 |
apt | #1492 |
adrb2 | #1493 |
hypomethylation | #1495 |
smaller | #1497 |
allele carriers | #1497 |
mri studies | #1497 |
lifespan | #1499 |
small sample sizes | #1499 |
twins monozygotic | #1499 |
converge | #1500 |
populationbased study | #1501 |
patients bipolar | #1502 |
cpt | #1503 |
multisite | #1505 |
ddc | #1505 |
male mothers | #1505 |
examination | #1508 |
salience network | #1510 |
manifestation | #1510 |
objectivity | #1511 |
existing literature | #1511 |
attained | #1513 |
reports | #1513 |
emotions female | #1513 |
messaging | #1514 |
cognitive ability | #1515 |
pedigree | #1516 |
eicosapentaenoic acid | #1517 |
screening instrument | #1517 |
repeat | #1518 |
criminal behavior | #1519 |
165 | #1521 |
topic | #1523 |
114 | #1523 |
cna | #1523 |
inconsistency | #1526 |
bipolar patients | #1526 |
inferior frontal | #1528 |
nacetylaspartate | #1528 |
psychiatric disorder | #1528 |
symptomatology | #1530 |
512 | #1535 |
began | #1536 |
arntl | #1540 |
nucleotide risk | #1541 |
default | #1541 |
adult life | #1542 |
dopamine receptor | #1542 |
poses | #1542 |
stress disorders | #1543 |
gwass | #1544 |
treatment schizophrenia | #1545 |
yale | #1545 |
omission | #1547 |
traits | #1549 |
card | #1551 |
influenced | #1554 |
problem behaviors | #1554 |
automobile | #1556 |
857 | #1556 |
early exposure | #1559 |
failed | #1559 |
loci | #1560 |
0009 | #1561 |
0013 | #1564 |
475 | #1565 |
subscales | #1565 |
insular | #1565 |
interpersonal | #1566 |
humans interpersonal | #1569 |
wise | #1570 |
191 | #1573 |
swedish | #1573 |
consortium | #1573 |
depression children | #1574 |
neurochemistry | #1575 |
attempted | #1576 |
meta | #1579 |
life quality | #1579 |
selfreport questionnaires | #1580 |
gene networks | #1580 |
single nucleotide polymorphism | #1582 |
located | #1582 |
findings studies | #1582 |
cutoffs | #1583 |
network dmn | #1583 |
models male | #1583 |
social functioning | #1584 |
hyperactivation | #1587 |
major depressive | #1588 |
firstepisode schizophrenia | #1588 |
rs4680 | #1588 |
pain patients | #1589 |
genetic data | #1589 |
edinburgh | #1590 |
advent | #1591 |
55 | #1592 |
phobias | #1593 |
temperament | #1594 |
162 | #1596 |
subcortical structures | #1596 |
symptom presentation | #1598 |
moderators | #1599 |
tpv | #1599 |
statistics nonparametric | #1601 |
psychotropic medications | #1601 |
jan | #1602 |
managed | #1603 |
utr | #1604 |
suffer | #1604 |
spontaneously | #1605 |
heritabilities | #1606 |
classifying | #1608 |
academic achievement | #1609 |
1979 | #1610 |
proneness | #1610 |
monoamine oxidase | #1611 |
alcoholism | #1613 |
emotional faces | #1613 |
status | #1614 |
ancestry female | #1615 |
male maternal | #1616 |
drawn | #1619 |
broadly | #1620 |
large body | #1622 |
risk mental | #1622 |
distinguishing | #1622 |
hbr | #1624 |
childhood asthma | #1624 |
snp | #1626 |
paucity | #1626 |
spatial organization | #1627 |
ht2a receptor | #1627 |
dysphoria | #1628 |
louis | #1628 |
verbal behavior | #1629 |
genomics humans | #1629 |
kyoto | #1630 |
study children | #1630 |
ambiguous | #1631 |
emrs | #1631 |
memory task | #1631 |
198 | #1633 |
susceptibility gene | #1634 |
supporting | #1635 |
mental illnesses | #1637 |
positive predictive | #1638 |
lag | #1639 |
brain female | #1640 |
social communication | #1643 |
rack1 | #1643 |
tendency | #1643 |
alpha7 | #1643 |
bprs | #1644 |
potential effects | #1646 |
socially | #1647 |
interrelations | #1649 |
treating | #1650 |
controlled | #1653 |
rea | #1653 |
nucleotide polymorphisms | #1655 |
adolescents age | #1657 |
maximize | #1658 |
detect | #1658 |
require | #1659 |
psychotic disorder | #1659 |
personality disorders | #1661 |
symptom severity | #1662 |
presentations | #1663 |
comorbid depression | #1663 |
asm | #1664 |
510 | #1665 |
mood symptoms | #1666 |
chronic patients | #1666 |
dlpfc | #1666 |
association analysis | #1667 |
human rights | #1670 |
indexed | #1670 |
bipolar disorder patients | #1671 |
13 years | #1672 |
transmitted | #1673 |
asd symptoms | #1674 |
alcohol spectrum | #1675 |
statements | #1675 |
early signs | #1675 |
53 | #1677 |
introns | #1678 |
calling | #1678 |
registers | #1678 |
social anxiety | #1679 |
homogeneous | #1679 |
beagle | #1680 |
seat | #1680 |
mathematical models | #1682 |
prescribed | #1684 |
46 | #1684 |
mildly | #1684 |
memory deficit | #1685 |
ancestries | #1685 |
mdd | #1689 |
autistic disorder | #1689 |
github | #1689 |
agenda | #1692 |
psychotropic drugs | #1692 |
impulse control | #1693 |
recruited | #1698 |
motor skills | #1698 |
diagnose | #1699 |
91 | #1702 |
memory consolidation | #1704 |
item | #1704 |
conceptualization | #1705 |
middle frontal | #1710 |
reduced activation | #1711 |
personality characteristics | #1712 |
health records | #1712 |
neuroscience | #1712 |
rater | #1712 |
schizophrenia spectrum | #1713 |
net | #1716 |
perpetrators | #1725 |
nhe1 | #1728 |
autistic | #1729 |
epigenetics | #1730 |
inhibitory control | #1731 |
107 | #1731 |
cbs | #1732 |
hindered | #1733 |
machine | #1735 |
highlight | #1735 |
stand | #1736 |
identical | #1736 |
aimed | #1739 |
predictors | #1739 |
dopamine receptors | #1741 |
sex age | #1743 |
forum | #1746 |
curated | #1746 |
longitudinal analysis | #1747 |
cognitive difficulties | #1748 |
pds | #1749 |
occipital lobe | #1750 |
tremors | #1752 |
02 | #1753 |
selfreport measures | #1753 |
questionnaires young | #1755 |
326 | #1756 |
sertraline | #1756 |
5ht2a | #1758 |
120 | #1758 |
social | #1761 |
genetic models | #1761 |
ventral striatum | #1761 |
drowsiness | #1763 |
bipolar affective | #1763 |
includes | #1765 |
chance | #1765 |
adult onset | #1766 |
mystery | #1768 |
operant | #1768 |
reflects | #1769 |
sisters | #1770 |
dopamine | #1772 |
treatment implications | #1773 |
dizygotic twins | #1773 |
depressive episode | #1775 |
patients systemic | #1775 |
patients adult | #1776 |
267 | #1776 |
establishing | #1777 |
mental recall | #1777 |
utrs | #1779 |
10−7 | #1780 |
early childhood | #1781 |
major | #1786 |
higher doses | #1786 |
commonalities | #1786 |
social anxiety disorder | #1787 |
defined | #1789 |
male motor | #1791 |
frustration | #1791 |
transdermal | #1793 |
disorder mdd | #1795 |
harbor | #1796 |
disabilities | #1797 |
positive association | #1797 |
causal variants | #1797 |
autism spectrum disorders | #1800 |
aged models | #1801 |
reporters | #1801 |
members | #1801 |
genetic variance | #1802 |
chapters | #1803 |
shr | #1804 |
females | #1805 |
families children | #1806 |
covariation | #1807 |
based analysis | #1807 |
168 | #1809 |
expanded | #1812 |
nucleotide polymorphism | #1812 |
aetiology | #1813 |
146 | #1813 |
european descent | #1813 |
frequently | #1815 |
internationality | #1815 |
brain imaging | #1816 |
purchases | #1816 |
hippocampal volume | #1819 |
cohens | #1819 |
lds | #1819 |
correlate | #1823 |
suicide attempt | #1825 |
endpoint | #1827 |
followup | #1830 |
splenium | #1831 |
binocular | #1833 |
foundation | #1833 |
psychotic patients | #1837 |
suggested | #1838 |
94 | #1840 |
patterns | #1841 |
neural activity | #1841 |
assessment tools | #1842 |
trauma exposure | #1842 |
distinctions | #1845 |
twins | #1845 |
initiative | #1845 |
literacy | #1846 |
pertinent | #1847 |
psychological | #1847 |
warrant | #1848 |
environmental risk | #1848 |
polymorphisms | #1849 |
limited | #1850 |
vocabulary | #1851 |
individual | #1851 |
fearful | #1851 |
nonparametric | #1852 |
differentiating | #1853 |
brainderived neurotrophic factor | #1853 |
young | #1853 |
persons | #1855 |
abuse | #1856 |
auditory hallucinations | #1856 |
prevalence | #1859 |
tph | #1859 |
incentives | #1860 |
behavioral measures | #1860 |
cnb | #1861 |
affiliation | #1861 |
8p | #1862 |
obstacle | #1864 |
poison | #1865 |
switch | #1865 |
multilevel | #1865 |
vocalization | #1865 |
severely | #1867 |
18 | #1869 |
structural functional | #1875 |
constitute | #1876 |
manuscript | #1877 |
histograms | #1879 |
roc curve | #1879 |
shrs | #1880 |
animal model | #1880 |
delusions | #1881 |
longer duration | #1882 |
afb | #1882 |
common genetic variation | #1883 |
genome | #1885 |
false | #1888 |
differs | #1888 |
metaanalysis studies | #1890 |
substance abuse | #1890 |
spanning | #1894 |
heterogeneous | #1894 |
susceptibility genes | #1896 |
maintained | #1899 |
latent class analysis | #1899 |
correspondences | #1901 |
psychostimulant | #1902 |
analyses | #1903 |
chinese | #1903 |
illicit drug | #1904 |
actigraphy | #1905 |
increasingly | #1907 |
specific symptoms | #1907 |
emotion | #1908 |
majority | #1909 |
epidemiologic | #1909 |
ads | #1910 |
support vector machine | #1911 |
disorders mental | #1911 |
structural differences | #1912 |
generation antipsychotics | #1913 |
africanamericans | #1915 |
χ2 | #1916 |
10h | #1920 |
inform | #1921 |
association maternal | #1923 |
satisfied | #1923 |
liking | #1923 |
child cross | #1926 |
aggregate | #1926 |
overview | #1927 |
251 | #1928 |
sleep problems | #1928 |
advertising | #1928 |
empirical studies | #1929 |
ssri | #1930 |
95 cis | #1934 |
asd children | #1934 |
simulation study | #1937 |
borderline personality disorder | #1937 |
exomes | #1938 |
stratified | #1939 |
general | #1942 |
25 years | #1945 |
literature review | #1947 |
neurobehavioral | #1949 |
representing | #1950 |
traumatic brain injury | #1950 |
trait loci | #1952 |
accumbens | #1953 |
normal children | #1954 |
efficacious | #1957 |
msp | #1958 |
neurotransmitter release | #1959 |
mems | #1961 |
intolerant | #1962 |
micronesia | #1963 |
896 | #1964 |
sdq | #1967 |
brain networks | #1968 |
vital signs | #1969 |
sorting | #1971 |
correctly | #1972 |
clinical implications | #1972 |
depression | #1972 |
connectivity | #1974 |
hoc | #1975 |
factors surveys | #1976 |
repeats | #1977 |
child depression | #1977 |
conflicting | #1978 |
listing | #1978 |
hippocampus humans | #1981 |
ptsd | #1981 |
chinese population | #1984 |
common mental disorders | #1984 |
phase 3 trial | #1986 |
pax5 | #1986 |
secondary analysis | #1987 |
brain | #1989 |
school | #1990 |
predisposing | #1991 |
current paper | #1994 |
genetic differences | #1996 |
226 | #1997 |
fmr | #1998 |
pattern | #1999 |
diagnosed | #2001 |
comparable | #2002 |
spouses | #2003 |
asian continental ancestry | #2005 |
formulations | #2005 |
harm avoidance | #2007 |
functional variants | #2010 |
behavioral symptoms | #2011 |
nos1 | #2012 |
absence | #2014 |
akt1 | #2014 |
muscle function | #2014 |
noradrenergic | #2015 |
sms | #2015 |
possibility | #2016 |
cognitive deficits | #2016 |
prescribers | #2021 |
schoolage children | #2023 |
159 | #2023 |
serve | #2026 |
phenomenology | #2030 |
sleep disturbances | #2030 |
brain responses | #2031 |
memory verbal | #2031 |
regional brain | #2032 |
neurodevelopmental disorders | #2033 |
morbid | #2036 |
prenatally | #2037 |
receptors nicotinic | #2037 |
diminished | #2040 |
retest reliability | #2040 |
asperger | #2041 |
erythematosus systemic | #2041 |
nicotinic acetylcholine | #2045 |
227 | #2046 |
cognitive processing | #2046 |
informants | #2048 |
erythematosus | #2049 |
cognition | #2050 |
functional | #2050 |
juvenile | #2052 |
contribute | #2054 |
adolescent behavior | #2056 |
external control | #2057 |
chapman | #2058 |
insula | #2061 |
common diseases | #2061 |
educated | #2062 |
stabilizers | #2064 |
ongoing | #2065 |
overweight obesity | #2066 |
demography | #2066 |
val158met polymorphism | #2067 |
preschool humans | #2068 |
massachusetts | #2069 |
functional mri | #2069 |
0008 | #2071 |
phenotypic | #2072 |
parental education | #2072 |
psychotic symptoms | #2077 |
degree | #2078 |
international consensus | #2078 |
wake disorders | #2079 |
descent | #2079 |
heterogeneity studies | #2082 |
psychomotor | #2084 |
male gender | #2085 |
5 ht2a | #2087 |
43 | #2090 |
latent class | #2090 |
factors child | #2093 |
49 | #2095 |
wky shr | #2096 |
aud | #2096 |
subsets | #2099 |
69 | #2100 |
dopaminergic | #2100 |
142 | #2102 |
general factor | #2106 |
age children | #2107 |
ht2a | #2108 |
adult population | #2108 |
causation | #2109 |
child relations | #2112 |
specific genetic | #2112 |
nicotinic | #2112 |
brain dysfunction | #2115 |
279 | #2115 |
83 | #2117 |
postpartum period | #2119 |
monoamine | #2119 |
relative age | #2119 |
poorer | #2119 |
84 | #2121 |
51 | #2122 |
career | #2122 |
pgs | #2122 |
sixth | #2124 |
pbls | #2126 |
identifies | #2126 |
dysfunctional | #2128 |
biased | #2129 |
ovid | #2130 |
functional polymorphism | #2132 |
rates | #2134 |
episode schizophrenia | #2137 |
dbh | #2137 |
psychosocial factors | #2140 |
adversities | #2141 |
interpretability | #2141 |
discrepant | #2142 |
relevant literature | #2143 |
methods participants | #2145 |
pvs | #2145 |
behavioral disorders | #2146 |
intraclass | #2147 |
105 | #2147 |
receptors adrenergic | #2147 |
juveniles | #2148 |
abnormalities | #2149 |
glutamatergic | #2150 |
finemapping | #2150 |
represents | #2150 |
232 | #2150 |
repositioning | #2151 |
assessing | #2151 |
mao | #2153 |
rrr | #2153 |
psychiatric patients | #2155 |
differentiated | #2164 |
abdominal obesity | #2164 |
clinical assessments | #2166 |
declarative memory | #2167 |
shr wky | #2167 |
differing | #2168 |
differential diagnostic | #2168 |
genetic association studies | #2168 |
glx | #2169 |
major depressive disorder | #2170 |
adversely | #2171 |
mb | #2171 |
prevalences | #2171 |
severity | #2172 |
tardive dyskinesia | #2172 |
aggregated | #2177 |
irt | #2180 |
externalizing | #2181 |
moderating | #2181 |
environmental factors | #2183 |
author | #2185 |
report measures | #2186 |
teachers | #2187 |
computerassisted imaging | #2188 |
thought | #2188 |
differential expression | #2189 |
processing speed | #2189 |
generalized anxiety disorder | #2192 |
regular | #2192 |
scale | #2192 |
serotonin 5 | #2193 |
imaging fmri | #2195 |
conceptual | #2197 |
lifecycle | #2197 |
pharmacological agents | #2199 |
achievement | #2200 |
ages | #2201 |
confounding | #2201 |
double | #2205 |
developing brain | #2206 |
brain mapping | #2206 |
abstract background | #2207 |
ottawa | #2209 |
remained | #2209 |
169 | #2209 |
accidents | #2210 |
surveys questionnaires | #2210 |
homozygosity | #2210 |
illness severity | #2211 |
antenatal | #2211 |
genetic relationship | #2212 |
occurrences | #2217 |
adverse event | #2217 |
intronic | #2219 |
biologically | #2220 |
complex diseases | #2220 |
hippocampal formation | #2220 |
completed | #2220 |
autism | #2221 |
val66met | #2222 |
visuospatial | #2225 |
cognitive task | #2225 |
20th | #2226 |
replicating | #2227 |
single | #2228 |
caudate putamen | #2229 |
trail making | #2230 |
clinical profile | #2232 |
attainment | #2234 |
community sample | #2235 |
controls age | #2238 |
prototypical | #2241 |
hexokinase | #2241 |
implications | #2242 |
qualities | #2244 |
insensitivity | #2245 |
consultation | #2246 |
preliminary data | #2248 |
hamilton | #2253 |
val66met polymorphism | #2254 |
pubertal development | #2257 |
genomic analysis | #2260 |
treatment guidelines | #2260 |
cognitive deficit | #2263 |
novo mutations | #2263 |
cigarette | #2264 |
earlier | #2264 |
criterion | #2265 |
rewards | #2266 |
bds | #2266 |
pathways | #2266 |
clinical measures | #2267 |
evident | #2273 |
overdiagnosis | #2274 |
cognitive development | #2275 |
gray matter volume | #2275 |
remain | #2275 |
axis | #2275 |
tend | #2276 |
imaging male | #2277 |
random allocation | #2277 |
mtl | #2277 |
systemic lupus | #2279 |
apneahypopnea | #2279 |
moderation | #2283 |
lithium | #2283 |
psychiatric illness | #2285 |
cognitive | #2287 |
controlling | #2290 |
minority | #2292 |
update | #2293 |
diverse populations | #2294 |
regions | #2294 |
physical health | #2294 |
socialization | #2295 |
retained | #2297 |
monitored | #2298 |
11 years | #2299 |
corticotropin | #2301 |
239 | #2304 |
biology | #2304 |
clinic | #2304 |
adjunctive | #2306 |
virtue | #2307 |
consisting | #2308 |
difficult | #2310 |
lupus | #2310 |
enormous | #2311 |
brain anatomy | #2313 |
pregnancy | #2313 |
edition | #2315 |
behaviors | #2317 |
adequate | #2318 |
performance reaction | #2319 |
brain systems | #2321 |
tests | #2321 |
fmri | #2325 |
casecontrol study | #2326 |
memory performance | #2328 |
higher prevalence | #2330 |
257 | #2331 |
organ size | #2332 |
questionnaires | #2332 |
subset | #2333 |
mind | #2334 |
covariate | #2335 |
archives | #2335 |
disorganization | #2335 |
early risk | #2336 |
depression female | #2340 |
lesser extent | #2342 |
utility | #2342 |
functional networks | #2344 |
nature | #2344 |
20th century | #2345 |
cingulate | #2346 |
schedule | #2350 |
providing | #2353 |
time perception | #2353 |
mapping child | #2358 |
powered | #2362 |
adolescent brain | #2364 |
endosome | #2365 |
factor structure | #2367 |
concurrently | #2368 |
limited evidence | #2368 |
smallest | #2369 |
symptoms schizophrenia | #2369 |
efforts | #2376 |
social cognitive | #2377 |
catecholamine | #2379 |
antipsychotic agents | #2379 |
tapping | #2384 |
predicts | #2385 |
ecologically | #2386 |
gyrus | #2388 |
drugs abuse | #2391 |
unresolved | #2393 |
convergence | #2395 |
raising | #2395 |
problem solving | #2398 |
gray matter | #2401 |
essence | #2401 |
frontal | #2403 |
pubmed | #2406 |
sirolimus | #2407 |
addictive | #2407 |
adolescent alcohol | #2408 |
distinguished | #2410 |
validate | #2412 |
preserved | #2414 |
genetic factor | #2417 |
statistical significance | #2418 |
alternative | #2418 |
modules | #2419 |
illumina | #2422 |
starting | #2423 |
classified | #2425 |
disease genetic | #2426 |
salience | #2426 |
143 | #2428 |
term outcome | #2429 |
bdnf | #2429 |
confounders | #2431 |
fmri data | #2431 |
clinical trial | #2433 |
241 | #2433 |
protein interactions | #2433 |
protein interaction | #2436 |
analyzes | #2440 |
careful | #2443 |
intellectual | #2447 |
dimorphism | #2448 |
timepoints | #2448 |
items | #2449 |
multiple studies | #2450 |
deconvolution | #2452 |
mvr | #2452 |
overweight children | #2456 |
systemic lupus erythematosus | #2456 |
prefrontal cortical | #2456 |
moderately | #2458 |
myoinositol | #2459 |
genetic susceptibility | #2459 |
anxiety symptoms | #2460 |
brain maturation | #2460 |
traumatic stress | #2461 |
logistic | #2461 |
concordance | #2461 |
autosomes | #2462 |
crossover study | #2464 |
sex distribution | #2464 |
factor bdnf | #2466 |
hungary | #2469 |
unclear | #2473 |
unique | #2473 |
relatedness | #2482 |
brain activation | #2486 |
reaction time | #2488 |
prescriptions | #2489 |
higher scores | #2489 |
psychomotor performance | #2491 |
cerebrum | #2494 |
normative data | #2495 |
180 | #2496 |
hoc analysis | #2496 |
caucasian | #2497 |
israeli | #2500 |
workplace | #2502 |
original | #2504 |
establish | #2504 |
random forest | #2507 |
interactome | #2509 |
randomized placebo | #2511 |
21st | #2512 |
preschool diagnosis | #2512 |
heterosis | #2513 |
thresholds | #2515 |
quotient | #2515 |
preceded | #2516 |
tricyclic antidepressants | #2518 |
evaluate | #2521 |
perceptual | #2523 |
temporal gyrus | #2526 |
12 years | #2528 |
rel | #2531 |
october | #2532 |
alterations | #2532 |
preliminary report | #2533 |
indicators | #2534 |
thinner | #2539 |
limitations | #2541 |
categories | #2545 |
neurosecretory | #2546 |
medication adherence | #2548 |
animals anxiety | #2550 |
risky | #2553 |
psychotic features | #2553 |
depressive disorders | #2554 |
quantitative | #2555 |
neural responses | #2555 |
exploratory study | #2555 |
memory tasks | #2557 |
bipolar affective disorder | #2557 |
income | #2560 |
chronological | #2560 |
risk loci | #2560 |
assisted magnetic | #2561 |
060 | #2562 |
273 | #2563 |
demographic characteristics | #2565 |
447 | #2565 |
sensation seeking | #2569 |
174 | #2570 |
discontinued | #2571 |
document | #2572 |
30 years | #2573 |
numerous | #2573 |
19 years | #2574 |
cool | #2575 |
depressed | #2576 |
socioeconomic | #2579 |
osmosis | #2580 |
smoking alcohol | #2581 |
adolescent females | #2584 |
correction | #2585 |
elucidate | #2585 |
pvalues | #2586 |
problems | #2586 |
brothers | #2586 |
pituitary adrenal | #2587 |
baseline | #2591 |
post traumatic | #2594 |
exist | #2595 |
disrupted | #2595 |
229 | #2596 |
brain response | #2598 |
internalizing externalizing | #2598 |
temporal pole | #2600 |
encouraging | #2601 |
simplex | #2603 |
iowa | #2603 |
n10 | #2605 |
neo | #2606 |
percentile | #2607 |
literature | #2608 |
infrequent | #2610 |
advances | #2611 |
increased activation | #2611 |
occipital | #2612 |
draft | #2614 |
lateralization | #2616 |
surveys humans | #2619 |
pooling | #2620 |
genotype | #2623 |
evidence role | #2624 |
multiple levels | #2624 |
kynurenine | #2625 |
psycinfo | #2625 |
mothers | #2630 |
imaging studies | #2633 |
bdnf gene | #2633 |
preliminary | #2634 |
institute | #2636 |
odors | #2638 |
182 | #2639 |
global functioning | #2642 |
fetal alcohol | #2642 |
preschool female | #2644 |
genetic variants | #2644 |
behavior | #2644 |
medical conditions | #2645 |
inability | #2645 |
future | #2648 |
borderline personality | #2652 |
brain derived | #2655 |
tmax | #2659 |
dysregulation | #2663 |
electronic health | #2664 |
puzzle | #2665 |
periodicals | #2665 |
n14 | #2666 |
health disorders | #2669 |
089 | #2669 |
chromosome | #2670 |
genetic evidence | #2670 |
88 | #2670 |
polysomnography | #2671 |
spectrum | #2675 |
pcps | #2675 |
inconclusive | #2676 |
mediating | #2676 |
partially | #2676 |
memory tests | #2678 |
adolescent development | #2678 |
physiotherapy | #2678 |
maternal behavior | #2679 |
increased activity | #2681 |
disadvantaged | #2685 |
adrenergic | #2687 |
widespread | #2688 |
conditional | #2689 |
age range | #2689 |
triad | #2689 |
listening | #2690 |
reading | #2692 |
entry | #2692 |
promoter region | #2694 |
evaluating | #2695 |
tfs | #2696 |
immaturity | #2698 |
evidenced | #2698 |
extended | #2700 |
chr | #2701 |
interrogation | #2702 |
neurite | #2702 |
attenuate | #2702 |
flares | #2703 |
ext | #2707 |
delinquency | #2707 |
hemispheric asymmetry | #2709 |
internalizing problems | #2710 |
404 | #2713 |
aggressive | #2714 |
occurring | #2714 |
quarter | #2718 |
positively correlated | #2719 |
purposes | #2721 |
choosing | #2723 |
thinking | #2724 |
internalizing | #2726 |
hold | #2727 |
curve | #2731 |
teens | #2731 |
awakening | #2732 |
doubt | #2733 |
thicker | #2733 |
systematic literature review | #2733 |
alcohol dependence | #2736 |
potential association | #2740 |
pdi | #2752 |
cortices | #2753 |
prepubertal | #2753 |
eventually | #2755 |
naa | #2760 |
patients bipolar disorder | #2760 |
collaboration | #2760 |
gt | #2761 |
manifestations | #2762 |
4 years | #2765 |
unadjusted | #2765 |
created | #2768 |
ccs | #2769 |
reproducibility | #2773 |
psychiatric diseases | #2773 |
phencyclidine | #2775 |
depression severity | #2776 |
25 | #2777 |
preventive measures | #2777 |
mechanisms underlying | #2783 |
clinical heterogeneity | #2783 |
bivariate | #2784 |
children symptoms | #2784 |
panic attacks | #2785 |
6 12 | #2788 |
tactile | #2790 |
411 | #2791 |
dna copy | #2791 |
dyslexia | #2792 |
neurotrophic factor | #2794 |
overt | #2794 |
auditory perception | #2796 |
constellation | #2796 |
suicidality | #2799 |
explained | #2802 |
958 | #2803 |
dependence | #2804 |
references | #2806 |
recognition visual | #2808 |
clinical experience | #2808 |
monetary | #2809 |
misdiagnosis | #2809 |
397 | #2809 |
goodness | #2810 |
predefined | #2812 |
disc1 | #2815 |
gene polymorphism | #2816 |
midnight | #2816 |
primary caregivers | #2817 |
subsequent | #2819 |
circuitry | #2823 |
indexes | #2823 |
1300 | #2824 |
telephone | #2824 |
comorbidities | #2825 |
pediatric obesity | #2827 |
intervention strategies | #2828 |
and or | #2830 |
refusal | #2833 |
disorder characterized | #2835 |
tested | #2838 |
discriminant validity | #2839 |
early recognition | #2839 |
adoption | #2841 |
reelin | #2843 |
treatment study | #2843 |
prefrontal cortex | #2844 |
socioeconomic status | #2846 |
emotional intelligence | #2849 |
early identification | #2850 |
matter volume | #2852 |
parent child | #2853 |
disabled | #2856 |
restless legs syndrome | #2857 |
suicide attempted | #2858 |
continental ancestry | #2863 |
depression scale | #2863 |
parenting parents | #2865 |
addresses | #2866 |
screened | #2866 |
internal external | #2867 |
mothers children | #2867 |
discordance | #2868 |
cognition humans | #2868 |
focus | #2869 |
silico | #2870 |
psychosocial stress | #2872 |
splicing | #2875 |
diagnosis differential | #2876 |
gwa | #2878 |
sixteen | #2880 |
appeared | #2884 |
measure | #2884 |
shifting | #2885 |
citations | #2885 |
age differences | #2885 |
rare variants | #2887 |
protective effects | #2889 |
trinucleotide | #2890 |
brain size | #2900 |
asr | #2901 |
alternate | #2902 |
debate | #2903 |
duplicate | #2905 |
low birth weight | #2906 |
alcohol disorder | #2907 |
newer | #2909 |
independent component analysis | #2911 |
etiologies | #2912 |
behavior children | #2913 |
precursor | #2914 |
amph | #2916 |
cognitive control | #2916 |
institutes | #2919 |
variability | #2919 |
biological mechanisms | #2919 |
age study | #2921 |
genetic contributions | #2922 |
115 | #2924 |
attentional | #2925 |
subject | #2928 |
486 | #2931 |
behavioral outcomes | #2931 |
adherence | #2932 |
92 | #2935 |
machine learning | #2941 |
disorders sleep | #2942 |
causal relationship | #2942 |
disorders patients | #2946 |
distinct | #2946 |
motor control | #2953 |
pcb | #2956 |
smoked | #2959 |
journal | #2965 |
facilitating | #2967 |
previous | #2968 |
331 | #2970 |
markers | #2971 |
overlaps | #2971 |
models neurological | #2976 |
stratification | #2981 |
qtl | #2983 |
725 | #2983 |
weight height | #2988 |
investigators | #2989 |
attempts | #2991 |
imaging mri | #2991 |
performance measures | #2997 |
tic | #2997 |
overweight | #2998 |
variants | #2999 |
subjective | #3000 |
bold | #3002 |
referral | #3005 |
196 | #3006 |
centres | #3006 |
377 | #3007 |
19th century | #3010 |
genetic variation | #3011 |
remission | #3011 |
genetic promoter regions | #3012 |
resonance imaging | #3016 |
987 | #3017 |
chen | #3018 |
worldwide | #3020 |
response relationship | #3021 |
inferior frontal gyrus | #3022 |
disease susceptibility | #3023 |
mouse models | #3024 |
choice | #3028 |
conference | #3030 |
models psychological | #3033 |
familiarity | #3034 |
emotion dysregulation | #3036 |
symptoms patients | #3039 |
difficulties questionnaire | #3039 |
female humans life | #3040 |
thomson | #3044 |
neural correlates | #3047 |
variants genes | #3053 |
developmental | #3054 |
treatment adherence | #3054 |
protective factor | #3057 |
improvement | #3058 |
pilot | #3061 |
280 | #3061 |
fear female | #3063 |
117 | #3064 |
ultimately | #3065 |
339 | #3068 |
216 | #3072 |
stress reactivity | #3073 |
p0004 | #3074 |
frontal lobe | #3076 |
appears | #3077 |
cortical | #3078 |
driving | #3078 |
positive | #3079 |
sociodemographics | #3081 |
males | #3089 |
key findings | #3092 |
pairwise | #3093 |
allelic | #3094 |
pregnancy women | #3095 |
stressful life | #3098 |
predictable | #3098 |
modified version | #3099 |
central nervous | #3104 |
intron | #3105 |
brain health | #3107 |
076 | #3107 |
naïve | #3110 |
siemens | #3111 |
interviewed | #3114 |
symptoms study | #3116 |
amygdala hippocampus | #3123 |
articles | #3123 |
marijuana abuse | #3124 |
mass screening | #3125 |
383 | #3127 |
ptsd symptoms | #3127 |
functional laterality | #3129 |
tcc | #3132 |
psychiatrist | #3133 |
temporal cortex | #3134 |
childhood adversity | #3135 |
pharmacies | #3137 |
maternal | #3142 |
accuracies | #3144 |
european countries | #3146 |
nation | #3146 |
exploratory | #3150 |
99 | #3150 |
ancestry | #3151 |
behavior social | #3152 |
oxford | #3157 |
pharmacokinetic | #3157 |
explanations | #3165 |
spd | #3165 |
biological processes | #3166 |
functional consequences | #3166 |
aggregation | #3168 |
hippocampal | #3169 |
teenagers | #3170 |
status humans | #3171 |
caution | #3171 |
report | #3174 |
hypophyseal | #3175 |
math | #3176 |
wealth | #3178 |
contrast | #3180 |
adolescents young adults | #3187 |
imaging study | #3187 |
methyltransferase | #3187 |
receiver | #3188 |
prodrug | #3189 |
view | #3190 |
published | #3190 |
collect | #3195 |
emotion processing | #3195 |
comprehension | #3201 |
initial treatment | #3202 |
attempt | #3202 |
erythematosus sle | #3205 |
answers | #3208 |
normative | #3209 |
naming | #3212 |
snvs | #3214 |
pathophysiological | #3216 |
gene polymorphisms | #3216 |
psychotherapy | #3222 |
environment | #3223 |
angeles | #3228 |
discontinuity | #3229 |
situation | #3229 |
scanner | #3229 |
65 | #3235 |
depression study | #3236 |
mediation analysis | #3237 |
htt | #3237 |
414 | #3239 |
abstinence | #3241 |
databases genetic | #3247 |
determine | #3250 |
features | #3254 |
210 | #3255 |
211 | #3257 |
correlated | #3257 |
publicly | #3265 |
caudate nucleus | #3265 |
humans magnetic | #3266 |
17p | #3266 |
interactive effects | #3266 |
moderator | #3269 |
370 | #3270 |
symbols | #3271 |
researchers | #3272 |
prefrontal cortex pfc | #3274 |
expertise | #3276 |
memory processing | #3281 |
increased likelihood | #3282 |
longitudinal cohort | #3282 |
cognitive functioning | #3289 |
condition | #3291 |
glutamate receptor | #3296 |
replication | #3297 |
surveys | #3299 |
strict | #3304 |
contributed | #3305 |
synaptic function | #3306 |
clinical severity | #3306 |
genomics | #3309 |
restrictions | #3314 |
corrected | #3315 |
attribute | #3316 |
spearman | #3321 |
digit | #3322 |
neuroimaging data | #3323 |
differently | #3325 |
fewer | #3331 |
earlier studies | #3333 |
mrt | #3334 |
ambiguity | #3336 |
clock gene | #3336 |
metropolitan | #3336 |
417 | #3340 |
6 | #3343 |
slide | #3345 |
revealing | #3348 |
clinical | #3351 |
hoc analyses | #3352 |
healthy control | #3354 |
affect | #3357 |
national institute | #3359 |
functional studies | #3361 |
april | #3362 |
friend | #3366 |
motivational | #3367 |
retest | #3369 |
067 | #3370 |
battery | #3371 |
frontal regions | #3371 |
glycolysis | #3371 |
treatment strategies | #3373 |
cortex pfc | #3375 |
088 | #3376 |
marker | #3379 |
functional neuroimaging | #3382 |
initially | #3384 |
sex chromosomes | #3385 |
typically developing | #3386 |
impaired performance | #3386 |
stressful life events | #3387 |
monozygotic | #3389 |
clock genes | #3390 |
multimorbidity | #3390 |
health children | #3392 |
cnp | #3393 |
accounting | #3393 |
ifg | #3398 |
358 | #3402 |
baseline followup | #3404 |
traumatic brain | #3405 |
depression symptoms | #3405 |
desirability | #3406 |
oxidase | #3411 |
performing | #3413 |
pool | #3413 |
aucs | #3415 |
lack | #3419 |
health surveys | #3422 |
therapeutic response | #3423 |
longitudinal data | #3426 |
stepwise | #3431 |
03 | #3433 |
pediatric population | #3436 |
definition | #3439 |
experiencing | #3439 |
exert | #3441 |
fluency | #3446 |
lca | #3448 |
showing | #3448 |
children mothers | #3448 |
schoolaged children | #3449 |
lowered | #3450 |
psychotropic medication | #3455 |
supports | #3455 |
inception | #3457 |
schooling | #3461 |
estimating | #3463 |
differentiate | #3464 |
cognitive behavioral | #3466 |
hallucinations | #3466 |
genomewide association study | #3466 |
male sex | #3472 |
bilaterally | #3473 |
scan | #3475 |
remaining | #3477 |
methylation | #3477 |
behavioral response | #3478 |
irr | #3480 |
postmortem | #3482 |
transmission | #3482 |
slower | #3488 |
lesser | #3489 |
convergent | #3489 |
exposure pregnancy | #3489 |
applying | #3492 |
epidemiological study | #3492 |
short stature | #3497 |
083 | #3497 |
alpha2 | #3497 |
social behaviors | #3497 |
aged polymorphism | #3497 |
matched healthy | #3502 |
p002 | #3506 |
brain function | #3506 |
identifier | #3506 |
antidepressants | #3512 |
checklist | #3514 |
sans | #3518 |
104 | #3519 |
specificity | #3519 |
113 | #3520 |
antipsychotic | #3524 |
spouse | #3525 |
constitutes | #3527 |
pediatricians | #3527 |
basis | #3527 |
asperger syndrome | #3529 |
reflect | #3529 |
clinical phenotype | #3533 |
rett syndrome | #3535 |
reliable | #3536 |
preferentially | #3536 |
enrichment analysis | #3538 |
social behavior | #3539 |
school aged | #3540 |
mother child | #3541 |
fact | #3544 |
cognitive behavioral therapy | #3544 |
sleep wake | #3544 |
coming | #3545 |
rts | #3546 |
documentation | #3547 |
score | #3548 |
dmn | #3550 |
344 | #3557 |
preventive interventions | #3558 |
neuronal function | #3558 |
ecgs | #3558 |
prevalence estimates | #3563 |
suggestions | #3564 |
genetic analysis | #3567 |
psychiatrists | #3568 |
prevent | #3569 |
prospectively | #3570 |
developmental stages | #3573 |
psychosocial interventions | #3579 |
genotyping | #3580 |
reliability | #3583 |
mse | #3585 |
collaborative | #3585 |
neurite outgrowth | #3587 |
mpfc | #3587 |
crh | #3603 |
interrater reliability | #3604 |
major gene | #3606 |
cardio | #3606 |
consists | #3609 |
299 | #3613 |
screen | #3614 |
modalities | #3617 |
methylation status | #3618 |
questions | #3618 |
348 | #3620 |
races | #3621 |
pharmacogenetics | #3622 |
objectives | #3623 |
reviewed | #3624 |
article | #3625 |
214 | #3626 |
101 | #3628 |
neglect | #3630 |
185 | #3631 |
hypothalamo | #3634 |
posttraumatic stress | #3640 |
prior | #3640 |
seeking | #3641 |
wgs | #3648 |
cohesion | #3653 |
enrolment | #3654 |
facilitate | #3660 |
negative | #3661 |
downward | #3662 |
study association | #3663 |
increased prevalence | #3666 |
socioeconomic factors | #3668 |
weight | #3669 |
93 | #3670 |
administration oral | #3672 |
captured | #3675 |
360 | #3681 |
1st | #3682 |
genotype data | #3686 |
behavior problems | #3690 |
frontal lobes | #3691 |
marijuana | #3695 |
online survey | #3696 |
nacetylcysteine | #3700 |
disorders animals | #3703 |
oe | #3705 |
problem behavior | #3707 |
effort | #3711 |
brain cognition | #3719 |
manipulations | #3722 |
9 years | #3729 |
situations | #3730 |
pha | #3732 |
070 | #3733 |
ultimate | #3734 |
daily life | #3735 |
neurotransmission | #3735 |
fifty | #3736 |
depressed mood | #3737 |
hapmap | #3737 |
population | #3738 |
international | #3744 |
therapy cbt | #3744 |
relative | #3745 |
offer | #3746 |
reply | #3750 |
persisted | #3751 |
shortterm | #3753 |
epigenesis genetic | #3755 |
depression risk | #3756 |
proportional | #3757 |
neurophysiological | #3758 |
333 | #3758 |
interim analysis | #3760 |
comprehensive assessment | #3767 |
315 | #3777 |
addiction | #3780 |
transitions | #3781 |
recognition psychology | #3782 |
cocaine disorders | #3783 |
peers | #3787 |
promoter polymorphism | #3787 |
1012 | #3791 |
nonresponse | #3794 |
predictive validity | #3797 |
discriminate | #3800 |
forecast | #3802 |
monozygotic twins | #3803 |
statistical analyses | #3806 |
355 | #3809 |
ways | #3814 |
scientific | #3822 |
dimensions | #3824 |
030 | #3825 |
neurotransmitter | #3829 |
acetylcysteine | #3835 |
inclusion | #3837 |
exchanger | #3844 |
male marijuana | #3844 |
disease genes | #3850 |
developmental disorders | #3850 |
children aged | #3850 |
elevations | #3851 |
risk development | #3851 |
midlife | #3852 |
36 | #3854 |
rely | #3856 |
test | #3858 |
animal dopamine | #3859 |
superior temporal | #3862 |
strong | #3863 |
drug administration | #3866 |
prospective | #3872 |
explain | #3874 |
influences | #3876 |
74 | #3876 |
208 | #3876 |
p001 | #3879 |
ireland | #3882 |
mark | #3883 |
globus | #3886 |
child cohort | #3888 |
reevaluation | #3888 |
tesla | #3890 |
p0003 | #3895 |
plasma membrane | #3898 |
neurology | #3898 |
histories | #3901 |
obstetric | #3905 |
congruent | #3913 |
clinicians | #3915 |
ethnicities | #3922 |
monotherapy | #3923 |
variable | #3924 |
illnesses | #3925 |
robust | #3929 |
dbd | #3930 |
drug targets | #3931 |
suicidal behavior | #3932 |
antidepressant treatment | #3935 |
preexisting | #3937 |
frontal gyrus | #3937 |
specific factors | #3937 |
females males | #3944 |
2nd | #3945 |
directions | #3947 |
controversy | #3951 |
integrate | #3953 |
nicotine | #3956 |
normalization | #3959 |
support | #3960 |
systematic review metaanalysis | #3962 |
indicating | #3967 |
older children | #3969 |
trauma | #3970 |
disease control | #3971 |
untreated | #3976 |
alcohol | #3978 |
brain functional | #3980 |
forecasts | #3981 |
factorial | #4000 |
categorization | #4000 |
preliminary evidence | #4000 |
vulnerabilities | #4003 |
medial prefrontal | #4004 |
primary aim | #4005 |
initiating | #4012 |
kappa | #4013 |
cortex | #4018 |
eqtls | #4021 |
construct | #4023 |
fusiform gyrus | #4032 |
represent | #4036 |
clinical improvement | #4046 |
diabetes risk | #4047 |
common variants | #4047 |
mathematics | #4051 |
discussion | #4051 |
modeled | #4051 |
consequences | #4052 |
relevant | #4057 |
contextual factors | #4058 |
jointly | #4058 |
criminal | #4060 |
divergent | #4062 |
intellectual disability | #4063 |
causal role | #4064 |
serotonin uptake | #4068 |
cag | #4068 |
magnetic resonance | #4068 |
forecasting | #4071 |
statistics | #4072 |
118 | #4074 |
portion | #4075 |
child age | #4076 |
outcomes children | #4078 |
birth order | #4082 |
belgium | #4086 |
genetic loci | #4088 |
study efficacy | #4090 |
heroin | #4090 |
clinical characteristics | #4096 |
temporal lobe | #4098 |
lobe | #4098 |
genetic variations | #4100 |
maternal depression | #4100 |
limbic | #4102 |
psychologists | #4103 |
age matched | #4103 |
list | #4105 |
evidence base | #4107 |
062 | #4109 |
eicosapentaenoic | #4113 |
traumatic | #4115 |
vary | #4117 |
plausible | #4121 |
comprises | #4121 |
epigenesis | #4128 |
cortical areas | #4130 |
relationship | #4136 |
principal components | #4139 |
244 | #4140 |
german | #4145 |
dosing | #4145 |
span | #4146 |
neuronal migration | #4148 |
sectional | #4150 |
mj | #4156 |
regression | #4158 |
extensively | #4160 |
259 | #4161 |
124 | #4164 |
indicative | #4166 |
pathophysiology | #4167 |
fm | #4169 |
somatization | #4170 |
risk depression | #4174 |
bioinformatics | #4177 |
mapping | #4178 |
sedation | #4180 |
340 | #4182 |
dopamine d3 | #4184 |
109 | #4187 |
mri scans | #4188 |
preventive | #4190 |
military | #4191 |
lupus erythematosus | #4192 |
morphometry | #4193 |
structural connectivity | #4194 |
study differences | #4195 |
268 | #4196 |
describes | #4198 |
116 | #4199 |
transporter | #4204 |
growing | #4213 |
children age | #4215 |
helpful | #4216 |
route | #4216 |
based sample | #4218 |
subgroups | #4219 |
suicidal thoughts | #4219 |
functional magnetic | #4223 |
copy variations | #4224 |
determining | #4227 |
valproic | #4230 |
calcineurin | #4237 |
administration | #4239 |
tap | #4245 |
rat model | #4247 |
1987 | #4251 |
gpcr | #4253 |
predict | #4253 |
differential female humans | #4254 |
emerge | #4256 |
mortem | #4259 |
trajectory | #4263 |
representative | #4263 |
confers | #4264 |
posttreatment | #4268 |
antipsychotic medication | #4269 |
225 | #4270 |
follow‐up | #4273 |
early intervention | #4276 |
paediatric | #4280 |
principal component analysis | #4282 |
contributors | #4285 |
polymorphisms genes | #4292 |
select | #4293 |
deletion | #4296 |
pressor | #4302 |
outpatients | #4305 |
demographic variables | #4309 |
child development | #4314 |
adequacy | #4315 |
potential targets | #4315 |
highest risk | #4319 |
mutual | #4324 |
cardiovascular effects | #4326 |
patients diagnosed | #4327 |
buprenorphine | #4332 |
occasion | #4341 |
cingulate cortex | #4348 |
occurs | #4350 |
chart review | #4352 |
acute treatment | #4353 |
catechol | #4353 |
segregation | #4358 |
dropouts | #4361 |
searched | #4362 |
adjunct | #4363 |
166 | #4369 |
cambridge | #4370 |
aging brain | #4372 |
logistic regression analysis | #4373 |
relation | #4375 |
exists | #4375 |
mediate | #4378 |
intolerance | #4378 |
066 | #4382 |
clarity | #4383 |
psychological adolescent | #4383 |
solving | #4391 |
docosahexaenoic | #4391 |
transcriptomic | #4391 |
human | #4393 |
volumetric | #4395 |
privacy | #4396 |
low dose | #4399 |
exon | #4404 |
sexual dimorphism | #4409 |
corpus striatum | #4410 |
impulse | #4412 |
survive | #4413 |
diverse | #4413 |
membrane glycoproteins | #4416 |
polychlorinated biphenyls | #4418 |
ethnic differences | #4424 |
intranasal | #4426 |
opioids | #4429 |
terminology | #4434 |
concurrent | #4438 |
morbidities | #4444 |
197 | #4445 |
bias | #4447 |
human studies | #4449 |
striatal dopamine | #4449 |
62 | #4454 |
genotypes | #4454 |
192 | #4461 |
symposium | #4462 |
locomotor | #4464 |
serotonergic | #4465 |
outgrowth | #4467 |
dna methylation | #4470 |
219 | #4471 |
entered | #4473 |
emissioncomputed | #4476 |
smell | #4477 |
synapse | #4482 |
compilation | #4486 |
ethical | #4490 |
criterion validity | #4491 |
fourth | #4495 |
informal | #4500 |
superior temporal gyrus | #4501 |
parametric | #4508 |
313 | #4509 |
disorders cognitive | #4516 |
visits | #4516 |
valuation | #4516 |
alcohol abuse | #4517 |
investigate | #4521 |
notion | #4525 |
laterality | #4526 |
considerable | #4540 |
postnatal day | #4540 |
multiple | #4541 |
children families | #4542 |
incentive | #4546 |
transmit | #4548 |
pharmacology | #4552 |
employment | #4553 |
higher level | #4553 |
preschool children | #4564 |
birth | #4564 |
emr | #4565 |
component | #4572 |
22 | #4573 |
psd | #4587 |
neuronal differentiation | #4587 |
address | #4593 |
origin | #4595 |
initiated | #4599 |
006 | #4603 |
≤ | #4609 |
february | #4610 |
009 | #4612 |
indices | #4613 |
israel | #4617 |
attributed | #4630 |
genomic data | #4633 |
ssris | #4634 |
television | #4636 |
head injury | #4638 |
clinical risk | #4643 |
q1 | #4643 |
question | #4648 |
trouble | #4651 |
unmet | #4651 |
regression model | #4652 |
marriage | #4658 |
microsatellite | #4660 |
centers | #4660 |
deliveries | #4660 |
anterior cingulate cortex | #4661 |
243 | #4662 |
trajectories | #4662 |
children study | #4665 |
homogeneity | #4667 |
fg | #4668 |
mitigate | #4668 |
european | #4669 |
healthy individuals | #4670 |
psychometric properties | #4673 |
routes | #4676 |
disease onset | #4679 |
subsequently | #4680 |
pregnancy risk | #4682 |
264 | #4684 |
names | #4689 |
hunt | #4696 |
accurate diagnosis | #4699 |
concerns | #4705 |
5 | #4706 |
cardiorespiratory | #4707 |
imply | #4710 |
autosomal | #4711 |
hazards models | #4715 |
vector machine | #4715 |
estimate | #4716 |
smd | #4717 |
mbr | #4719 |
sed | #4719 |
appropriateness | #4720 |
positional | #4725 |
cinahl | #4729 |
fusiform | #4730 |
eqtl | #4731 |
participants included | #4732 |
biological factors | #4735 |
drug addiction | #4736 |
prototypes | #4745 |
unemployment | #4747 |
val | #4747 |
pons | #4753 |
cooperative | #4755 |
drug | #4757 |
taiwan | #4757 |
conflict | #4760 |
77 | #4760 |
tasks | #4762 |
heavily | #4763 |
portions | #4763 |
fumarate | #4773 |
231 | #4774 |
mother | #4782 |
subjects risk | #4784 |
noncarriers | #4791 |
samples | #4791 |
sharing | #4795 |
mp | #4798 |
publication administration | #4798 |
cleaning | #4804 |
coronary artery disease | #4814 |
fractional anisotropy | #4820 |
modafinil | #4825 |
cognitive tests | #4825 |
excluding | #4832 |
surge | #4835 |
visual perception | #4836 |
experts | #4837 |
223 | #4838 |
continuity | #4843 |
sparse | #4849 |
recognized | #4853 |
imaging female | #4858 |
41 | #4865 |
rg | #4873 |
specific | #4874 |
207 | #4875 |
deterioration | #4880 |
wave | #4880 |
cigarettes | #4881 |
young age | #4881 |
subsamples | #4881 |
fp | #4882 |
omega3 | #4882 |
prisma | #4885 |
facts | #4890 |
cascades | #4891 |
eliminated | #4894 |
antiepileptic drugs | #4910 |
operating | #4914 |
002 | #4915 |
preclinical studies | #4916 |
achievements | #4923 |
early adolescence | #4923 |
additive | #4924 |
scored | #4929 |
bdi | #4929 |
parietal lobe | #4930 |
outcome measures | #4932 |
034 | #4933 |
brain activity | #4937 |
inventory | #4941 |
relating | #4947 |
delays | #4949 |
hemispheric | #4949 |
powerful | #4951 |
pooled analysis | #4951 |
snap | #4957 |
rule | #4959 |
diffusion tensor imaging | #4962 |
acetylcholine receptor | #4965 |
srs | #4967 |
212 | #4969 |
altered expression | #4972 |
eye tracking | #4973 |
explosion | #4978 |
empirical data | #4979 |
continental | #4983 |
lower | #4994 |
170 | #4995 |
022 | #5001 |
treatment modalities | #5005 |
timing | #5008 |
esr1 | #5015 |
aged nerve | #5017 |
caucasians | #5021 |
selective attention | #5021 |
disagreement | #5024 |
aug | #5025 |
rarely | #5027 |
serotonin receptors | #5029 |
variation | #5030 |
adolescent health | #5031 |
specialty | #5036 |
task | #5038 |
discuss | #5039 |
probabilistic | #5039 |
distinguish | #5040 |
correct | #5040 |
auc | #5047 |
anxiety depression | #5047 |
cingulate gyrus | #5047 |
sga | #5050 |
early | #5051 |
convergent validity | #5051 |
marital | #5051 |
predictor | #5052 |
2003 | #5055 |
analgesics | #5056 |
obesity | #5064 |
bidirectional | #5067 |
gender identity | #5067 |
18 years | #5070 |
continuation | #5077 |
cadherins | #5079 |
decreasing | #5085 |
reductions | #5086 |
chinese children | #5092 |
placebo patients | #5095 |
aes | #5097 |
epilepsy | #5099 |
09 | #5101 |
reached | #5101 |
screening | #5104 |
103 | #5104 |
relative contributions | #5105 |
qtc | #5106 |
volume reduction | #5107 |
ancestral | #5112 |
time points | #5118 |
relevance | #5119 |
variables | #5127 |
substances | #5129 |
single nucleotide polymorphisms | #5132 |
mediation | #5132 |
maladaptive | #5133 |
ppv | #5134 |
individuals risk | #5136 |
mechanisms | #5142 |
readers | #5143 |
mental retardation | #5145 |
difference | #5146 |
inherent | #5146 |
involves | #5147 |
pharmacogenomics | #5147 |
carrying | #5158 |
enrichment | #5160 |
administered | #5162 |
homozygote | #5166 |
dropout | #5168 |
biological | #5170 |
diffusivity | #5177 |
picture | #5178 |
ventral | #5181 |
reuptake inhibitors | #5182 |
extent | #5183 |
dopamine d1 | #5187 |
adjustment | #5190 |
disability | #5193 |
238 | #5193 |
predictive | #5195 |
weighted | #5197 |
pleiotropy | #5205 |
characteristic | #5212 |
remains | #5215 |
molecular biology | #5215 |
term | #5218 |
conclude | #5223 |
dopaminergic neurons | #5224 |
167 | #5226 |
nonsmokers | #5231 |
dutch | #5233 |
256 | #5234 |
fail | #5237 |
smoking behavior | #5240 |
interaction | #5242 |
accurately | #5245 |
119 | #5246 |
critical period | #5248 |
tolerated | #5255 |
generated | #5260 |
boundaries | #5261 |
americans | #5263 |
exceeded | #5264 |
delineation | #5266 |
genotypic | #5269 |
daytime sleepiness | #5278 |
ws | #5278 |
cell surface receptors | #5280 |
brain injuries | #5283 |
001 | #5286 |
participated | #5287 |
variety | #5289 |
normality | #5290 |
written | #5291 |
billion | #5295 |
trend | #5295 |
eye movements | #5296 |
motor | #5298 |
oligodendrocytes | #5299 |
thalamus | #5299 |
learning | #5301 |
234 | #5302 |
emotion recognition | #5306 |
life events | #5308 |
072 | #5308 |
52 | #5309 |
healthy participants | #5310 |
environmental | #5312 |
observer | #5313 |
dense | #5316 |
hints | #5321 |
definite | #5322 |
treatment initiation | #5323 |
genomic imprinting | #5333 |
credibility | #5335 |
inferences | #5339 |
predictive tests | #5345 |
individual level | #5345 |
social interactions | #5345 |
classic | #5351 |
prenatal | #5353 |
word | #5354 |
estimated | #5359 |
cerebellum | #5363 |
nonresponders | #5368 |
nervosa | #5369 |
interplay | #5375 |
eventrelated potentials | #5376 |
higher frequency | #5380 |
penetrance | #5380 |
lost | #5382 |
suicide attempts | #5382 |
internet addiction | #5390 |
sweden | #5391 |
huntington disease | #5392 |
domains | #5396 |
potential confounders | #5402 |
37 | #5403 |
label | #5403 |
empirical | #5410 |
register | #5411 |
daily | #5413 |
0007 | #5419 |
average | #5424 |
tensor imaging | #5432 |
224 | #5436 |
pcp | #5449 |
172 | #5451 |
wiley | #5452 |
adjunctive therapy | #5454 |
modifiers | #5464 |
hour | #5467 |
york | #5468 |
risk individuals | #5468 |
× 10 | #5471 |
aim | #5474 |
settings | #5475 |
borderline | #5478 |
environmental effects | #5484 |
brains | #5486 |
copy | #5488 |
recall | #5491 |
confirms | #5494 |
locomotor activity | #5499 |
homozygotes | #5502 |
year | #5505 |
clinics | #5517 |
commission | #5518 |
termed | #5519 |
promoter regions | #5525 |
verbal fluency | #5525 |
fdr | #5534 |
320 | #5536 |
anxiety behavior | #5537 |
modulate | #5547 |
155 | #5547 |
closely | #5549 |
elevated | #5549 |
prevention | #5551 |
flanking | #5552 |
restraint | #5552 |
occur | #5553 |
154 | #5559 |
copy variation | #5562 |
health conditions | #5563 |
icd10 | #5564 |
frontal cortex | #5565 |
baseline treatment | #5565 |
european ancestry | #5567 |
15 | #5567 |
213 | #5574 |
significance | #5578 |
predominance | #5578 |
mediators | #5579 |
240 | #5579 |
spatial memory | #5581 |
subacute | #5584 |
175 | #5590 |
locus | #5592 |
epidemiological | #5593 |
scientists | #5596 |
narcolepsy | #5597 |
nrg1 | #5607 |
anhedonia | #5608 |
amygdala | #5623 |
percent | #5628 |
heavier | #5631 |
total | #5640 |
allocation | #5657 |
perinatal | #5663 |
lower risk | #5663 |
divided | #5666 |
exploring | #5670 |
probability | #5677 |
calculate | #5678 |
proportional hazards | #5684 |
40 years | #5686 |
1999 | #5686 |
gene variants | #5687 |
markov | #5688 |
vbm | #5688 |
published data | #5689 |
oculomotor | #5690 |
brain development | #5694 |
normal | #5696 |
databases | #5696 |
systems biology | #5703 |
primary outcome measure | #5713 |
cognitive functions | #5713 |
58 | #5723 |
signal detection | #5725 |
pleasure | #5727 |
focused | #5728 |
thirty | #5728 |
psychological surveys | #5735 |
020 | #5739 |
19 | #5745 |
definitions | #5746 |
cognitive tasks | #5751 |
missing data | #5755 |
divorce | #5758 |
approaches | #5761 |
nac | #5762 |
interactive | #5765 |
aged children | #5767 |
additional | #5773 |
deficient | #5778 |
oral | #5779 |
72 | #5780 |
rats inbred | #5786 |
susceptibility locus | #5788 |
extracted | #5792 |
206 | #5796 |
preferential | #5797 |
16 | #5799 |
139 | #5802 |
deaths | #5811 |
intracranial | #5814 |
nuclear | #5815 |
0002 | #5819 |
0005 | #5820 |
aaa | #5823 |
133 | #5826 |
nerve net | #5827 |
98 | #5827 |
ethnic groups | #5834 |
multidimensional | #5836 |
fell | #5841 |
dependency | #5846 |
cannabis | #5849 |
deletions | #5857 |
current understanding | #5860 |
signaling peptides | #5862 |
gene expression profiles | #5869 |
fetuses | #5872 |
membership | #5874 |
auditory | #5875 |
retrospective chart review | #5879 |
sexual behavior | #5880 |
synaptophysin | #5887 |
16 years | #5894 |
small | #5898 |
september | #5901 |
council | #5910 |
imputation | #5910 |
appendix | #5916 |
characterizing | #5917 |
activity level | #5919 |
broad | #5919 |
ethics | #5923 |
parietal | #5925 |
region | #5928 |
linked | #5928 |
statement | #5928 |
individuality | #5929 |
rights | #5930 |
prolactin | #5931 |
medical treatment | #5933 |
rapamycin | #5937 |
biphenyls | #5940 |
striatal | #5955 |
community | #5956 |
electroencephalography evoked | #5964 |
clearance | #5965 |
132 | #5966 |
cmax | #5969 |
091 | #5971 |
missed | #5974 |
explore | #5994 |
website | #6000 |
exclusively | #6001 |
threshold | #6003 |
moderating role | #6005 |
rois | #6005 |
matched | #6006 |
chromosomal | #6009 |
module | #6011 |
functional connectivity | #6013 |
newcastle | #6017 |
extreme | #6020 |
レポートを実行します | |
Prominent publications by Stephen V Faraone∗
IMPORTANCE: Attention-deficit/hyperactivity disorder (ADHD) is a heritable neurodevelopmental disorder. It has been linked to reductions in total brain volume and subcortical abnormalities. However, owing to heterogeneity within and between studies and limited sample sizes, findings on the neuroanatomical substrates of ADHD have shown considerable variability. Moreover, it remains unclear whether neuroanatomical alterations linked to ADHD are also present in the unaffected siblings of ...
で知られている Unaffected Siblings | Putamen Volume | Participants Adhd | Hyperactivity Disorder | Total Brain |
Motor coordination problems in children and adolescents with ADHD rated by parents and teachers: effects of age and gender
[ PUBLICATION ]
Summary.Objective. ADHD is frequently accompanied by motor coordination problems. However, the co-occurrence of poor motor performance has received less attention in research than other coexisting problems in ADHD. The underlying mechanisms of this association remain unclear. Therefore, we investigated the prevalence of motor coordination problems in a large sample of children with ADHD, and the relationship between motor coordination problems and inattentive and hyperactive/impulsive ...
で知られている Motor Coordination Problems | Children Adhd | Boys Girls | Hyperactivity Child Child | Parents Prevalence |
Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia
[ PUBLICATION ]
We examined the status of the neural network mediating the default mode of brain function, which typically exhibits greater activation during rest than during task, in patients in the early phase of schizophrenia and in young first-degree relatives of persons with schizophrenia. During functional MRI, patients, relatives, and controls alternated between rest and performance of working memory (WM) tasks. As expected, controls exhibited task-related suppression of activation in the default ...
で知られている Default Network | Patients Relatives | Rest Task | Wm Performance | Mpfc Dlpfc |
Patterns of Psychopathology and Dysfunction in High-Risk Children of Parents With Panic Disorder and Major Depression
[ PUBLICATION ]
OBJECTIVE: The purpose of the study was to evaluate 1) whether an underlying familial predisposition is shared by all anxiety disorders or whether specific risks are associated with specific disorders, and 2) whether panic disorder and major depression have a familial link.
METHOD: The study compared four groups of children: 1) offspring of parents with panic disorder and comorbid major depression (N=179), 2) offspring of parents with panic disorder without comorbid major depression ...
で知られている Major Depression | Panic Disorder | Offspring Parents | Risk Children | Factors Social |
OBJECTIVE: Attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and obsessive-compulsive disorder (OCD) are common neurodevelopmental disorders that frequently co-occur. The authors sought to directly compare these disorders using structural brain imaging data from ENIGMA consortium data.
METHODS: Structural T1-weighted whole-brain MRI data from healthy control subjects (N=5,827) and from patients with ADHD (N=2,271), ASD (N=1,777), and OCD (N=2,323) from 151 ...
で知られている Adhd Asd | Cortical Thickness | Children Adolescents | Brain Volume | Disorder Ocd |
BACKGROUND: Neuroimaging studies have shown structural alterations in several brain regions in children and adults with attention deficit hyperactivity disorder (ADHD). Through the formation of the international ENIGMA ADHD Working Group, we aimed to address weaknesses of previous imaging studies and meta-analyses, namely inadequate sample size and methodological heterogeneity. We aimed to investigate whether there are structural differences in children and adults with ADHD compared with ...
で知られている Brain Volume | Adults Adhd | Attention Deficit | Hyperactivity Disorder | Subcortical Structures |
AIMS: To determine comorbidity patterns in treatment-seeking substance use disorder (SUD) patients with and without adult attention deficit hyperactivity disorder (ADHD), with an emphasis on subgroups defined by ADHD subtype, taking into account differences related to gender and primary substance of abuse.
DESIGN: Data were obtained from the cross-sectional International ADHD in Substance use disorder Prevalence (IASP) study.
SETTING: Forty-seven centres of SUD treatment in 10 ...
で知られている Disorder Patients | Psychiatric Comorbidity | Attention Deficit | Seeking Substance | Presence Adhd |
CONTEXT: Controversy exists about the appropriate criteria for a diagnosis of adult attention-deficit/hyperactivity disorder (ADHD).
OBJECTIVE: To examine the structure and symptoms most predictive of DSM-IV adult ADHD.
DESIGN: The data are from clinical interviews in enriched subsamples of the National Comorbidity Survey Replication (n = 131) and a survey of a large managed health care plan (n = 214). The physician-administered Adult ADHD Clinical Diagnostic Scale (ACDS) was used to ...
で知られている Adult Adhd | Hyperactivity Disorder | Illness Surveys | Clinical Diagnostic | Symptoms Childhood |
The Massachusetts General Hospital studies of gender influences on attention-deficit/hyperactivity disorder in youth and relatives
[ PUBLICATION ]
With the single exception of SUDs, no statistically significant gender-by ADHD interactions were identified in the multiple, outcomes evaluated. These results suggest that with the exception of SUDs, ADHD expresses itself similarly in boys and girls relative to comparison subjects of the same gender, indicating that ADHD-associated impairments are correlates of ADHD in both genders. Gender differences, such as the higher prevalence of symptoms of inattention and lower rates of ...
で知られている Girls Adhd | Hyperactivity Disorder | Gender Differences | Higher Prevalence | Symptoms Inattention |
OBJECTIVE: To complete an exploratory uncontrolled study of the effects of lisdexamfetamine dimesylate (LDX) on growth of children treated for attention-deficit/hyperactivity disorder (ADHD).
METHOD: Height, weight, and body mass index (BMI) from 281 children ages 6 to 13 years from longitudinal assessments up to 15 months were compared to norms from the Centers for Disease Control.
RESULTS: At study entry, children were taller and heavier than average. Growth delays were largest for ...
で知られている Lisdexamfetamine Dimesylate | Height Weight | Growth Children | Ldx Bmi | Centers Disease Control |
Psychopathology in Adolescent Offspring of Parents With Panic Disorder, Major Depression, or Both: A 10-Year Follow-Up
[ PUBLICATION ]
OBJECTIVE: The authors examined the specificity and course of psychiatric disorders from early childhood through adolescence in offspring of parents with confirmed panic disorder and major depressive disorder.
METHOD: The authors examined rates of psychiatric disorders at 10-year-follow-up (mean age, 14 years) in four groups: offspring of referred parents with panic and depression (N=137), offspring of referred parents with panic without depression (N=26), offspring of referred parents ...
で知られている Panic Disorder | Offspring Parents | Parental Depression | Disruptive Behavior | Year Follow |
BACKGROUND: The goal of this study was to investigate the occurrence, severity and clinical correlates of emotional lability (EL) in children with attention deficit/hyperactivity disorder (ADHD), and to examine factors contributing to EL and familiality of EL in youth with ADHD.
METHODS: One thousand, one hundred and eighty-six children with ADHD combined type and 1827 siblings (aged 6-18 years) were assessed for symptoms of EL, ADHD, associated psychopathology and comorbid psychiatric ...
で知られている Symptoms Adhd | Emotional Lability | Hyperactivity Disorder | Attention Deficit | Odd Disruptive Behavior |
A Controlled Study of Behavioral Inhibition in Children of Parents With Panic Disorder and Depression
[ PUBLICATION ]
OBJECTIVE: "Behavioral inhibition to the unfamiliar" has been proposed as a precursor to anxiety disorders. Children with behavioral inhibition are cautious, quiet, introverted, and shy in unfamiliar situations. Several lines of evidence suggest that behavioral inhibition is an index of anxiety proneness. The authors sought to replicate prior findings and examine the specificity of the association between behavioral inhibition and anxiety.
METHOD: Laboratory-based behavioral observations ...
で知られている Behavioral Inhibition | Major Depression | Children Parents | Panic Disorder | Controlled Study |
Traumatic Brain Injury and Schizophrenia in Members of Schizophrenia and Bipolar Disorder Pedigrees
[ PUBLICATION ]
OBJECTIVE: Schizophrenia following a traumatic brain injury could be a phenocopy of genetic schizophrenia or the consequence of a gene-environment interaction. Alternatively, traumatic brain injury and schizophrenia could be spuriously associated if those who are predisposed to develop schizophrenia have greater amounts of trauma for other reasons. The authors investigated the relationship between traumatic brain injury and psychiatric diagnoses in a large group of subjects from families ...
で知られている Traumatic Brain Injury | Bipolar Disorder | Subjects Schizophrenia | Mental Illness | Genetic Vulnerability |
のための重要な人々 Hyperactivity Disorder
Stephen V Faraone∗:専門家の影響
その概念Stephen V Faraone∗直接的な影響があります:Hyperactivity disorder, Bipolar disorder, Attention deficit, Deficit hyperactivity, Disorder adhd, Anxiety disorders, Disorder hyperactivity, Children adhd.
Stephen V Faraone∗:KOLインパクト
他の著者の仕事に関連する概念for which Stephen V Faraone∗ 影響力があります:Bipolar disorder, Attention deficit, Children adhd, Executive function, Mental health, Schizophrenia patients.
Tools
これはあなたのプロフィールですか? あなたのプロフィールを主張します URLをコピーします プロフィールへのリンクを埋め込みます |